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CANCER IN THE SOCIETY  
The World Health Organization has recognized cancer as a leading cause of morbidity 
and mortality worldwide, with an effective 14 million new cases and 8.2 million annual 
deaths in 2012. Furthermore, cancer incidence is expected to increase by approximately 
70% over the next twenty years (1). There are more than 100 different types of cancer 
and the ultimate aim of anti-cancer therapy is to provide a personalized treatment that 
targets and cures (systemic) disease. There are three main cancer treatment modalities: 
surgery, radiotherapy and chemotherapy. Surgery physically removes malignant lesions, 
radiotherapy targets a radiation dose towards the tumour and conventional cytotoxic 
chemotherapeutic agents usually kill rapidly dividing cells in the body by interfering with 
cell division. A fourth new treatment modality, immunotherapy, represents the most 
promising approach since the development of the first chemotherapies (2). The general 
principle of immunotherapy is the modulation of a patient’s own immune system to 
target their cancer. The immune system of all patients is as unique as their tumour, and 
therefore these therapies may hold great promise. Immunotherapies have the potential 
to target the invisible (micro)metastases and offer long-term protection (3). New 
therapies are under development, and frequently several of these four treatment 
modalities are combined in order to achieve the optimal anti-cancer treatment.  
Cancer development – A role for the immune system 
In 2000, Hanahan and Weinberg published a review article explaining six biological 
capabilities acquired during the multistep development of human tumours (sustaining 
proliferative signalling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis and activating invasion and metastasis), 
named the six hallmarks of cancer (4). However, for cancers to grow progressively they 
must have evaded the anti-tumour immune response. Indeed, in the past decade it 
became more and more clear that the immune system has a pivotal role in the 
prevention of tumours, by identifying and eliminating tumour cells on the basis of their 
expression of tumour-specific (neo)antigens or molecules induced by cellular stress (5), 
and therefore the ‘evading of immune destruction’, was added as an additional 
hallmark in their updated review published over a decade later (6). This hallmark, also 
called immuno-editing, is a process divided into three phases: elimination, equilibrium 
and escape (Fig. 1).  
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Figure 1: The process of immuno-editing. In the first phase, the immune system recognizes and eliminates
malignant cells. In the second phase, tumour cells can develop in different variants (equilibrium), eventually 
escaping (third phase) the killing mechanism of the immune cells (adapted from (7)).  
 
In the first phase, the immune system can detect and eliminate tumour cells. Both 
innate and adaptive immune cells actively prevent neoplastic development in this first 
phase. Innate immune cells mediate an immediate tumour cell attack by producing 
cytokines that can directly lyse tumour cells (natural killer (NK) cells) (8) and by 
capturing tumour debris and antigens (including dendritic cells (DCs), neutrophils and 
macrophages) (9). Eosinophils and basophils are thought to be involved in attacking 
large antibody-coated parasites and mast cells can trigger local inflammatory responses 
in response to antigens and are well known to cause allergic reaction (9). In patients 
and animal models, the loss of proper NK function has been associated with an increase 
in the incidence of a variety of cancers (10). As members of the innate immune system, 
NK cell functions are tightly regulated by a balance between activating and inhibitory 
signals. These signals are provided by receptors expressed at their cell surface, enabling 
NK cells to recognize and spontaneously kill target cells, such as virus infected and 
tumour cells, without prior sensitization. Therefore, these abnormal cells trigger NK 
effector functions (cytotoxicity, cytokine production and proliferation) directly, either 
through the loss of MHCI class molecules (i.e. loss of self-identification) that can 
otherwise bind to inhibitory receptors on the NK cells or by upregulating of ligands that 
activate NK cells to overcome these inhibitory signals (Fig. 2) (11). 
Several cell types of the innate immune system, including macrophages and DCs, can 
perform the recognition, capturing and elimination of foreign cells. As with NK cells, 
recognition occurs via an interaction with cell-surface pattern recognition receptors 
that are able to recognize PAMPs (pathogen-associated molecular patterns) conserved 
among microbes and DAMPs (damage-associated molecular patterns) released from 
and expressed on tissue injuries. Macrophages were initially known to pick up and 
eliminate tumour cells (12), however, they have also been shown to be recruited to 
tumours and correlate with poor prognosis (13). The function of DCs seems to be more 
straight-forward as they capture, process and eliminate foreign cells (including tumour 
Chapter 1 
10 
cells) in their role as innate immune cell, and in addition, they have an important role in 
the initiation of the adaptive immune response. After processing the antigen, DCs have 
the ability to migrate from the antigen capturing side (e.g. the tumour) into draining 
secondary lymphoid organs, where they encounter naïve helper (CD4+) and cytotoxic 
(CD8+) T cells, triggering their proliferation and eventually migration of antigen-specific 
T cells into peripheral tissues, thereby starting the adaptive immune response (14, 15). 
 
 
Figure 2: Regulation of NK cells. Loss of self-identification through a lack of MHCI expression or the
upregulation of activating ligands can both overcome inhibitory signals of healthy cells and activate NK
function (adapted from (11)).  
 
 
 
Figure 3: Overview of cells from the innate and adaptive immune system. Cells from the innate immune 
response target and destroy foreign cells immediately after recognition. Dendritic cells have a crucial role in
capturing of debris and initiating the adaptive immune response. T cells from the adaptive immune response
can develop into CD4+ (helper) and CD8+ (cytotoxic) T cells, which have the potential to rapidly develop into 
memory T cells able to kill target cells upon recognition (adapted from (67)).  
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Cancer immunotherapy – modulating the immune system 
Tumour (neo)antigens derived from mutations associated with carcinogenesis (16) have 
the potential to be recognized by T cells of the adaptive immune system. Upon 
recognition of a matching tumour antigen, T cells have the ability to attack and destroy 
these cells, completing the process of elimination. Indeed, activated anti-tumour T cells, 
endowed with antigen specificity (and memory), are required to achieve complete and 
long-lasting tumour clearance (17). However, the regulation of T cell responses is a 
complex process as a result of a sophisticated balance consisting of stimulatory and 
inhibitory signalling pathways, chemokines and cytokines. The first stage (elimination of 
tumour cells) can be unsuccessful, often because tumour cells can progress in different 
variants (during equilibrium) eventually escaping the killing mechanism of immune cells 
(Fig. 1 (5)). This large variety of tumour cells is able to interact and manipulate their 
environment (also called the tumour microenvironment), thereby recruiting tumour 
supporting fibroblasts, blood vessels and (regulatory) immune cells (18, 19). In order to 
effectively execute their anti-tumour role, T cells of the adaptive immune system 
require additional costimulatory signals and stimulatory cytokines, such as interleukin-2 
(IL2), secreted by antigen-stimulated CD4+ and CD8+ T cell, NK cells and activated DCs 
(20, 21). In order to maintain self-tolerance and to be able to control the duration and 
amplitude of a physiological immune response with minimal collateral tissue damage, T 
cells additionally have the possibility to activate several inhibitory pathways (22). Both of 
these principles of the anti-cancer immune response can be manipulated: the addition 
of stimulatory cytokines has the potential to make the response stronger and the 
addition of the so-called checkpoint inhibitors can combat the inhibitory pathways.  
Checkpoint inhibitors - releasing the brakes of inhibitory pathways 
Despite the immune escape, solid tumours are often highly infiltrated by several immune 
cells. There is evidence showing a positive association between intra-tumoural 
lymphocytes and increased survival in patients with solid tumours (23). Therefore, the 
search for mechanisms involved in the dysfunction and exhaustion of the anti-tumour 
immune response (i.e. ways to combat the inhibitory pathways) and ways to restore and 
manipulate this broad and unique process, has gained a lot of interest over the last 
decade. Indeed, the field of immunotherapy was recognized as breakthrough of the year 
2013 by Science (2), because of their ground-breaking findings (24-27) and their totally 
different way of treating cancer: by targeting the tumour indirectly via the immune 
system. Recently, profound progress in immunotherapy research was achieved in the 
field of checkpoint inhibitors (22).  Among recently FDA (Food and Drug Administration) 
approved immune checkpoint inhibitors are anti-CTLA4 (ipilimumab) and the anti-PD-
1/PD-L1 inhibitors (atezolimab, pembrolizumab and nivolumab), all releasing the brakes 
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elicited by the immune system or tumour cells and showing encouraging durable tumour 
regression in a percentage of (metastatic) cancer patients (22).  
(Targeted)-IL2 - pushing the accelerator using stimulatory cytokines 
To initiate an anti-tumour immune response, immune cells need to recognize tumour-
specific (neo)antigens, they need to be activated (without developing an exhausted 
phenotype) and they need to be stimulated by the correct repertoire of 
immunostimulatory cytokines. One cytokine, IL2, is secreted by activated CD4+, CD8+, 
NK and dendritic cells and it can stimulate cells that express the IL2 receptor (CD25). IL2 
is known to stimulate CD8+ T cell growth and differentiation and represents the first 
FDA approved immunotherapy that mediates the regression of large number of human 
cancers. It is also an important factor responsible for the maintenance of CD4+ 
regulatory T cells and plays a role in CD4+ T cell differentiation and NK cell activation 
(21, 28). Despite the great potential of IL2 treatment in, for example, metastatic 
melanoma, its clinical application remains restricted due to its short half-life, making it 
necessary to give high doses to achieve optimal immune-modulatory effects but causing 
severe toxicities (hypotension, vascular leak syndrome and heart toxicities) (29-31). A 
way to circumvent toxicities caused by the high dose systemic IL2 treatment is intra-
tumoural IL2 administration (21) or through selective delivery of IL2 in the form of a 
cytokine fusion protein, or immunocytokine (32). L19-IL2 is such an immunocytokine, 
containing the monoclonal antibody L19 in a diabody format, which recognizes the 
extra-domain B (ED-B) of fibronectin, a marker associated with tumour angiogenesis 
(33). ED-B is present in newly formed vasculature structures of most solid tumours and 
absent in healthy tissues (with exception of tissues of female reproductive cycle and 
during foetal development), making it an interesting tumour (microenvironment) 
targeting protein. Indeed, previous studies using L19 for imaging and targeted 
(radio)immunotherapy, have shown that L19 targets the tumour vasculature (34-36). 
Moreover, in a phase I clinical study in patients with melanoma or renal cell carcinoma, 
the administration of L19-IL2 alone or combined with chemotherapy (decarbazine), was 
safe and showed clinical activity (37, 38). Currently, a phase II study is ongoing 
investigating the efficacy of L19-IL2 combined with L19-TNF (tumor necrosis factor-
alpha) in stage III and IV melanoma patients (NCT02076633).  
Radiotherapy and immunotherapy - the best of two worlds 
Although recent developments in immunotherapy research are extremely promising, 
recent data suggest that greater success can be achieved by combining immuno-
therapeutic approaches with radiotherapy (39, 40). Radiotherapy (RT) is one of the 
major treatment options in cancer management and approximately 52% of all cancer 
patients receives RT during their treatment (41). For decades, the direct and local 
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effects of RT on tumour cells, depending on DNA damage and the intrinsic repair 
capacity of irradiated cells (42), was the focus of RT-related research. Additionally, RT 
causes an immunogenic death of cancer cells characterized by calreticulin (CRT) 
translocation to the surface of dying tumor cells (43) together with high-mobility group 
box-1 (HMGB-1) and adenosine triphosphate (ATP) release, which promotes uptake and 
cross-presentation of released tumor (neo)antigens by DCs to T cells in the draining 
lymph node (16, 44-46) (Fig. 3). It has been shown that RT provides key components to 
initiate an immune response and to convert the irradiated tumour into an effective in 
situ personalized tumour vaccine (47). The immune response initiating role of RT, the 
formation of an in situ personalized vaccine and immune modulating effects triggered 
by RT, can in theory form the basis for novel personalized ‘super’ therapies, when 
combined with immunotherapy.  
On the other hand, the administration of an immunotherapy has also great potential in 
transforming RT into a systemic and long-lasting therapy, a phenomenon known as the 
abscopal effect (50-54). Because its clinical appearance is sporadic (55) and it has been 
established to be immune-mediated (56-61), the rational of transforming the local RT 
treatment into a systemic therapy, has recently gained a lot of interest (62). A strong 
systemic anti-tumour response, could in theory target tumours (and tumour cells) 
outside the RT field, providing a treatment for (micro-)metastatic disease (Fig. 3). 
Furthermore, once irradiated, tumour antigens are successfully converted into an in situ 
vaccine eliciting tumour-specific T cells, the host can be endowed with immune 
memory. An increase in long-term survival can be derived from successful immunization 
against the primary tumour using radiotherapy (63, 64), therefore these memory T cells 
have the potential to form protection against a pleiotropy of tumour associated 
antigens for the life time of a host (65). To conclude, the RT-induced immunogenic cell 
death mechanisms initiating an anti-tumour immune response have the potential to 
improve and personalize available immunotherapeutic approaches and these have the 
potential to transform localized RT into a systemic and long-lasting therapy (Fig. 3). In 
other words, RT has the potential to make the therapeutic effects of immunotherapy 
(including L19-IL2) more targeted and immunotherapy has the potential to make RT 
effects more systemic. Combining both therapies creates a diversity of treatment 
opportunities and possibilities without searching for new targets and therapies.  
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OUTLINE OF THE THESIS 
In this dissertation we investigate the immune initiating effects of RT in combination 
with L19-IL2, a highly promising and targeted way to activate immune cells. The overall 
aim of this dissertation was to investigate the possibilities of transforming the effects of 
local radiotherapy into a systemic treatment using the immunocytokine L19-IL2 (Fig. 4).  
 
 
Figure 4: Combining radiotherapy with L19-IL2, a schematic overview of the supposed hypotheses of this
dissertation. Radiotherapy has the potential to initiate an anti-tumour immune response and immunotherapy
(L19-IL2) has the potential to increase this anti-tumour immune response systemically (modified (48, 49)).  
 
A review article (chapter 2) explores the new possibilities of bimodal treatment 
combining (stereotactic) RT with immunotherapeutic approaches and gives an overview 
of recent (ongoing) preclinical and clinical studies. We describe the potential 
mechanistic synergy between both treatment modalities and explain the large variety of 
possibilities. In chapter 3 the possible synergy between RT and the ED-B targeted 
immunocytokine L19-IL2 is investigated. We hypothesized that the initiated anti-tumour 
immune response of RT can be enhanced when combined with L19-IL2 and that this 
effect is dependent on the expression of ED-B. For this purpose, 3 different tumour 
models with varying ED-B expression levels were used. Furthermore, we investigated if 
the therapeutic effect of RT combined with L19-IL2 is dependent on the RT dose and if a 
causal relationship exists with the amount of CD8+ cytotoxic T cells by depleting these T 
cells with specific monoclonal anti-CD8+ antibody. Chapter 4 gives a summary of the 
study described in chapter 3, and places these findings into a broader perspective. In 
DC
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chapter 5, we investigate if the observed effect on irradiated tumours can be translated 
as well to tumours outside the RT field. We introduce a new terminology in this chapter, 
namely the OFRI effect, i.e. the Out-of-Field RadioImmune effect. We hypothesize that 
RT and L19-IL2 treatment can induce a curative OFRI effect and can result in long-lasting 
protection provided by the memory potential of the immune system. We investigated if 
both single dose and fractionated RT can induce this OFRI effect when combined with 
L19-IL2. Additionally, we assessed the causal relationship between the OFRI effect and 
both helper and cytotoxic T cells and whether OFRI is a tumour-specific or is a general 
effect. For this purpose, secondary tumours were the same (C51) or different (CT26) as 
compared with the primary tumour (C51). Furthermore, and of great importance, we 
investigated the potential of RT + L19-IL2 to provide a long-lasting protection against 
the tumours. We investigated differences to obtain this long-lasting protective effect 
between RT + L19-IL2, surgery + L19-IL2 and high dose RT + vehicle treatment groups. 
We additionally assessed if this protection can be predicted using immunological 
biomarkers (CD44+CD127+ expression on CD8+ T cells), preferentially in the blood. This 
might potentially open doors for new biomarker strategies, enabling the classification of 
long-term responders versus non-responders, creating a possibility to modify treatment 
for the latter group. In chapter 6, we hypothesize that the combination therapy of RT + 
L19-IL2 can also trigger a NK dependent anti-tumour response in a model lacking MHCI 
expression with the purpose to extend the usefulness of this combination therapy to 
MHCI negative tumours or mixed tumours as can be expected in patients. Chapter 7 
describes our point-of-view of how to place L19-IL2 in ‘the age of the check-point 
inhibitors’ as an answer on an editorial written based on chapter 6. In chapter 8 we 
describe the possibility to combat an immunological suppressive mechanisms, the 
checkpoint CTLA-4 (66) in an attempt for trimodal therapy. In this chapter we have 
combined the RT (2Gy) + L19-IL2 treatment with anti-CTLA-4 (ipilimumab) and assessed 
if the therapeutic efficacy of the bimodal combination of RT + L19-IL2 could be 
improved. Chapter 9 provides a general discussion on all chapters, places our results in a 
broader context and describes the future perspectives of this exciting research. 
Inherent to this, chapter 10 describes the way to create impact for patient and society: 
the valorization.  
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ABSTRACT  
Radiotherapy is along with surgery and chemotherapy one of the prime treatment 
modalities in cancer. It is applied in the primary, neoadjuvant as well as the adjuvant 
setting. Radiation techniques have rapidly evolved during the past decade enabling the 
delivery of high radiation doses, reducing side-effects in tumour-adjacent normal 
tissues. While increasing local tumour control, current and future efforts ought to deal 
with microscopic disease at a distance of the primary tumour, ultimately responsible for 
disease progression. This review explores the possibility of bi-modal treatment 
combining radiotherapy with immunotherapy. 
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STEREOTACTIC ABLATIVE BODY RADIOTHERAPY  
Stereotactic ablative body radiotherapy (SABR) is a form of high-precision radiotherapy 
delivering extremely high ablative doses of radiation, usually in 3-8 fractions, combining 
reproducible patient immobilization, tumour motion tracking and steep dose gradients, 
resulting in reduced normal tissue toxicity (1). SABR achieves excellent local control 
rates in patients with stage I/II non-small cell lung cancer (NSCLC) and liver metastases 
of colorectal cancer (CRC) (2). Nowadays, these favorable results of SABR are being 
transferred to patients with limited sites of metastatic disease (oligometastatic; ≤5 
metastases in ≤3 organs) originating from solid tumours (e.g., breast, NSCLC, head and 
neck, renal cell carcinoma, melanoma, CRC), both at primary diagnosis (synchronous) 
and during the course of disease (3-10). Tree et al. reports on favorable local control 
rates of approximately 80% using SABR with few treatment-related side-effects (10). 
Recently, our group (11) found NSCLC patients with synchronous oligometastases to 
have a median progression-free survival (PFS) of 12.1 months when treated radically to 
all known metastatic sites. However, in the vast majority of patients, disease-
progression at distance from the treated site occurs ultimately leading to extensive 
metastatic disease and cancer-related death. 
TUMOURIGENESIS AND THE IMMUNE SYSTEM 
The immune system closely monitors the process of tumourigenesis first by registering 
the presence of cells undergoing neoplastic transformation, and second by interacting 
with neoplastic cells to mediate their destruction. Solid tumours have developed 
mechanisms to escape “cancer immunosurveillance”, i.e., detection by the immune 
system. This is achieved by, among other mechanisms, the secretion of potent immune-
suppressive cytokines and the expression of T-cell inhibitory molecules, which are able 
to down-regulate an anti-tumour immune response (12). There is conclusive evidence 
that, apart from its direct effects, RT can induce “immunogenic cell death”, which 
serves as a trigger or “in situ vaccine” for the innate and adaptive immune system (13-
15). RT induces immunogenic cell death by the release of tumour antigens and damage 
associated molecular patterns (DAMPS), including high-mobility group protein B1 
(HMGB1), adenosine triphosphate (ATP) and the exposure of calreticulin on the tumour 
cell surface. Also, several cellular surface expression molecules, including Fas and ICAM-
1, are upregulated (16, 17). These factors promote uptake of dying cells by dendritic 
cells, cross-presentation of tumour antigens to T cells, and activation of anti-tumour 
(cytotoxic) T cells (18, 19). 
Recent preclinical and clinical data indicate that immunogenic cell death may be an 
important consequence of ionizing radiation (18), and that localized radiotherapy can 
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evoke and/or modulate tumour-associated immune responses (20). Even though clinical 
evidence of systemic anti-tumour response from local irradiation is scarce, tumour 
regression outside the irradiated field was already recognized in 1953 and termed 
abscopal effect (21-25). In general, it is unlikely that radiotherapy alone provides a 
sufficient anti-tumour immune response and the addition of active immunotherapy (IT) 
to SABR may increase the therapeutic potential and induce abscopal effects in a more 
systematic way (24, 26). 
RECENT CLINICAL SUCCESSES USING IMMUNOTHERAPY 
Breaking the immune tolerance using checkpoint modulators  
Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the 
immune system. These are crucial for maintaining self-tolerance and modulating the 
duration and amplitude of physiological immune responses in peripheral tissues, in 
order to minimize collateral tissue damage. It is now clear that tumours use certain 
immune-checkpoint pathways as a major mechanism of immune resistance, particularly 
against tumour antigen specific T-cells. Examples of these immune-checkpoints are the 
cytotoxic T lymphocyte-associated antigen 4 (CTLA4), or the programmed death 
receptor 1 (PD-1) and its ligand PD-L1. New strategies aim at breaking this tolerance.  
Monoclonal antibody-mediated (ipilimumab) blockade of CTLA-4 on T cells seems to be 
sufficient to elicit an effective anti-tumour immunity (27), which paved the way for 
clinical studies. Two phase III studies evaluated the clinical effects of ipilimumab in 
metastatic melanoma patients. Treatment with ipilimumab as monotherapy improved 
median overall survival rates from 6.4 to 10 months (28), and bi-modal treatment with 
standard of care chemotherapy (dacarbazine) increased 3-year overall survival from 
12.2% to 20.8% (29). Although the percentage of patients responding to ipilimumab was 
limited (complete response ~1%, partial response in 5-10%), the effects of response 
were long-lasting in those who responded. Even though treatment-related adverse 
effects occurred in almost all patients, with several immune effects-related deaths in 
the first trial, and despite the high costs, ipilimumab received FDA approval in 2011 for 
treatment of advanced melanoma patients due to its clear clinical effect. 
Immunotherapy for other solid tumours 
The effect of immunotherapy has increasingly been evaluated in both immunogenic and 
non-immunogenic (metastatic) solid tumours, including prostate cancer, renal cell 
carcinoma, melanoma, and head and neck cancer. In the subsequent paragraph the 
diversity and recent merits of this approach are highlighted. The autologous active 
cellular immunotherapy, Sipuleucel-T, significantly reduced the risk of death in 
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metastatic castration-resistant prostate cancer (mCRPC) patients compared to the 
placebo group (30). Also, prostate-specific antigen (PSA)-targeted poxviral vaccines 
were well-tolerated and associated with an 8.5-month improvement in median overall 
survival for mCRPC patients (31). Recent advances for mCRPC were well summarized by 
Flemming (32). Rini et al. (33) randomized patients with metastastic RCC into two 
cohorts, one receiving bevacizumab plus interferon alpha (IFN-α), the other IFN-α only. 
The combination treatment led to a slightly prolonged overall survival time but did not 
meet expectations, i.e., it was impossible to identify patient subgroups benefitting from 
the combined treatment. Autologous cytokine-induced killer cell immunotherapy was 
found to be superior to combined IL2 and IFNα treatment in terms of 3-year PFS and OS 
in metastatic RCC patient (34). For head and neck cancer (HNSCC) patients, research 
efforts include the development of the vaccine DRibble, stimulating tumour-infiltrating 
T-lymphocytes (35) and immunotherapy of Human Papilloma Virus (HPV)-associated 
HNSCC (36) amongst others. 
SABR COMBINED WITH IMMUNOTHERAPY 
Preclinical results 
Several studies have focused on the immunogenic response of tumours to different 
dose schedules of radiotherapy. Lee et al. (37) observed that a single dose of ablative 
radiotherapy (RT; 20 Gy) generated a CD8+ T cell–dependent immunity leading to 
tumour reduction and eradication of metastasis. In comparison, mice treated with 4 × 5 
Gy initially responded to RT but tumours relapsed over time. One possible explanation is 
that fractionated low-dose RT may kill infiltrating CD8+ T cells over time. However, 
when ablative RT (2 x 12 Gy) was combined with ad-LIGHT-based immunotherapy, 
circulating cytotoxic T cells increased again and micrometastases were eradicated (37). 
Lugade et al. (38) observed activated and expanded anti-tumour CD8+ T cells in 
response to 5 fractions of 3 Gy, however without resulting in tumour growth delay. 
Although these studies indicate that ablative RT is able to provoke a CD8+ T cell 
mediated immune response, most studies only detected an immune response after RT 
combined with different immunotherapies.  
Several in vivo studies have investigated the combination of radiotherapy with anti-
CTLA-4 based immunotherapy. In a metastasizing breast cancer mouse model, a single 
dose (12 Gy) of radiotherapy to the primary tumour combined with systemic anti-CTLA-
4 blocking antibody 9H10 immunotherapy decreased metastatic burden, but the effect 
on the primary tumours was minimal. Two RT fractions of 12 Gy delivered to the 
primary tumour in combination with CTLA-4 blockade resulted in complete regression 
of the irradiated tumour and metastases in the majority of the mice, a response which 
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was CD8+ T cell mediated (39). Dewan et al. (40) tested different radiation regimens 
similar to SABR (1 x 20 Gy, 3 x 8 Gy or 5 x 6 Gy) in combination with anti-CTLA-4 in two 
poorly immunogenic tumour models and observed a growth delay of the irradiated 
tumour in all treatment schedules. However, an anti-tumour effect outside the 
radiation field (abscopal effect) was only observed for the combination of anti-CTLA-4 
with fractionated RT (3 x 8 Gy). Furthermore, Verbrugge et al. (41) investigated a 
combination of antibodies against the immune modulators CD137 and PD-1, in 
combination with single dose (12 Gy) or fractionated (4 x 4 or 5 Gy) radiotherapy in an 
orthotropic mice model. Antibody combination therapy with single dose RT was 
effective and the combination with either 4 × 4 Gy or 4 × 5 Gy showed tumour rejection 
rates of 40% and 80%, respectively. Furthermore, combination of single dose (12 Gy) RT 
with anti-PD-L1 treatment activated a cytotoxic T cell response, which resulted in 
tumour regression. An additional explanation for the local tumour control is the 
reduction of local accumulation of myeloid-derived suppressor cells (42). Additionally, 
RT has been shown to reduce tumour growth within and outside the radiation field 
when combined with the DC growth factor Flt3-L (43), the human macrophage 
inflammatory protein-1 alpha variant (ECI301) (44) or with IL-2 administration (45, 46). 
Experiments with syngeneic tumour-bearing mice showed that blocking AnnexinA5 
resulted in decreased DC clearance by macrophages, improved tumour immuno-
genicity, and combination with RT led to an effective tumour growth inhibition (47). 
Recently, RT combined with adenoviral-mediated vaccination against the colorectal 
cancer antigen GUCY2C resulted in a specific T cell response leading to tumour 
eradication (48).  
Clinical results 
There are limited clinical results on the combination of SABR with immunotherapy. 
Postow et al. (24) were the first to observe an anti-tumour immunologic rejection of a 
metastatic lesion at distance from the irradiated site and more reports followed (49-51). 
In parallel, several phase II/III clinical trials have been conducted leading to recent 
publications. The phase I/II study in patients with mCRPC found ipilimumab ± 
radiotherapy to induce anti-tumour activity with disease control and manageable side-
effects (52). However, Kwon et al. (53) randomized between ipilimumab or placebo 
after radiotherapy in mCRPC patients and found no difference in terms of overall 
survival. Several clinical studies on combining immunotherapy (ipilimumab, PD-1 and 
PD-L1) with (stereotactic ablative body) radiotherapy in diverse solid tumours (i.e., 
melanoma, CRC, HNSCC, cervical cancer, (non-) small cell lung cancer, prostate and 
pancreatic cancer) are currently being conducted and results are awaited eagerly 
(www.clinicaltrials.gov). 
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CONCLUSION 
In conclusion, these data show that immunogenic cell death caused by different 
strategies of RT can be used in combination with immunotherapy to induce a CD8+ T 
cell mediated anti-tumour response, which leads to tumour control of the irradiated 
tumour and often to tumour control outside the radiation field, i.e., an abscopal effect 
in different preclinical models. However, there is not yet a uniform combination 
strategy for the best RT schedule/dose and immunotherapeutic approach. Furthermore, 
these preclinical studies often show no effect when immunotherapy is used without RT, 
suggesting that RT plays a key role as immunogenic trigger, which can be further 
enhanced when boosting the immune system. Clinical studies are focusing on different 
immunotherapies, often trying to activate or prolong specific anti-tumour T-cell 
responses, showing promising responses. However, the administration of immuno-
therapy adjuvantly to RT thus activating or prolonging T-cell responses specific to the 
irradiated tumour may increase the immune response inside the radiation field and at 
metastatic sides. Therefore, it may be important to start with a trigger received from 
SABR before administrating immunotherapy, because of the ‘priming’ role of RT in this 
anti-tumour process.  
 
 
Immunogenic cell death by SABR. SABR can induce immunogenic cell death by the release of tumour antigens 
and damage associated molecular patterns (DAMPS), including high-mobility group protein B1 (HMGB1),
adenosine triphosphate (ATP), Fas, ICAM-1 and the exposure of calreticulin on the tumour cell surface. These 
factors promote uptake of dying cells by dendritic cells, cross-presentation of antigens to CD8+ T cells and
activation of cytotoxic T cells. However, it is unlikely that radiotherapy alone provides a sufficient anti-tumour 
immune response. The addition of immunotherapy that stimulate DC’s, such as Flt3-L or that activate and 
prolong T cell responses, including anti-CTLA-4, anti-PD-1 or anti-CD137 can be combined with SABR to
increase therapeutic potential and abscopal effects in a more systematic way. 
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ABSTRACT  
Radiotherapy (RT) causes the release of tumour antigens activating the immune system, 
which can be enhanced by interleukin-2 (IL2) immunotherapy. L19 targets the extra 
domain B (ED-B) of fibronectin, a marker for tumour neo-angiogenesis, and can be used 
as immunocytokine when fused to IL2 (L19-IL2). We hypothesized that RT in 
combination with L19-IL2 provides an enhanced anti-tumour effect, dependent on ED-B 
expression. In mice bearing syngeneic C51 colon carcinoma, Lewis lung carcinoma (LLC) 
or 4T1 mammary carcinoma, having high, intermediate or low ED-B expression, 
respectively, tumour growth delay and immunological mechanisms were evaluated 
after local tumour irradiation combined with systemic administration of L19-IL2 or 
equimolar controls. The combination therapy (RT+L19-IL2) showed a long-lasting 
synergistic effect for the C51 model with 9 of 12 tumours cured, an additive effect for 
the LLC model and no additional effect for the 4T1 model. Depletion of CD8+ T cells in 
consecutive experiments prevented the beneficial effects of RT+L19-IL2 co-therapy. To 
our knowledge, these data provide the first evidence for an increased therapeutic 
potential by combining RT with L19-IL2 and legitimates further evaluation in phase-I 
clinical studies.  
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INTRODUCTION 
Radiotherapy (RT) causes cell cycle arrest or programmed cell death in rapidly 
proliferating cancer cells through the induction of DNA damage. Irradiated tumours 
stimulate the immune system by releasing tumour antigens, damage associated 
molecular patterns (DAMPs), and an upregulation of immunomodulatory cell surface and 
secretory molecules (1-3). This promotes the uptake of dying cells by antigen presenting 
cells, and provides cross-presentation of the tumour-derived antigens to T cells, thereby 
triggering a cytotoxic T-lymphocyte response, which might cause immunogenic cell death 
(ICD) (1, 4, 5). In some cases, tumour growth inhibition outside the field of radiation is 
observed, termed abscopal effect, which suggests the presence of a systemic radiation-
induced anti-tumour immune response (6-9). However, in general, it is unlikely that 
radiotherapy alone provides a sufficient anti-tumour immune response. Therefore, the 
addition of active immunotherapy (IT) may increase the therapeutic potential (10-12). 
Active immunotherapy is used to stimulate the immune system acting against tumour 
cells. Cytotoxic T-lymphocytes and Natural Killer (NK) cells play an important 
complementary role in the anti-tumour immune response since they release specialized 
lytic granules, which upon interaction with the tumour cell create pores in the lipid 
bilayer of the target cell resulting in cell death (13, 14). Interleukin-2 (IL2) is a cytokine 
with an essential role in the activation phase of the immune response; it stimulates the 
proliferation of cytotoxic T cells, NK cells and regulatory T cells, providing a balance 
between a pro- and anti-inflammatory immune response (15, 16). Systemic 
administration of IL2 was introduced as immunotherapy for patients with metastatic 
melanoma and renal cell carcinoma, which resulted in a higher tumour response and 
survival (17). However, to reach an effective intra-tumoural dose of IL2 by systemic 
administration, high doses ought to be administered, which often leads to toxicity (e.g. 
capillary leakage syndrome, severe flu-like symptoms, and coma) (18). Currently, the use 
of intra-tumoural injections of IL2 are investigated to reach a higher local concentration 
of IL2 (19, 20), which shows promising results in combination with RT in a preclinical 
setting (21), however these intra-tumoural injections are limited to accessible lesions. 
An interesting alternative is the selective delivery of IL2 to the tumour by use of fusion 
proteins (15, 22). During tumour progression, synthesis of extracellular matrix 
components occurs, with in particular a modulation of vascular cell behaviour and 
angiogenesis (15). Fibronectin of the tumour neovasculature expresses extradomain-B 
(ED-B), which is preserved in mouse, human and other mammals. ED-B expression can 
be used for targeted therapies because it is over-expressed in various solid tumours 
(e.g. melanoma, RCC, breast, colorectal, and non-small cell lung cancer), but absent in 
plasma and normal tissue fibronectin (except for regenerating tissues) (23-28). The 
small-immuno-protein (SIP) L19 was developed to specifically target the ED-B domain of 
fibronectin. In previous studies L19 was used for imaging and targeted (radio-) 
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immunotherapy, proving that L19 actually targets the tumour (29-31). Moreover, in 
phase I clinical studies in patients with metastatic melanoma or RCC, administration of 
the immunocytokine L19-IL2 solely or combined with chemotherapy (dacarbazine) was 
safe and showed clinical activity according to RECIST criteria or progression-free-survival 
(32, 33). Dacarbazine has however not the potential to induce an anti-tumour immune 
response, stimulate the exposure of DAMPs or activate ICD (34), which are all 
favourable characteristics induced by RT. Therefore, based on the known immunogenic 
effects of RT and the targeted immune stimulating potential of L19-IL2, we hypothesize 
that the combination of radiotherapy with L19-IL2 will cause an enhanced anti-tumour 
effect, which is dependent on the expression of ED-B. 
RESULTS 
Representative sections of the ED-B expression in the C51, LLC and 4T1 tumours and 
their respective fluorescent intensity, corrected for the intensity of the negative controls 
are shown in figure 1. We observed a high, intermediate and low ED-B expression for the 
C51 (451±99), LLC (326±70) and 4T1 model (157±143), which were significantly different 
from each other (all P<0.01). For none of the treatment combinations, toxicity was 
observed based on body weight measurements and animal well fare monitoring. 
Figure 1 High, intermediate and low ED-B expressing tumour models. A: ED-B expression for C51 colon carcinoma, 
Lewis Lung Carcinoma (LLC) and 4T1 mammary carcinoma. ED-B expression is detected by L19(sip) biotinilated
(green), vessels by anti-CD31 (red) and cell nuclei (DAPI staining) in blue. Scale bar 100 µm B: Quantification of the 
ED-B expression (intensity) is corrected for negative control (KSF(sip) biotinilated). ** P<0.01, ***P<0.001.  
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Combination therapy results in complete remission of 75% in the C51 model. 
We evaluated the time to reach 4 times start volume (T4xSV) for all treatment groups in 
the C51 model with high ED-B expression. L19, IL2 or L19-IL2 monotherapy increased 
the T4xSV to 6.1±0.9 (P<0.01), 6.3±1.2 (P<0.01) and 6.0±1.6 days (P<0.05), respectively, 
as compared to the vehicle (4.8±0.8 days) treated C51 tumour-bearing animals, while 
no significant differences between these three treatment groups were observed. Single-
dose radiotherapy (10Gy) significantly enhanced tumour growth delay when preceding 
vehicle (P<0.001), L19 (P<0.001) or IL2 (P<0.001) treatment. Upon combination with 
L19-IL2 therapy, a highly significant (P<0.0001) synergistic anti-tumour effect was 
observed with 9/12 cures (Figure 2A). Reduction of the single-dose radiations to 5 or 2 
Gy showed a dose-dependent treatment effect. For tumours treated with the 
combination of ionizing radiation and L19-IL2, a cure rate of 6/12 and 1/12 was 
observed for irradiation with 5 Gy (P<0.001) and 2 Gy (P=0.002), respectively, as 
compared to the combination with vehicle treatment (Figure 2B). 
FACS analysis was performed to evaluate the underlying immunological parameters. 
The percentage of baseline cytotoxic T cells in the tumour was 22.2±9.2% of CD45+ cells 
in vehicle treated animals. Radiotherapy slightly enhanced the cytotoxic T cell 
subpopulation (28.1±5.7%), however, without being significant (P=0.24). The 
percentage of cytotoxic T cells during combination treatment was significantly higher 
than in vehicle (38.6±10.8%, P<0.01) or L19-IL2 only (22.0±8.8%, P=0.01) treated 
animals. There was no significant difference in the CD45+ population in the tumour 
between different treatment groups. In addition, no significant differences were 
observed in NKp46+ NK cells, CD4+ T cells or CD19+ B-cells between the treatment 
groups (Figure 2C and Supplementary Table 1). Flow cytometry of the lymph node and 
spleen tissue showed no significant difference for any of the analyzed immune 
subpopulations (CD8+, CD4+, CD19+ and NK; Supplementary Table 1).  
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Figure 2: Combination therapy results in complete remission of 75% in the C51 model. C51 colon carcinoma 
model. A: Fraction of tumours not reaching 4 times start-volume (T4xSV). B: Time to reach 4 times start 
volume for the different treatment groups. C: Results of flow cytometry analysis, shown is the percentage of
CD8+ and NKp46+ cells of all CD45+ cells present in the tumour. Data represent the mean of n = 6 - 12 
tumours. *p<0.05, **p<0.01, ***p<0.001. 
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Combination therapy results in increased growth delay in LLC model. 
Next, we investigated the possible therapeutic effect of combined RT with L19-IL2 in the 
LLC model with intermediate ED-B expression. There was no significant difference in 
tumour growth delay for L19 (4.3±1.2 days) or IL2 (5.1±1.1 days) compared to vehicle 
(4.4±1.1 days) treated animals. L19-IL2 monotherapy resulted in a significant tumour 
growth delay (P=0.02), increasing T4xSV to 6.0±1.4 days. Single-dose radiotherapy (10 
Gy) only showed an increased growth delay (6.9±2.0 days; P=0.02), however, the 
combination of RT with L19-IL2 resulted in the largest growth delay (10.5±2.6). This was 
significantly longer than after RT or L19-IL2 only (P<0.01 and P<0.001, respectively; 
Figure 3A, 3B). There was no significant interaction between RT and L19-IL2 (2-way 
ANOVA; P=0.15), the effect of the combination therapy in LLC was additive. 
The observed baseline percentage of cytotoxic CD8+ T cells in this LLC model was 
significantly lower than in the C51 model (P=0.002). The number of cytotoxic T cells as a 
percentage of CD45+ cells increased significantly upon L19-IL2 treatment: from 
2.7±1.0% (vehicle) to 7.4±4.1% (L19-IL2, P=0.04), and from 1.9±0.8% (RT) to 4.4±2.6% 
(RT+L19-IL2, P=0.04; figure 3C). Radiation caused a significant decrease in the 
percentage of CD19+ and CD4+ cells in the tumour compared to vehicle treatment 
(Supplementary Table 1). No differences were observed in the percentage of NKp46+ 
cells in the tumour (Figure 3A, 3B). Analysis of the lymph nodes and spleen tissue 
showed no significant differences (Supplementary Table 1). 
In the low/negative ED-B expressing 4T1 model, the addition of L19-IL2 to 
radiotherapy has no effect.  
Next, we investigated if L19-IL2 had any off-target effects using the low ED-B expressing 
4T1 model. For the 4T1 model, no statistically significant differences were observed 
between vehicle, IL2 and L19-IL2 treated animals, with an average T4xSV of 7.9±2.8, 
8.7±1.6 and 9.2±2.4 days, respectively. Single-dose radiotherapy (10 Gy) increased 
growth delay significantly for all treatment groups: RT + vehicle (13.3±3.7 days, P=0.01), 
RT + IL2 (17.0±5.4 days, P<0.01) or RT + L19-IL2 (17.7±4.2 days, P<0.001), however, no 
statistically significant differences (P=0.47 and P=0.59) were observed between these 
irradiated groups (Figure 3A, 3B). There is no significant interaction between RT and 
L19-IL2 (2-way ANOVA; p=0.20). 
Radiotherapy caused a significant increase in the presence of CD8+ T cells in the 4T1 
tumour. The percentage of CD8+ T cells increased from 6.9±1.8 (vehicle) to 18.0±12.6 
(RT + vehicle, P=0.04) and from 6.4±2.9 (L19-IL2) to 14.2±6.4 (RT + L19-IL2, P<0.01). 
Albeit, no significant differences (P=1.0) were observed for L19-IL2 treated animals 
compared to vehicle. No significant differences were observed for the percentage of NK 
cells in the tumour for any of the treatment groups (Figure 3C). The percentage of 
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CD19+ cells were significantly higher for treatment with L19-IL2 alone (4.0±1.6) 
compared to vehicle (2.5±0.6, P=0.03), RT + vehicle (2.0±0.7, P=0.02) and RT + L19-IL2 
(1.6±1.2, P=0.04; Supplementary Table 1). Analysis of the spleen and lymph nodes 
showed no significant difference for any of the analyzed immune cells. 
 
 
Figure 3: Combination therapy: Additive effect in LLC model (intermediate ED-B) and no effect in the 4T1 
model (low ED-B). Lewis Lung Carcinoma (LLC), and 4T1 mammary carcinoma model. Survival curves LLC
model (A) and 4T1 model (D), showing the fraction of tumours not reaching 4 times start-volume (T4xSV).
Scatter-plots LLC model (B) and 4T1 model (E), showing the time to reach 4 times start volume (T4xSV). Flow
cytometric analyses of tumour leukocyte content in the LLC (C) and the 4T1 (F) model, showing the 
percentage of CD8+ and NKp46+ cells of al CD45+ cells in the tumour. *p<0.05, **p<0.01, ***p<0.001.  
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Depletion of cytotoxic T cells prohibits complete remission.  
Based on our observation that radiotherapy + L19-IL2 immunotherapy significantly 
increases the CD8+ T cell subpopulation, we assessed the causal relationship between 
the therapeutic effect and CD8+ T cells by depleting the CD8+ T cells in the C51 tumour 
model. Tumour cell injection did not result in changed immune subpopulations 
(Supplementary figure 4B). Treatment with the CD8+ T cell depleting (JTS169) antibody 
abolished CD8+ T cells in the blood 2 days after injection (0.06±0.06%; >99% depletion). 
Cytotoxic CD8+ T cells were detectable again at day 3 (1.6±0.7%) after depletion and 
levels increased over time to 5.7±3.0% at day 5 (Figure 4A). On the basis of these data 
we opted for 3-daily administration of CD8+ depleting antibody in order to effect 
sustained ablation of CD8+ T cells (Figure 4B). After depletion (3 days p.i.), the CD8+ T 
cell population was significantly reduced in blood (P<0.0001), whereas, the control 
groups receiving either isotype IgG (15.7±0.9%) or vehicle (18.1±3.1%) showed similar 
numbers of CD8+ cells as baseline (Figure 4C). CD8+ T cells were also depleted in the 
tumour (2.2±2.6%, vs 38.6±10.8% at baseline; Figure 4D), spleen and lymph nodes 
(Supplementary Figure 4). Upon depletion of cytotoxic T cells, the combination of 
radiotherapy with L19-IL2 lost its therapeutic effect (T4xSV=11.25±3.0d) and was not 
superior (P=0.31) to radiotherapy only (T4xSV=10.0±3.0d). However, in agreement with 
previous results, the animals in the control groups (without CD8+ T cell depletion), still 
showed sustained anti-tumour effects (IgG: cure 5/8, vehicle: cure 3/8) after 10 Gy 
irradiation and L19-IL2 (Figure 4E). 
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Figure 4: Depletion of cytotoxic T cells prohibits complete remission. CD8 depletion in the C51 model. A: % of 
CD8+ cells of CD45+ cells 2, 3 and 5 days after single i.p. anti-CD8 administration. B: Cartoon of treatment 
schedule. C: % CD8+ cells of CD45+ cells 3 days after i.p. anti-CD8, IgG or PBS (vehicle) and an example of the
flow cytometry results showing the percentage of CD3+CD8+ cells present in the blood 3 days after anti-CD8 or 
IgG administration. D: % of CD8+ cells present in the tumour of CD8 depleted and non-depleted mice treated 
with RT and L19-IL2 analyzed by flow cytometry and an immunofluorescent CD8 staining (green), cell nuclei
stained with DAPI (blue). E: Fraction of tumours not reacting 4x start volume (T4xSV) and time to reach T4xSV
for the different treatment groups. *p<0.05, **p<0.01, ***p<0.001 
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DISCUSSION 
Radiation-induced cell death is an immunogenic process which can be used to initiate 
tumour-specific immune responses (35). The selective delivery of IL2 to tumour vascular 
components is promising in cancer immunotherapy (15, 36, 37) and may be used to 
enhance the therapeutic potential of RT. We hypothesized that the combination of RT 
with the targeted immunocytokine L19-IL2 may cause an enhanced anti-tumour effect 
dependent on the expression of ED-B. In this study, we assessed the therapeutic 
potential and underlying mechanisms of the combination therapy in three different 
tumour models with varying ED-B expression. 
Based on growth delay experiments, the combination therapy showed a therapeutic 
gain compared with the single treatment arms with an additive effect for the LLC model 
and a long-lasting highly synergistic effect for the C51 model for which a cure rate of 
75% was observed. As expected no effect was observed for the 4T1 model, which has a 
low ED-B expression. The results show that ED-B expression is essential for the efficacy 
of combined irradiation and L19-IL2 administration. The C51 model showed the highest 
ED-B expression and the most promising results for the combination therapy suggesting 
that high ED-B expression may assure a better L19-IL2 tumour targeting. Like our C51 
model, ED-B is overexpressed in many solid tumours (23-25, 27, 37), which makes this 
combination therapy (RT + L19-IL2) potentially interesting for the majority of cancer 
types.  
The highly synergistic effect observed in the C51 model upon radiotherapy and tumour-
targeted L19-IL2 treatment is in agreement with previous results described by Yasuda et 
al. (21). They observed a complete eradication of a colon carcinoma cell line (Colon26) 
in Balb/c mice after the combination of radiotherapy with intra-tumoural injections with 
IL2. For the models presented in this study, no additional benefit was observed for the 
use of the single treatment with L19-IL2 in comparison to IL2 treatment. This is in 
contradiction with the results from previous studies, showing that L19-IL2 provides a 
stronger anti-tumour effect compared with equimolar dosing of untargeted IL-2 in an F9 
teratocarcinoma or a human pancreatic carcinoma xenograft model (15, 38). This might 
be explained by the use of different mouse strains, tumour models and treatment 
schedules. However, in combination with radiotherapy, we did find a stronger anti-
tumour effect when using L19-IL2 compared to IL2. This shows that, in agreement with 
previous results, L19-IL2 has an increased anti-tumour effect.  
Upon combination therapy an increased number of cytotoxic T cells was observed in the 
tumour of the LLC and C51 model. A comparison between the used models shows that 
already at baseline, the number of cytotoxic T cells is higher for the C51 model than for 
the LLC and 4T1 models. Results are in agreement with previous publications, where it 
was already shown that, dependent on tumour model, the efficacy of IL2 treatment can 
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be based on T cells (39, 40), or a combination of NK and T cells (15). In mice bearing C51 
colon carcinoma, L19-IL2 as single treatment already showed an increased number of 
tumour-infiltrating cytotoxic T- and NK cells in immunohistochemical analysis (15), 
which was confirmed in the clinical setting where both cell types were up-regulated in 
the peripheral blood of patients as a result of L19-IL2 treatment (32). Johnson et al. (41) 
combined an alternative immunocytokine, KS-IL2, with radiofrequency ablation in a 
murine colon adenocarcinoma (CT26). The combination increased growth suppression, 
and a greater proportion of CD4+ and CD8+ cells was observed. Furthermore, the 
therapeutic effect of IL2 coupled to the human monocloncal antibodies F8 and F16 that 
recognize the ED-A and ED-B domains of fibronectin and the A1 domain of tenascin-C, 
respectively, was shown to be mediated by CD8+ and NK cells in an in vivo AML model 
(42). Moreover, the antibody-based targeted delivery of IL4 and IL12 to tumour 
neovasculature has also shown to eradicate tumours by both NK and CD8+ T cells (43). 
In our study, we irradiated the tumours prior to administration of the immunocytokine 
L19-IL2. It is known that radiotherapy can promote a DC-mediated cytotoxic T-
lymphocyte (CTL) response, the so-called immunogenic cell death (44). This form of cell 
death may be further enhanced by the targeted delivery of IL2 to the irradiated 
tumours. Our combination therapy may therefore favour the CTL response, because NK 
cells are able to detect and destroy malignant and virally infected cells directly (14). 
Indeed we have shown that depletion of the cytotoxic T cells in the C51 model inhibits 
the anti-tumour effect after combination therapy, providing evidence that the complete 
remission observed in the majority of C51 tumours, is attributed to the high number of 
cytotoxic T cells present in the tumour after combination therapy.  
Evidence suggests that local radiation always elicits activation of the immune system, 
even though the proportion of tumour cells undergoing immunogenic cell death will 
vary (4, 6). Demaria et al. (6) showed that a single low dose of RT (2Gy) in combination 
with Flt3-Ligand (enhancing the number of available dendritic cells) could already 
trigger anti-tumour T cell responses. To test this hypothesis in our study, the 
radiotherapy dose was reduced from 10Gy to 5Gy or 2Gy for the C51 model. The 
decrease in dose of irradiation resulted in a reduced number of tumour eradications, 
showing that in this model and experimental set-up the radiotherapy dose is an 
important parameter to generate cure. We therefore suggest that a minimal 
radiotherapy dose is necessary to provide sufficient immunogenic cell death to trigger 
the anti-tumour immune response. In our experiments, we only tested one single RT 
dose in combination with L19-IL2, showing excellent results. Therefore we expect that 
the use of a few high doses of radiotherapy (SBRT) is sufficient to release DAMPs and 
initiate the anti-tumour immune response, while limiting the damage to essential 
immunological (CD8+) cells. In a previous clinical trial, Seung et al (45) combined SBRT 
with systemic IL2 in patients with metastatic melanoma or RCC, this provided already a 
higher response rate compared to historical data. Based on our results the use of L19-
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IL2, instead of systemic IL2, will increase the potential and decrease toxicity. Therefore 
the clinical set-up combining SBRT with L19-IL2 seems very promising and will be 
investigated in a clinical trial (NCT02086721). 
Since ED-B has an identical amino sequence in mice and humans, the human single 
chain Fv monoclonal antibody fragment L19 combined with IL2 can be directly used in 
clinical setting. In Phase I trials, L19-IL2 was already safely administered in melanoma 
and renal cell carcinoma, even in combination with decarbazine, which is not an ICD 
inducer like RT (32-34). Based on our current results that ED-B expression is essential to 
obtain a therapeutic benefit, L19-SIP imaging should be included in a clinical trial set-up, 
to evaluate the possibility to select patients for L19-IL2 treatment. The ultimate aim is 
however to increase progression fee survival by the irradiation of accessible, larger solid 
tumours/metastasis, initiating an anti-tumour immune response which will attack the 
solid lesions and its micro-metastasis.  
In conclusion, the combination therapy of RT with L19-IL2 can enhance the immune 
response against diverse solid tumours, providing an additive or synergistic anti-tumour 
effect in the presence of ED-B. These findings can directly be translated to a Phase I 
clinical study in patients with an oligometastatic solid tumour, since the use of L19-IL2 is 
proven to be safe in patients. This promising new opportunity for cancer treatment is 
subject of clinical investigation. 
MATERIALS AND METHODS 
Tumour cell lines. 
Exponentially growing C51 colon carcinoma (kindly provided by Philogen S.p.A., Siena, 
Italy), Lewis lung carcinoma (LLC; kindly provided by G. Molema, UMCG, The 
Netherlands), and 4T1 mammary carcinoma (ATCC CRL-2539) cell lines were cultured in 
Dulbecco's Modified Eagle Medium (DMEM; Lonza) supplemented with 10% fetal calf 
serum (FCS) in a humidified 5% CO2 chamber at 37 °C. 
Chemicals/reagents/antibodies. 
The L19-IL2 immunocytokine and L19 (Philogen S.p.A.) were diluted with sterile 
phosphate buffered saline (PBS, Lonza) to concentrations of respectively 200µg/ml and 
133µg/ml. Interleukin-2 (Proleukin, Novartis, Basel, Switserland) was dissolved as 
described by the manufacturers’ guidelines and diluted with PBS to a concentration of 
67µg/ml.  
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For the depletion experiments, the anti-CD8 antibody (Clone JTS169) and the isotype 
control (anti-Phyt IgG AFRC MAC 51), kindly provided by Bioceros Bv, Utrecht, The 
Netherlands, were diluted with PBS to a concentration of 2mg/ml.  
Flow-cytometric analysis was performed on cells exposed to RBC lysis buffer 
(eBioscience, San Diego, CA), FC-block CD16/CD32 (BD Biosciences, San Jose, CA) and a 
combination of the antibodies CD3-FITC, CD4-APC-H7, CD8-PE-CY7, CD19-PE, CD45-
V500, CD45-Percp, CD45-PE, CD45-FITC, CD45-APC, CD45-PE-CY7, CD3e-eFLUO450, 
CD4-FITC, CD8a-V500 (BD Biosciences) and NKp46-APC (Miltenyi Biotec B.V., Leiden, 
The Netherlands).  
In vivo experiments.  
All experiments were performed in accordance with local institutional guidelines for 
animal welfare and were approved by the Animal Ethical Committee of the University of 
Maastricht. To induce tumours, approximately 8 weeks old immune competent mice 
were subcutaneously injected with syngeneic C51 (Balb/c; 1.5x106), LLC (C57bl/6; 
0.5x106) or 4T1 (Balb/c; 1x106) tumour cells, resuspended in Basement Membrane 
Matrix (MatrigelTM, BD Biosciences). Upon an average tumour volume of 200 mm³, 
tumours were irradiated with a single dose (10 Gy for all models, additional groups with 
2 and 5 Gy for C51) on day 0, followed by systemic therapy (vehicle PBS / L19 13.3µg / 
IL2 6.7µg / L19-IL2 20µg) on day 1, 3 and 5. Tumour growth and treatment toxicity 
(based on body-weight) were monitored until reaching 4 times the volume at irradiation 
time (T4xSV). Flow cytometry was performed on tumours, spleen and lymph nodes 
excised at day 4 of the treatment schedule. Detailed treatment schedules are shown in 
supplementary figure 1. 
To evaluate the causal relationship between the presence of cytotoxic T cells and 
tumour growth delay, an experimental set-up was designed to deplete cytotoxic-T cells 
in the Balb/c mice bearing C51 tumours. Similar to previous experiments, local 
irradiation was performed on day 0 (10 Gy) and systemic therapy (vehicle or L19-IL2) 
was administrated (day 1, 2, 5). In addition, CD8+ cells were depleted by intraperitoneal 
injection of 0.2 mg (100µL) anti-CD8 antibody or the negative control anti-Phyt IgG. The 
timing for the anti-CD8 injections was determined by blood withdrawal, via puncture of 
the saphenous vein (i) before, (ii) after tumour cell injection and (iii) 2,3 or 5 days after 
injection with the blocking antibodies. The percentage CD8+ cells in the blood was 
determined as described below. At the end of the experiment the tumours were 
harvested for immunohistochemical analysis for CD8 positivity. 
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Flow cytometry. 
The number of immune cell subpopulations present in tumour, spleen and lymph nodes 
during treatment was analyzed using FACSCanto II flow cytometry (FACS, BD 
Biosciences). Single cell suspensions of the tissues were obtained using the gentleMACS 
dissociator and the tumour dissociation kit (Miltenyi Biotec B.V.) according to 
manufacturer’s guidelines. Of the acquired single cell suspension, 1.0x106 cells were 
suspended in FACS buffer (PBS + 1% FCS) for analysis. Cells were incubated with FC-
block to avoid non-specific binding and staining was performed using the antibodies 
CD3-FITC, CD4-APC-H7, CD8-PE-CY7, CD19-PE, NKp46-APC and CD45-V500. The total 
CD45+ immune cells were selected from the viable population of cells (filtered for debris 
and doublets) for further sub-classification according to the strategy described in 
supplementary figure 2.  
To determine the efficacy of anti-CD8 blocking antibody on the presence of specific 
immune subpopulations, collected blood was incubated with RBC lysis buffer and FC-
block. Next cells were incubated with CD45-Percp, CD3e-eFLUO450, CD4-FITC, CD8a-
V500, NKp46-APC and CD19-PE, and FACS and data analysis was performed 
(Supplementary Figure 3).  
Immunofluorescence. 
To investigate baseline ED-B expression, 7mm cryostat sections of C51, LLC and 4T1 
tumours were fixed in acetone (4°C) and stained according to previous published 
methods (46). In brief, sections were incubated with the purified antibodies L19-SIP or 
KSF-SIP (2ug/ml; Philochem, Otelfingen, Switzerland), with rabbit anti-human-IgE (Dako, 
Glostrup, Denmark) and subsequently detected using goat anti-rabbit IgG Alexa Fluor 
488 (Life Technologies, Bleiswijk, The Netherlands). Blood vessels and cell nuclei were 
detected with rat anti-mouse CD31 (BD Biosciences) followed by donkey anti-rat Alexa 
594 (Life Technologies) and DAPI (Life Technologies), respectively.  
To quantify the ED-B expression, 3-12 photomicrographs (805.5 µ x 805.5 µ), depending 
on tumour size, from viable tumour regions in the largest tumour cross-section were 
acquired using an Olympus BX51WI (Center Valley, PA) fluorescence microscope 
equipped with a Hamamatsu EM-CCD C9100 digital camera, a motorized stage (Ludl 
Mac 2000) and a 10x objective. Micromanager 1.4 software was used for automated 
image acquisition (47). All image recordings were performed with the same settings and 
analyzed by an investigator blinded to the subject coding. Images were processed using 
ImageJ software v.1.49b (NIH, Bethesda, MD). The mean fluorescent intensity after 
correction for cutting and staining artefacts per image was averaged over all images per 
section to obtain ED-B intensity per tumour.  
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For the detection of CD8+ T cells residing in tumours, sections were first incubated with 
anti-CD8 (clone 53.62.7, Department of Pathology, MUMC, Maastricht, The Netherlands) 
and visualized with goat anti-rabbit IgG Alexa Fluor 488 (Life Technologies). DAPI was 
used as nuclear counterstain.  
Statistics. 
Statistical analyses were performed using GraphPad Prism Software (v5.03, San Diego, 
CA). For all parameters mean ± standard deviation (SD) are reported. The non-
parametric Mann-Whitney test was used to determine the statistical differences 
between the different treatment groups. The log-rank (Mantel-Cox) test was used to 
compare the survival curves. We used a 2-way ANOVA to test the interaction 
(synergism) between radiotherapy and L19-IL2. A p-value smaller than 0.05 was 
considered statistically significant. 
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Supplementary figure 1: Treatment schedules used in in-vivo experiments. A: Schedule used for follow-up of 4 
times starting volume of the tumours. B: Schedule used for flow cytometry and fluorescent stainings, mice are
sacrificed at day 4. 
 
 
Supplementary figure 2: FACS gating strategy (tumour). Gating strategy used for flow cytometry analysis of
tumors, lymph nodes and spleens, shown is the gating for a tumour. 
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Supplementary figure 3: FACS gating strategy (blood). Gating strategy used for flow cytometry analysis of 
blood in CD8 depletion experiment. 
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Supplementary figure 4: Cytotoxic T cells (CD8+) as a % of CD45+ cells. A: % of CD8+ T cells of CD45+ cells in 
spleens or lymph nodes after CD8 depletion (anti-CD8 i.p.) compared with control mice (tumor bearing mice, 
treated with RT+L19-IL2 without CD8 depletion). Data are analyzed with flow cytometry. B: % of CD8+ T cells of 
CD45+ cells in the blood 6 days before and 1 day after tumor cell (Tc) injection. **p<0.01. 
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ABSTRACT 
Recently, we have shown that radiotherapy combined with L19-IL2 can induce a long-
lasting anti-tumour effect, dependent on ED-B expression and infiltration of cytotoxic T 
cells. These findings will be translated to a Phase I clinical study (NCT02086721) in 
patients with oligometastatic solid tumours. See this link for the animation:  
http://youtu.be/xHbwQuCTkRc. 
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AUTO-COMMENTARY 
Radiotherapy (RT) has several effects in the tumour micro-environment, it causes the 
release of a broad range of tumour-associated antigens and damage molecular patterns 
(DAMPs) and upregulates immunomodulatory cell surface and secretory molecules (1-
3). These changes can increase the immunogenicity of the tumour and promote the 
uptake of tumour antigens by antigen presenting cells that cross-present these tumour 
antigens to T cells, thereby triggering a cytotoxic T-lymphocyte response resulting in 
immunogenic tumour cell death (1, 3, 4). Unfortunately, this systemic immune response 
against tumour cells provoked by local tumour RT alone is mostly insufficient to totally 
eradicate all tumour cells. Therefore, the addition of active immunotherapy (IT) to 
enhance the effect of RT may be an interesting approach to enhance the therapeutic 
potential (5). 
The administration of IL2 as immunotherapy has the ability to stimulate and expand 
functional active T cells which has been shown to lead to durable and curative 
regressions in patients with metastatic melanoma and renal cancer (6). However, a 
major drawback of this immunotherapy is the occurrence of several toxicities (e.g. 
capillary leakage syndrome, severe flu-like symptoms and coma) and therefore targeted 
delivery of IL2 to the tumour could be used to overcome these side effects. The 
selective delivery of IL2 via the small-immuno-protein L19 to the ED-B domain, a part of 
the fibronectin of the tumour neo-vasculature, has shown to have excellent tumour 
targeting properties and an improved therapeutic index over IL2 treatment alone (7). 
Based on the known immunogenic effects of RT on tumours, the immune stimulating 
effects of IL2 and the possibility of targeted delivery via the immunocytokine L19-IL2, 
we recently demonstrated that a combination of RT with L19-IL2 causes an enhanced 
anti-tumour effect, dependent on ED-B expression (8).  
In our preclinical study, we used three immunocompetent mouse tumour models; a 
colon carcinoma (C51), the Lewis Lung Carcinoma (LLC) and a breast carcinoma (4T1) 
model showing respectively high, intermediate and low ED-B expression levels. 
Combination of RT with L19-IL2 resulted in long-lasting, highly synergistic effects with a 
cure rate of 75% in the high ED-B expressing model C51. Lowering the RT dose to 5 and 
2 Gy decreased the cure rate of the combination therapy to 50% and 8%, respectively. 
In the LLC model, we observed an additive effect when a single RT dose of 10 Gy was 
combined with L19-IL2 compared to single treatment arms. In addition, the expression 
of ED-B seemed to be crucial, since the combination treatment showed no additional 
therapeutic improvement in the low ED-B expressing model 4T1. Further investigation 
of tumour immune infiltrate showed a significant increase of CD8+ cytotoxic T cells in 
C51 and LLC tumours treated with RT and L19-IL2, suggestion a pivotal role for these 
immune cells. Indeed, when depleting CD8+ cells in vivo using the same preclinical 
experimental setting as in the C51 model, no benefit of the combination therapy could 
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be observed, providing evidence that the complete remission of these C51 tumours is 
attributed to the presence and activity of cytotoxic T cells (8). Taken together, we have 
shown that combination therapy of RT with L19-IL2 can enhance the RT induced anti-
tumour immune reaction, providing a long-lasting anti-tumour effect when ED-B is 
present. Since L19-IL2 is proven to be safe in patients, these findings will be translated 
to a Phase I clinical study (NCT02086721) in patients with oligometastatic solid tumours.  
The previous results provide a basis to understand the anti-tumour immune response 
after the combination therapy. However, it also provides potential new mechanisms to 
investigate in pre-clinical setting. One interesting mechanism is the abscopal effect, an 
anti-tumour effect observed in tumour cells located outside the radiation field, possibly 
mediated by the immune system (9). We hypothesize that the immune system is an 
important mediator of the abscopal effect, and therefore therapy of RT with L19-IL2 
may be an interesting combination to induce and investigate this phenomenon.  After 
RT, a broad variation of tumour-associated antigens is systemically released to function 
as an ‘in situ vaccination’ and therefore DC uptake of this antigen mixture might be 
responsible for the stimulation of a broad cytotoxic T-cell mediated anti-tumour 
response, recognizing several antigens expressed on the heterogenic tumour cell 
population. This can be beneficial in the treatment of multiple tumours and metastases, 
in and outside the radiation field. Furthermore, an important feature of the adaptive 
immune system is its memory, which leads to an enhanced response when re-
encountering the same antigen. It will be of major interest to investigate if cytotoxic T-
cells triggered by RT+L19-IL2 treatment are indeed able to recognize the same tumour-
associated antigens and kill the tumour cells after cure. In other words: do these 
cytotoxic T-cells have a memory potential? The proliferation of cytotoxic T-cells at the 
tumour site is of major importance for the development of a strong enough anti-
tumour immune response. However, it is known that hypoxic regions inside solid 
tumoirs can prevent an adequate anti-tumour immune response (10), possibly 
explained by the lack of infiltration of cytotoxic T-cells inside the hypoxic areas of 
treated tumours, suggesting that the combination of this novel treatment (RT+L19-IL2) 
with anti-hypoxia therapy might be successful.  
In conclusion, we have shown a cytotoxic T-cell response after RT+L19-IL2 leads to cure 
in the large majority of treated mice in the C51 model and new research should 
therefore focus on the cellular and molecular mechanisms underlying this effect as well 
as on combination treatment which can break the hypoxia immuno-sanctuary. 
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Figure 1: Radiotherapy causes a synergistic and long-lasting anti-tumour immune response when combined 
with L19-IL2. This response is dependent on the presence of ED-B in tumour blood vessels and on the 
presence of cytotoxic T cells inside the tumour. 
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ABSTRACT 
We recently have shown that the administration of the tumour-targeted immunocytokine 
L19-IL2 after radiotherapy (RT) resulted in synergistic anti-tumour effects. Here we tested 
the hypothesis that RT and L19-IL2 can activate a curative out-of-field radioimmune (OFRI) 
effect, with a long-lasting immunological memory. Ionizing radiation (15Gy, 5x2Gy or 
5x5Gy) was delivered to primary C51 colon tumour-bearing immunocompetent mice in 
combination with L19-IL2 and therapeutic efficacy was assessed on the secondary C51 or 
CT26 colon tumours. We show, for the first time, that only 15Gy + L19-IL2 can trigger a 
curative OFRI effect, which is T cell dependent. Moreover only RT + L19-IL2, and not 
surgery + L19-IL2 or high dose RT alone, results in long-lasting immunological memory, 
associated with CD44+CD127+ expression on circulating T cells. This combination treatment 
can induce highly specific and long-lasting curative OFRI responses, and therefore it has 
great potential for treatment of (oligo)metastatic disease  
(https://youtu.be/a0eJXn7wNVQ). 
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INTRODUCTION 
Radiotherapy (RT) is known to enhance the release of a broad range of tumour-
associated antigens and damage associated molecular patterns (DAMPs). It also 
stimulates the upregulation of immunomodulatory cell surface molecules. Together this 
results in the creation of a personified ‘in situ vaccine’ thereby initiating an immune 
response (1-3). These changes in tumour immunogenicity promote the uptake of 
tumour antigens by antigen presenting cells that cross-present the tumour antigens to T 
cells, thereby triggering a cytotoxic T-lymphocyte response (1, 3-5). In some cases, 
tumour regression outside the radiation field can be observed, a phenomenon known 
as the abscopal effect (6-10). Although the principle of the abscopal effect is intriguing, 
its clinical appearance is sporadic (11). It has been established that the RT-induced 
abscopal effect is immune mediated (12-17) and therefore the rationale of combining 
RT with immunotherapeutic approaches to further increase systemic anti-tumour 
effects has recently gained a lot of interest (18). 
The cytokine interleukin 2 (IL2) stimulates the proliferation and differentiation of 
cytotoxic, helper and regulatory T cells, and natural killer (NK) cells, resulting in a 
balanced pro- and anti-inflammatory immune response (19). IL2 treatment has shown 
durable and curative regressions in patients with metastatic melanoma, renal cancer 
and advanced non-Hodgkin’s lymphomas and represents the first effective 
immunotherapy (20, 21). However, further clinical systemic use has been hampered 
due to the appearance of several severe toxicities (e.g. capillary leakage syndrome, 
severe flu-like symptoms, and coma) (22). Specific targeting of IL2 to the tumour using 
the vehicle L19, an antibody fragment directed against the angiogenesis-associated B-
fibronectin isoform (ED-B) typically overexpressed in solid tumours, resulted in 
achieving high intra-tumoural IL2 doses without increasing toxicity (22). The 
immunocytokine L19-IL2 has been investigated in a randomized phase II clinical trial in 
patients with metastatic melanoma in combination with dacarbazine or with L19-TNFα 
(tumour necrosis factor) showing encouraging anti-tumour activity (23-27). 
Furthermore, tumour-specific (neo)antigens are important recognition sites for immune 
cells (28, 29) and since RT increases the tumour (neo)antigen expression it has great 
immunotherapeutic improving potential for all solid tumours (5). 
Recently, we have demonstrated that the combination of a single RT dose with L19-IL2 
resulted in long-lasting, highly synergistic anti-tumour effects with a cure rate of 75% in 
the high ED-B expressing C51 mouse colon carcinoma. Expression of ED-B by the 
tumour vasculature as well as infiltration of CD8+ T cells was crucial for this pronounced 
anti-tumour immune response (30). Similar to the C51 tumour model, ED-B is 
overexpressed in the majority of solid tumours (31-35), making this combination 
therapy of great interest. These highly synergistic preclinical findings resulted in the 
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initiation of a phase I clinical study in our institute (NCT02086721), in which stereotactic 
radiotherapy is combined with L19-IL2 in patients with oligometastatic tumours.  
Our ultimate goal is to increase overall survival in patients with systemic (metastatic) 
cancer. However, in this context, RT is assumed to be of limited use as it is difficult to 
apply in these patients: first due to wide spread tumour burden and secondly due to the 
fact that RT cannot be directed towards invisible (micro)metastases. In the current 
study, we have investigated for the first time the systemic and long-lasting anti-tumour 
effects elicited by RT combined with L19-IL2, providing us a unique insight into their 
synergistic interplay and induced immune responses. Since we have shown that the 
synergistic effect of RT + L19-IL2 against irradiated tumours is highly dependent on the 
immune system, we hypothesize that this combination therapy can elicit Out-of-Field 
RadioImmune (OFRI) effects targeting macroscopic tumours. This study provides us with 
exclusive knowledge about the OFRI effect, comparing fractionated and single dose RT, 
irradiated and non-irradiated tumours, responding and non-responding mice and 
differences in potential to induce long-lasting protection (memory effect). The latter is 
of great importance, since most conventional treatment options only work during and 
shortly after their administration, i.e. have transient effect. These in vivo data reveal the 
possibility to create a long-lasting OFRI effect and form the basis of a preclinical 
treatment recommendation towards curative treatment of systemic cancer.  
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RESULTS 
A single RT dose combined with L19-IL2 triggers a curative OFRI effect 
Previously, we have shown that a single RT dose of 10Gy resulted in 75% cure when 
combined with L19-IL2 in the high ED-B expressing C51 model, while 5Gy and 2Gy led to 
a cure rate of 50% and 8%, respectively(30). To test whether RT to the primary tumour 
combined with L19-IL2 has an anti-tumour effect on non-irradiated secondary tumours, 
i.e. can induce an OFRI effect, we first determined which RT dose and schedule resulted 
in maximal anti-tumour activity (100% cure) when combined with L19-IL2. Previously, 
we have shown that a single RT dose of 10Gy resulted in 75% cure when combined with 
L19-IL2 in the high ED-B expressing C51 model, while 5Gy and 2Gy led to a cure rate of 
50% and 8% respectively (30). Increasing the RT dose to 15Gy, resulted in 100% cure 
when combined with L19-IL2 (supplementary Fig. 1a), which was significantly higher 
than 15Gy + vehicle control (supplementary Fig. 1b). However, in clinical setting, RT is 
often given still in multiple fractions. Therefore, we additionally investigated L19-IL2 in 
combination with fractionated RT. Combining 5 fractions of 2Gy with L19-IL2 (days 1, 3, 
5) resulted in 100% cure of the primary tumours (supplementary Fig. 1c).   
Next, we investigated the therapeutic effect of 15Gy, 5 x 2Gy and 5 x 5Gy delivered to 
the primary tumour in combination with systemic L19-IL2 treatment on the non-
irradiated secondary tumours (Fig. 1a). The extra fractionated RT treatment arm, 5 x 
5Gy, was included because it is biologically equivalent to 15Gy single dose. Starting 
volumes of secondary tumours were similar across different treatment groups 
(supplementary table 1). Secondary tumours of mice treated with 15Gy + L19-IL2 
showed a significant (p=0.03) delay of median T4xSV (9.6 [4.3-26.4] days) as compared 
with 15Gy + vehicle (5.7 [5.1-8.9] days) with a cure rate of 20% (2/10) (Fig. 1b). Addition 
of L19-IL2 to 5 x 2Gy significantly (p=0.003) increased T4xSV of the non-irradiated 
tumours from 5.9 [3.1-7.7] days to 8.8 [5.7-17.6] days, to a similar extent as 5 x 5Gy + 
L19-IL2 (T4xSV of 10.1 [6.6-12.9] days). In contrast to 15Gy, none of the secondary 
tumours of the fractionated RT groups could be cured (Fig. 1b), demonstrating that a 
single high radiation dose is a better trigger of RT + L19-IL2 mediated curative OFRI 
effect.  
For a single 15Gy RT dose in combination with L19-IL2, we observed at day 4 a 
significantly (p=0.02) higher percent of CD4+ T cells inside secondary tumours (8.3% 
[2.9-42.3]) as compared with the primary tumours (2.0% [0.2-3.4]) (Fig. 1c). In addition, 
the percentage of CD4+ T cells in 15Gy + L19-IL2 treated tumours is significantly lower as 
compared with L19-IL2 treated tumours (4.1% [1.2-5.2], p=0.02). At this time point, no 
involvement of infiltrating CD8+ cytotoxic T cells could be observed (Fig. 1c).  
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Figure 1: Radiotherapy and L19-IL2 induced OFRI effects and associated immune infiltrate. (A) Experimental 
setup and schedule used for OFRI study. (B) The fraction of non-irradiated tumours not reaching 4 times start
tumour volume. (C) Representative back gating (red), FACS image showing intratumoural CD3+CD4+ cells of 
gated CD45+ cells of irradiated (L) and non-irradiated (R) tumours, a quantification of the intratumoural 
CD3+CD4+ and CD3+CD8+ cells and the experimental schedule used. Data represent the median. *p<0.05. 
The curative OFRI effect is dependent on CD4+ and CD8+ T cells and is tumour cell 
specific 
To assess the causal relationship between the anti-tumour OFRI effect and CD4+ T cells, 
we depleted the CD4+ T cells 5 days after RT (Fig. 2a, supplementary table 1). In 
addition, in a similar manner, the contribution of CD8+ T cells to the OFRI effect was 
evaluated. CD8+ and CD4+ T cells were successfully depleted 2 days after the first i.p. 
injection to (0.2% [0-0.6]) and 0% as compared to IgG control (9.2% [6.2-13.7, p=0.003]) 
and (36.0% [19.2-52.5, p=0.003]), respectively (Fig. 2a). Depletion of CD8+ or CD4+ T 
cells had little to no effect on the cure rate of irradiated primary tumours 
(supplementary Fig. 2a). These observations suggest that the immunological activity 
against the primary tumour has already been completed and it is likely that the OFRI 
effect has already been initiated at the time point when depleting antibodies were 
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administered. Mice were randomized among the three depletion groups 
(supplementary Fig. 2c, supplementary table 1): CD8+ T cell, CD4+ T cell depleting 
antibodies or IgG control (Fig. 2a). IgG treatment resulted in a 29% (2/7) cure rate of 
secondary non-irradiated tumours (Fig. 2b) consistent with the results obtained in the 
previous independent experiment (Fig. 1b). Tumour response was not changed upon 
CD4+ T cell depletion as compared to IgG control (p=0.21) (Fig. 2b). Depletion of CD8+ T 
cells resulted in significantly (p=0.01) faster growth of secondary tumours as compared 
to IgG control, demonstrating a causal role for cytotoxic T cells in the RT + L19-IL2 
induced OFRI effect.  
Next, we investigated the specificity of the OFRI anti-tumour effect, using the ED-B 
positive CT26 tumour (36) as a non-irradiated secondary tumour (Fig. 2c and 
supplementary table 1). In contrast to the matched C51 secondary tumours, which 
showed a significant growth delay when mice were treated with 15Gy + L19-IL2 as 
compared with 15Gy + vehicle (Fig. 1b), the growth delay of mismatched CT26 
secondary tumours was not significantly (p=0.2) different: T4xSV= 14.1 [5.5-50.7] days 
in 15Gy + L19-IL2 treated vs 9.0 [6.5-12.9] days in 15Gy + vehicle treated mice. In 
addition, growth delay was not significantly different between the secondary C51 and 
CT26 tumours when mice were treated with 15Gy + L19-IL2 (p=0.9), though no tumour 
cures could be observed in the latter group (Fig. 2d).  
A single RT dose combats the intratumoural immunosuppressive T cell 
phenotype  
We have shown that a single 15Gy RT dose + L19-IL2 induced a curative OFRI effect in 
only 20-30% of the non-irradiated tumours. We hypothesized that the same immune 
response triggered by this treatment combination is immunosuppressive or exhausted 
in non-irradiated tumours. Based on our findings and recent developments in FDA 
(Food and Drug Administration) approved therapies (37), we ought to investigate the 
expression of Foxp3 (an intracellular marker for regulatory T cells) and the targetable 
immunosuppressive checkpoint receptors CTLA-4 and PD-1, on peripheral and 
intratumoural T cells.  
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Figure 2: The OFRI effect in immune depleted and mismatched tumour-bearing mice. (A) Depletion study 
schedule and confirmation of depletion in blood analyzed with FACS. (B) Fraction of tumours not reaching 4 
times start tumour volume. (C) Mismatch treatment schedule. (D) Fraction of tumours not reaching 4 times
start tumour volume for the different treatment groups. 
 
Although non-irradiated tumours from mice treated with 15Gy + L19-IL2 did not show 
higher PD-1 (Fig. 3a) or CTLA-4 (data not shown) expression on their CD8+ T cells as 
compared to irradiated tumours, the non-irradiated secondary tumour infiltrating CD4+ 
T cells expressed significantly (p=0.002) more PD-1 (4.2% [1.7-6.7]) as compared with 
irradiated primary tumours (0.8% [0.1-1.6]) and vehicle control (0.9% [0.8-5.0], p=0.02) 
(Fig. 3b). Furthermore, the non-irradiated tumours have a higher CD25+FoxP3+CD4+ T 
cell infiltrate (1.8% [0.4-6.6], p= 0.009) as compared with the irradiated tumours (0.2% 
[0.04-1.3]) (Fig. 3b). Strikingly, the immune infiltrate of irradiated tumours from mice 
treated with 15Gy + L19-IL2 showed a significantly lower percent PD-1+ expressing CD4+ 
T cells (0.8%, [0.1-1.6]) in comparison with 15Gy + vehicle (2.0% [1.3-4.6], p=0.01) and 
L19-IL2 (2.2% [0.5-3.0], p=0.005) treated tumours. A significantly (p=0.01) lower 
percentage of Foxp3+CD25+ expressing CD4+ T cells infiltrating irradiated tumours from 
RT + L19-IL2 treated mice (0.2% [0.04-1.3]) as compared with L19-IL2 monotherapy 
(1.7% [0.4-2.4]) was also observed. These data show that the addition of a single dose 
of 15Gy to the L19-IL2 monotherapy combats the immunosuppressive T cell infiltrate in 
irradiated tumours. Interestingly, this immunosuppressive combating potential could 
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not be observed when combining L19-IL2 with fractionated RT (5 x 2Gy) (Fig. 3c). 
Although CD4+ and CD8+ T cell tumour infiltration was not significantly different 
between the irradiated and non-irradiated tumours (Fig 3d, e), addition of L19-IL2 to 
fractionated RT significantly increases PD-1+ expression on CD4+ infiltrating cells in 
irradiated tumours (2.0% [1.2-2.7] p=0.01) as compared to the vehicle treated primary 
tumours (0.9% [0.5-2.0]) (Fig.  3d). In addition, L19-IL2 increases PD-1+ expression on 
CD8+ infiltrating non-irradiated tumours (20.1% [8.6-38.3], p=0.01) as compared with 5 
x 2Gy + vehicle treated non-irradiated tumours (7.5% [4.0-8.9]) (Fig. 3e). No differences 
in peripheral CD4+ T cells were observed between all treatment groups (data not 
shown). In addition, no differences in peripheral CD8+ T cells were observed 
(supplementary Fig. 3a, b). Interestingly, fractionated RT did result in a higher 
expression of PD-1 on CD8+ T cells when combined with L19-IL2 (13.0 [1.8-25.1], 
p=0.03) as compared with the 5 x 2Gy + vehicle treated mice (1.2 [0.4-12.1]) 
(supplementary Fig. 3b).  
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Figure 3: Co-expression of immune suppressive and exhausting receptors on T cells. (A) Treatment schedule 
used for figure A and B, % of intratumoural CD8+PD-1+ cells of the CD45+ cells and a representation of the 
distribution (medians) of PD-1+ within the CD8+ T cell population. (B) Representative FACS histogram and 
dotplot, the % of intratumoural CD4+PD-1+ cells and CD4+CD25+Foxp3+ T cells of CD45+ cells in different 
treatment groups and a representation of the distribution (medians) of PD-1+ and CD25+Foxp3+ expression 
within the CD4+ T cell population. (C) Fractionated treatment schedule used for figure D and E. (D)
Quantification of CD4+ T cells of gated CD45+ tumour infiltrating cells, FACS histogram of PD-1 expression on 
tumour infiltrating CD4+ T cells and a quantification of CD4+PD-1+ cells. (E) Quantification of CD8+ T cells of 
gated CD45+ tumour infiltrating cells, FACS histogram of PD-1 expression on tumour infiltrating CD8+ T cells 
and a quantification of CD8+PD-1+ cells. NTM: Normalized to Mode. *p<0.05, **p<0.01.  
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Single vs fractionated RT dose induced OFRI effect: more tumour infiltrating 
CD8+ and peripheral CD4+ T cells 
To be able to compare single dose with the biologically equivalent fractionated RT + 
L19-IL2 OFRI effect, we investigated mice from 15Gy and 5 x 5Gy combined with L19-IL2 
treatment schedules at day 5 (Fig. 4a). Mice treated with 5 x 5Gy + L19-IL2 had a 
significantly lower number of peripheral blood CD4+ T cells (8.7% [5.5-12.4] p=0.04) as 
compared with 15Gy + L19-IL2 treated mice (19.6 [6.2-29.2]) (Fig. 4b). No differences in 
PD-1+, CTLA-4+ or FoxP3+CD25+ T cells were found (Fig 4. b, c). At this time point, no 
differences in total number of tumour infiltrating CD4+ T cells could be observed (data 
not shown). The percentage of infiltrating CD8+ T cells however was significantly 
(p=0.03) higher in the 15Gy + L19-IL2 (49.3% [33.9 – 63]) as compared with 5 x 5Gy + 
L19-IL2 (23.4% [3.7 - 48.8]) non-irradiated tumours consistent with greater OFRI effect 
after the single dose regimen. The expression of PD-1 and CTLA-4 on CD8+ T cells was 
not significantly different (Fig. 4c).  
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Figure 4: Comparison fractionated and single dose triggered OFRI anti-tumour response. (A) Experimental 
setup and schedule used for figure B and C. (B) Representation and quantification of % CD4+, CD4+ PD-1+, CD4+
CTLA-4+ and CD4+Foxp3+CD25+ T cells of total peripheral CD45+ immune cells. (C) Representation and 
quantification of % CD8+, CD8+PD-1+, CD8+CTLA-4+ T cells of total tumour infiltrating CD45+ immune cells. 
*p<0.05.  
Long-lasting immunological memory associated with CD44+CD127+CD8+ T cells.  
Next we investigated if the anti-tumour immune response is modulated by the RT + L19-
IL2 treatment in such a manner that it remains active against its target, the tumour-
associated (neo)antigens. To test this hypothesis, mice cured from C51 tumours by a 
single dose of 10Gy + L19-IL2 (30), where re-injected with C51 tumour cells 150 days 
after cure. While age-matched naive mice reached a tumour volume of 500mm3 within 
17 days after cell injection, cured mice did not show any tumour formation (Fig. 5a). 
Though not significant, FACS analyses at endpoint revealed a higher CD44+CD127+ co-
expression on CD8+ T cells in spleens (Fig. 5b) and lymph nodes (data not shown) in the 
re-challenged mice that were able to reject tumours (4.8 [0.9-6.4]) as compared with 
naive (0.9 [0.3-1.7]) and tumour-bearing (1.0 [0.8-1.8]) age-matched controls (Fig. 5b). 
Next, we investigated whether this long-lasting anti-tumour response solely depends on  
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Figure 5: RT + L19-IL2 triggers long-lasting immunological memory. (A) Time to reach 500mm3 after tumour 
(re)-injection. (B) %CD44+CD127+ cells of CD8+ T cells in spleens. (C) Confirmation of CD127 depletion by FACS.
(D) Time to reach 500mm3 after tumour (re)-injection. (E) % of CD44+CD127+, CD44+CD62L+ and CD44+CD62L-
of total CD8+ T cells in the spleens and lymph nodes. (F) Median representation of different immune subsets
analyzed by FACS. 
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tumour cure by RT + L19-IL2 treatment and on CD127 expressing T cells. For this, 150 
days after mice were cured from C51 tumours by RT + L19-IL2, surgery + L19-IL2 or high 
dose RT (40 Gy) (supplementary Fig. 5), mice were re-challenged with C51 tumours. 
Two days after CD127 blocking, the expression of CD127 on CD3+ cells was significantly 
lower (1054 [761-1491], p=0.004) as compared with the IgG treated mice (2292 [2169-
2555) (Fig. 5c). Eight out of 12 mice cured by RT + L19-IL2, were not able to form new 
tumours and blocking of CD127 had no influence on this protective effect (Fig. 5d). In 
contrast, surgery + L19-IL2 and high dose RT induced significantly less protective effect 
as compared with the RT + L19-IL2 (p<0.05). Furthermore, non-tumour bearing mice 
pre-treated with RT + L19-IL2 were all able to form tumours (500mm3) within 13 days, 
similar to control mice (matrigel + sham RT + vehicle), proving that treatment alone is 
not sufficient to induce memory effect without prior tumour cure (Fig. 5d).  
Endpoint immunological analyses (supplementary Fig. 5) revealed that peripheral 
(blood) CD8+ T cells have high expression of CD44+CD127+ when mice were able to 
reject tumours (14.6% [5.4-29.1], p<0.05) after RT + L19-IL2 as compared with other 
treatment groups (1.6% [0.6-4.2] of other groups) (Fig. 5e). These high co-expression 
levels were not found on the CD8+ T cells of the two mice with tumour growth after re-
challenge (2.1 and 0.8%), showing that the co-expression of both receptors on CD8+ T 
cells can distinguish long-lasting immunological protection against tumours 
(supplementary Fig. 5e). RT + L19-IL2 cured mice able to reject tumours also showed a 
significantly higher percentage of CD44+CD127+ on CD8+ T cells in spleens (48.8% [35.4-
68.6, p<0.05) as compared with other treatment groups (8.4% [4.6-38.5] of other 
groups). Again, this high co-expression level was not found on the CD8+ T cells of the 
two mice with tumour growth after re-challenge (4.5 and 5.9%) (supplementary Fig. 6). 
Mice cured from C51 tumours by L19 + IL2 receiving IgG instead of CD127 blockage had 
a significantly higher expression of CD44+CD127+ on CD8+ T in lymph nodes (36.7% 
[26.9-52.5), p<0.05) as compared with all other groups except for the high dose RT 
upon tumour cell rejection (supplementary Fig. 6). These results show that the 
CD44+CD127+ expression on CD8+ T cells associates with but not causes the 
immunological protective effect since CD127+ blockage did not show any effect on 
tumour take after re-challenge.  
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CD8+ T cells in lymph nodes of cured mice able to reject tumours have a significantly 
higher (p=0.01) expression of CD44+CD62L+ (7.3% [5.7-9.8] IgG group and 12.9% [6.9-
21.6] anti-CD127 group) as compared with all other treatment groups (2.0% [1.0-4.0] of 
all other groups). Additionally, lymph nodes contained a higher percentage of 
CD44+CD62L- T cells (36.3%, [34.5-42.8] IgG group and 33.5% [28.7-38.6]) CD127 group) 
as compared with all other treatment groups (28.4% [17.7-40.3] (Fig. 5e, f). It appears 
that percentage of splenic CD44+CD62L+ and CD44+CD62L- CD8+ T cells were higher in 
cured mice able to reject tumours as compared with mice with tumour take 
(supplementary Fig. 6). No significant differences between CD44+CD62L+ expressing 
CD8+ T cells in blood could be observed between treatment groups (data not shown). 
DISCUSSION 
Over the last years, the improved understanding of RT-induced effects on the tumour 
microenvironment has resulted in the recognition that RT has a novel role as an inducer 
of the immunogenic death of tumour cells(38). Since this form of cell death is capable of 
converting the patient’s tumour into an in situ vaccine, it can initiate an anti-tumour 
immune response (39), which may be further increased when combined with 
immunotherapeutic approaches (38). The selective delivery of IL2 to tumour vascular 
components via the L19-IL2 fusion protein is a novel promising immunotherapy 
approach (22, 36, 40) and can enhance the therapeutic potential of RT in ED-B positive 
tumours in a CD8+ T cell (30) or NK cell mediated manner (41). These highly synergistic 
preclinical findings resulted in the initiation of a phase I clinical study in our institute 
(NCT02086721), which is currently ongoing. Since the therapeutic effect of this 
combination treatment is immune mediated, we hypothesized that it can elicit Out-of-
Field RadioImmune (OFRI) effects targeting macroscopic tumours directly and 
preventing new tumour formation (recurrence) later on.  
In this study, we have investigated three different RT schedules in combination with 
L19-IL2 including single dose and fractionated irradiation regimens. In all schedules, 
irradiated tumours were cured when radiation was combined with L19-IL2. 
Furthermore, we have shown for the first time that the single RT dose + L19-IL2 
mediated OFRI effect retarded tumour growth significantly and even cured 20% of the 
non-irradiated tumours. Since it is known that the RT dose, schedule and technique may 
provoke diverse systemic immune responses (5), we additionally used two fractionated 
RT regimes (5 x 2Gy and 5 x 5Gy) in combination with L19-IL2. Indeed, several preclinical 
studies showed significant growth delay and complete remission outside the RT field 
when immunotherapy (anti-CTLA-4) was combined with fractionated RT but not with a 
large single dose (42, 43). In the present study, we have shown that a significant growth 
delay of tumours outside the RT field could be observed using fractionated combination 
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treatment schedules, however, none of these tumours could be cured, demonstrating 
that a single high radiation dose is required to trigger RT + L19-IL2 mediated curative 
OFRI effects. In agreement with our results, a single RT dose (20Gy) initiated immune 
responses and tumour (including non-irradiated metastases) growth delay when 
combined with a CD8+ T cell activating immunotherapy (44). This systemic anti-tumour 
effect was not observed when combined with fractionated RT (4 x 5Gy) (45). Differences 
in tumour immunogenicity, composition of immune infiltrating cells at start of (RT) 
treatment (46), RT doses and different immunotherapeutic approaches may all explain 
the contradictory results to induce anti-tumour effects outside the RT field between 
different research groups. Fractionated RT might induce a more immunosuppressive 
microenvironment, favoring the use of checkpoint inhibitors instead of immune-
activating therapies such as L19-IL2, to obtain an optimal OFRI response.  
Mice treated with 15Gy + L19-IL2 revealed on day 4 after start treatment an increase in 
CD4+ but not in CD8+ T cell infiltration in tumours outside the RT field, indicating an 
association of the CD4+ T cells with the observed long-lasting OFRI effect. Despite we 
did not observe an increased percentage of CD8+ T cells inside the non-irradiated 
tumours at this time point, depletion of CD8+ T cells abrogated the OFRI effect of the 
combination therapy significantly. The known role of CD4+ T cells, to recognize tumour-
associated antigens and to bring CD8+ T cell responses up to a measurable level (47), 
may be the explanation why we did observe a significant increase in infiltrating CD4+ T 
cells but not yet CD8+ T cells in non-irradiated tumours; it might be a matter of timing. 
Furthermore, we have shown that depletion of CD4+ or CD8+ T cells at day 5 has no or 
little effect on tumour cure of the primary tumour. This suggests that the anti-tumour 
immune response against the irradiated tumour was complete at start of depletion, 
enabling us to follow up growth delay effects of the non-irradiated secondary tumours. 
These data provide direct evidence that the growth delay and complete remission of 
20% of the non-irradiated tumours is predominantly attributed to CD8+ T cells and at 
least in part to CD4+ T cells. However, in patients the OFRI effects against metastases 
might be difficult to monitor or predict by ‘Immunoscore’, which classifies cancer based 
on tumour immune infiltrate and has prognostic value proven for several malignancies 
(48) since biopsies of metastatic tumours are often not available. The systemic 
monitoring of OFRI effects using peptide-MHCI multimers labeled with DNA barcodes 
(49) and use of mathematical models (50-52) are interesting alternative options. 
Using the ED-B positive CT26 tumour (36) as a secondary tumour, we observed a similar 
growth delay of the mismatched tumour when administrating 15Gy to the primary C51 
tumour in combination with L19-IL2 compared to a C51 secondary tumour, however 
without showing tumour cure. The common expression of antigen(s) between the 
irradiated tumour and other tumour sites may be crucial for an anti-tumour immune 
response outside the RT field (52). Therefore, it is expected that the irradiated C51 
tumour and the non-irradiated CT26 tumour indeed share common tumour specific 
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antigens and differences in the antigen-expressing repertoire may explain the reduced 
OFRI effect observed in this mismatched tumour as compared with the matched (C51) 
tumour. In addition, differences in tumour-derived chemokines, which are responsible 
for shaping the tumour microenvironment and thereby determining the composition of 
tumour-infiltrating immune cells (53), differences in hypoxia creating an 
immunosuppressive tumour microenvironment, or differences in perfusion enabling 
penetration and binding of L19-IL2, may also explain the difference in vulnerability of 
the non-irradiated mismatched tumours to the systemic C51 tumour-derived OFRI 
effect, which warrants further investigation. 
 
Figure 6: Overview of radiotherapy and L19-IL2 induced anti-tumour effects described in this article. 1.
Radiotherapy induces immunogenic cell death, thereby releasing DAMPs (2), creating an in situ vaccine. 3.
Tumour-associated antigens are picked up by DCs, that migrate to LNs to activate CD8+ T cells (4). L19-IL2 can 
stimulate the proliferation of tumour specific CD8+ T cells (5) that can now target the irradiated tumours (6), 
non-irradiated tumours (7) and prevent the formation of new tumours months after tumour cure and
termination of the treatment (8).  
 
In this study, we have established the importance of T cells in the execution of the 
specific RT + L19-IL2 mediated OFRI effect (Fig. 6). Additionally we observed that part of 
these infiltrating T cells have a regulatory (Foxp3+CD25+) phenotype or they express PD-
1, resulting in the tolerance and exhaustion of these cells (54). This exhausted T cell 
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phenotype as well as increased infiltrate of regulatory T cells was not observed inside 
irradiated primary tumours, suggesting that large single radiation dose can shift the 
effector/regulatory balance into an effective immune response. Indeed, it is known that 
radiotherapy has a broad range of immune stimulating effects on the tumour 
microenvironment, transforming it into an immunogenic hub (5) and ablating the 
regulatory T cells (55) making it a highly attractive approach to improve 
immunotherapeutic efficacy, especially for less immunogenic solid tumours. However, 
using fractionated (5 x 2Gy) radiotherapy, we could, next to an increase of PD-1 
expressing T cells inside non-irradiated tumours, additionally show an increase of PD-1 
expressing T cells inside irradiated tumours. This suggests that fractionated RT results in 
a more exhausted T cell phenotype infiltrate than a single RT dose when combined with 
L19-IL2. The expression of PD-1 on T cells is identified as an important resistant 
mechanism to systemic radiotherapy triggered anti-tumour immune responses(56-58). 
Therefore the observed presence of PD-1 expressing T cells in non-irradiated tumours 
and in tumours receiving fractionated RT, creates a window-of-opportunity to further 
increase RT + L19-IL2 OFRI effects by the administration of a PD-1 targeting agent.  
Furthermore, several PD-1 inhibitors, including nivolumab, have recently obtained FDA 
approval (37) and show very promising anti-tumour activity in several clinical trials (59, 
60). Therefore, a trimodal treatment using RT and L19-IL2 combined with nivolumab 
might be an interesting approach to further increase the OFRI effect for patients with 
metastases in a relatively short time-span. Furthermore, direct comparison between 
non-irradiated tumours of 15Gy and 5 x 5Gy + L19-IL2 treated mice revealed that the 
single RT dose treated mice have a higher percentage of peripheral CD4+ T cells and a 
higher percentage of CD8+ T cells infiltrating their non-irradiated tumour. Since it is well 
known that CD8+ T cells have anti-tumour activity on irradiated tumours (30), and since 
we have shown in the depletion study that T cells are crucial for a RT + L19-IL2 OFRI 
effect, these differences may explain why single RT dose is a better inducer of a curative 
OFRI effect.  
Moreover, we have shown in this study that RT + L19-IL2 cured mice are able to develop 
long-lasting immunological memory (Fig. 6). Mice treated with RT + L19-IL2 did not 
develop this protective immunity when no tumour was present, showing the 
importance of the tumour to form the basis for this ‘in situ’ vaccine that can eventually 
be translated into a direct (irradiated), indirect (non-irradiated) and long-lasting (re-
challenged) anti-tumour immune response. In addition we show that RT is the best 
trigger to initiate the long-lasting anti-tumour immune response, since surgery + L19-IL2 
showed a reduced number of mice able to reject tumour cells upon re-injection, 150 
days post cure. High dose RT + vehicle induced significantly worse immunological 
memory effect, in addition to the elevated normal tissue toxicity, demonstrating the 
importance of L19-IL2 in triggering the immune response. Immunological analysis 
revealed a significant increase of CD44+CD62L+ and CD44+CD62L- expression on CD8+ T 
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cells in the lymph nodes. It has been reported that effector cells have a high expression 
of CD44 and a low expression of CD62L while central memory cells have a high 
expression of both CD44 and CD62L (61-63). Therefore, we conclude that effector T cells 
and central memory T cells are significantly increased in the lymph node compartments 
when mice are able to reject tumours after they are cured. Furthermore, we show that 
mice able to reject tumours have a significantly high expression of CD44+CD127+ on 
splenic, lymph nodes and on circulating CD8+ T cells (blood). It has been shown that the 
expression of CD44 and CD127 (i.e. the receptor for IL7) on CD8+ T cells can classify 
these cells as effector memory T cells (61-63), and indeed the expression of CD127 is a 
hallmark of primed CD8+ T cells to develop into long-lived memory cells (61, 64-66). The 
expression of CD44+CD127+ on CD8+ T cells seems to be even more pronounced in the 
blood, making this expression profile of great interest as a potential biomarker for 
further selection purposes. A selection can be made to distinguish patients with and 
without long-term anti-tumour potential. It creates the opportunity to adapt treatment 
modalities for the latter group, in order to obtain optimal long-lasting anti-tumour 
effects.  
To test the hypotheses in the present proof-of-principle study we have used the well-
established and -characterized C51 tumour model. To mimic metastasizing cancer, we 
implanted secondary tumours resembling metastasis (or a secondary tumour in 
mismatched experiments) outside the radiation field. The choice of this experimental 
model in these proof-of-principle experiments is governed by the possibility to control 
experimental conditions such as tumour volume at start of treatment and enable 
precise irradiation of the primary tumour as wells as accurate daily tumour monitoring, 
Importantly, all secondary tumours were clearly macroscopic and growing, which 
reduces potential bias resulting from incomplete tumour take due to technical reasons. 
It remains to be determined whether RT combined with L19-IL2 can induced the OFRI 
effect in other models of tumour metastases.  
To conclude, this study shows for the first time that a single dose, but not fractionated 
RT can result in a curative OFRI effect when combined with systemic L19-IL2 treatment 
dependent on T cells. Mismatching the secondary tumours attenuates this effect and 
might depend on the percentage of shared (neo)antigens. Single dose RT combined 
with L19-IL2 leads to an elevation of T cell infiltration in the non-irradiated tumours with 
a more immunosuppressive phenotype, a phenomenon which is enhanced upon 
fractionated irradiation. Finally, in this study we have shown that RT + L19-IL2 can 
induce a long-lasting immunological protection against tumours, which is associated   
with the presence of effector and central memory T cells (https://youtu.be/a0eJXn 
7wNVQ).   
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MATERIALS AND METHODS 
Tumour cell lines/ reagents/ Antibodies for in vivo studies 
Exponentially growing C51 and CT26 mouse colon carcinoma cell lines (kindly provided 
by Philogen S.p.A., Siena, Italy) were cultured in Dulbecco's Modified Eagle Medium 
(DMEM) and Roswell Park Memorial Institute (RPMI) (Lonza) respectively, supplemented 
with 10% fetal calf serum (FCS) in a humidified 5% CO2 chamber at 37°C. 
The L19-IL2 immunocytokine (Philogen S.p.A.) was diluted with sterile phosphate 
buffered saline (PBS, Lonza) to concentrations of 200µg/ml. For in vivo depletion 
experiments, the monoclonal antibodies anti-CD8a (clone YTS 169.4), anti-CD4 (clone 
YTS 191) and the isotype control anti-KLH rat IgG2b (clone LTF-2) (Bio X Cell, Lebanon, 
USA) were diluted with sterile PBS to a concentration of 1.67 mg/mL. For in vivo 
blocking experiments, the monoclonal anti-CD127 (clone A7R34) and rat IgG2a isotype 
control (clone 2A3) antibodies (Bio X Cell, Lebanon, USA) were diluted with sterile PBS 
to a concentration of 2 mg/mL.  
Mice and in vivo experiments 
All experiments were performed in accordance with local institutional guidelines for 
animal welfare and were approved by the Animal Ethical Committee of the University of 
Maastricht. To induce tumours, approximately 8 weeks old immune competent Balb/c 
(Harlan Laboratories) mice were subcutaneously injected with 1.5 x 106 syngeneic C51 
tumour cells suspended in Basement Membrane Matrix (MatrigelTM, BD Biosciences) 
10 days prior to RT. Tumours were irradiated upon a tumour volume between 210-
296mm³ with a single dose of 15Gy on day 0 or 5 x 2Gy (day 0, 1, 2, 3, 4) fractionated 
RT, combined with systemic therapy L19-IL2 (20µg)  or vehicle (PBS) on day 1, 3 and 5 
(Fig. 1a, 3a). For the OFRI experiments, C51 tumour cells were injected as described 
before (day -10) on the left flank and at 8 days prior to RT, C51 cells (1.5 x 106) or CT26 
cells (2.0 x 106) were suspended in matrigel and injected in the right flank. The volumes 
or primary and secondary tumours at start of treatment were not significantly different 
between different treatment groups in all experiments (supplementary table 1). 
To be able to compare tumour responses between 15Gy single dose and a fractionated 
regime we calculated dose per fraction do be delivered once a day for 5 days that 
results in the same biological effect as single dose RT using the linear quadratic 
formalism (67). We assumed that the α/β ratio of the mouse tumours equals to 10Gy. 
Dose recovered per day due to proliferation (Dprolif) was not taken into account in 
calculations because published data on repopulation of mouse tumours demonstrated 
that repopulation rate in differentiated adenocarcinomas, mammary carcinoma and in 
fast fibrosarcoma did not increase in the first week of radiotherapy(68). We calculated 
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that 5 x 5Gy (day 0, 1, 2, 3, 4) should give the same biological effect as a single dose of 
15Gy. This fractionated schedule was delivered only to the left tumour in combination 
with L19-IL2 (day 1, 3 and 5) (Fig. 4a).  
Tumour growth was monitored every 48 hours; tumour dimensions were measured 
using a Vernier caliper until endpoint, defined as 4 times starting volume (T4xSV). 
Tumour volume was calculated using the following formula: (π/6) × length × width × 
height each dimension corrected (minus 0.5 mm) for the skin thickness. For all these 
growth delay experiments, tumour volumes were normalized to day 0. In parallel, flow 
cytometry analysis of immunological parameters in tumours and blood at day 4 or day 5 
of the treatment schedules was performed.  
To evaluate the causal relationship between the presence of CD4+ or CD8+ T cells and 
tumour growth delay of the non-irradiated tumours, an experimental set-up was 
designed to deplete these cells (day 5, 8, 11, Fig. 2a) in C51 tumour-bearing Balb/c 
mice. Depletion of the cells has been confirmed by flow cytometry analysis (see below) 
of blood samples collected via puncture of the saphenous vein. Tumour volume data 
was normalized to start of depletion (day 5).  
For the immune memory effect study, animals were challenged with 1.5 x 106 C51 
tumour cells suspended in Matrigel or vehicle on the left flank. When tumours reached 
an average volume of 200 mm3, different treatment schedules were delivered as 
depicted in supplementary Fig. 5. Animals that demonstrated long-term survival 
(tumour cure) were re-challenged 150 days post-implantation with 1.5 x 106 C51 
tumour cells suspended in Matrigel (or vehicle) on left and right flanks. Tumour growth 
was monitored as described above and time to reach 500mm3 was calculated. Only 
animals that did not have tumour uptake of left and right tumours were considered to 
have a long-term immune memory effect. For CD127 in vivo blocking experiments, mice 
were injected intraperitoneally with anti-CD127 or rat IgG2a isotype control monoclonal 
antibodies one day before tumour re-challenge and then every 48 hours for 3 weeks.  
Blockade of CD127 has been confirmed in CD3+ peripheral blood mononuclear cells in 
blood samples extracted by saphenous vein puncture after second dose of blocking 
antibody was delivered (Fig. 5c).   
Surgical excision of tumours 
Before surgical excision of tumours, the skin around the tumour was shaved and the area 
was disinfected with 70% ethanol. All surgical procedures were done under general 
anesthesia with isoflurane inhalation. The surgical area was sterilized with iodine solution 
and a sterilized scalpel was used to make an elliptic incision around the tumour to dissect 
it away from the flank. To stop the bleeding, an electrocautery was used to close blood 
vessels and the surgical incision was closed by stitching using the U-stich with an 
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absorbable suture. Post-operative care of the animals included the administration of 
300mg/kg paracetamol to reduce discomfort. 
Flow cytometry 
Flow-cytometric analysis was performed on immune cells isolated from spleens, lymph 
nodes, blood and tumours. Single cell suspensions were obtained using a gentleMACS 
dissociator and filtered through a 70µm-pore cell strainer (Greiner, Bio-one). 
Additionally, tumours were enzymatically digested with a tumour dissociation kit 
(Miltenyi Biotec B.V.) before making single cell suspensions. Red blood cells lysis was 
performed on single cell suspensions of blood, spleens and tumours using RBC lysis 
buffer (eBioscience, San Diego, CA). Cells were stained with PBS containing 2% FCS, 
incubated with FC-block CD16/CD32 (clone 2.4G2; BD Biosciences, San Jose, CA) and 
stained with a combination of following the antibodies for cell surface markers: anti-
CD45-V500, PE, FITC, APC and PE-Cy7 (clone 30F-11), anti-CD3-FITC (17A2), anti-CD4-
APC-H7 (GK1.5), anti-CD8a-V500 (53-6.7), anti-CD19-PE (1D3), anti-CD25-APC (PC61), 
anti-CD44 APC-Cy7 (IM7), anti-CD127-PE (clone SB/199) and anti-CD127-PE (A7R34) (BD 
Biosciences); anti-NKp46-APC (29A1.4.9, Miltenyi Biotec B.V., Leiden, The Netherlands); 
anti-CD45-PerCP (30-F11), anti-CD152 (CTLA-4)-Brilliant Violet 421 (UC10-4B9) and anti-
279 (PD-1)-PE-Cy7 (RMP1-30) (Biolegend); anti-CD3e- eFLUO 450 (145-2c11), anti-CD4-
FITC (RM4-5), anti-CD62L-PE-Cy7 (Mel-14) (eBioscience). For intracellular staining, FC 
blockade and cell surface markers staining was performed, cells were washed with a 
fixation/permeabilization working solution (eBioscience) according to manufacturer’s 
guidelines and then stained with anti-mouse/rat FOXp3-PE staining set (FJK-16s; 
eBioscience). Eight-colour flow cytometric analysis was performed with a FACSCanto II 
instrument (BD Biosciences). Data were analyzed with FACSDiva v6.1.2 (BD Biosciences) 
and FlowJo v10.0.8 (Tree Star) software. The total CD45+ immune cells were selected 
from the viable population of cells (filtered for debris and doublets) for further sub-
classification according to the strategy described previously (30). Staining to assess the 
expression of immune memory markers were performed on freshly isolated and frozen-
thawed samples of spleens and lymph nodes and flow cytometric analysis yielded 
similar results. Gating strategies are described in Supplementary Fig. 4.  
Statistical analysis  
Statistical analyses were performed using GraphPad Prism Software (v5.03, San Diego, 
CA). For all immune parameters and tumour (start) volumes median [max-min] are 
reported. The non-parametric Mann-Whitney two-tailed test was used to determine the 
statistical differences between the different treatment groups. The log-rank (Mantel-
Cox) test was used to compare the survival curves. When comparing the tumour 
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volumes of three treatment groups, a one-way ANOVA, non-parametric (Kruskal Wallis) 
test was used. P-values smaller than 0.05 were considered statistically significant. 
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Supplementary table 1: Overview of tumour start volumes of different experiments. 
Figure  Treatment group Median [max-min] 
tumour volume at start 
treatment 
 
1b, 2d 15Gy + vehicle secondary tumour 126mm3 [56-146] P=0.18 
1b, 2d 15Gy + L19-IL2 secondary tumour 65mm3 [38-257] 
1b 5 x 2Gy + vehicle secondary tumour 67mm3 [36-119] P=0.41 
1b 5 x 2Gy + L19-IL2 secondary tumour 41mm3 [29-149] 
1b 5 x 2Gy + L19-IL2 secondary tumour 41mm3 [29-149] P=0.11 
1b 15Gy + L19-IL2 secondary tumour 65mm3 [38-257] 
1b 5 x 5Gy + L19-IL2 secondary tumour 98mm3 [71-163] 
2b 15Gy + L19-IL2 + depletion CD8 secondary tumour 166mm3 [31-304] P=0.70 
2b 15Gy + L19-IL2 + depletion CD4 secondary tumour 166mm3 [29-276] 
2b 15Gy + L19-IL2 + IgG secondary tumour 165mm3 [46-230] 
2d 15Gy + vehicle secondary tumour (CT26) 109mm3 [49-132] P=0.71 
2d 15Gy + L19-IL2 secondary tumour (CT26)  113mm3 [39-247] 
Supplementary 1b 15Gy + vehicle primary tumour 241.9mm3 [156-291] P=0.26 
Supplementary 1b 15Gy + L19-IL2 primary tumour 267mm3 [215-337] 
Supplementary 1c 5 x 2Gy + vehicle primary tumour 300mm3 [167-383 P=0.17 
Supplementary 1c 5 x 2Gy + L19-IL2 primary tumour 209mm3 [139-273] 
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Supplementary figure 1: Growth delay observed in irradiated tumours. (A) Fraction of irradiated tumours not 
reaching (T4xSV) for the different treatment groups (2, 5 and 10Gy are historical controls (30)). (B) Fraction of 
irradiated tumours not reaching (T4xSV) treated with 15Gy + L19-IL2 and 15Gy + vehicle. (C) Fraction of 
irradiated tumours not reaching (T4xSV) treated with 5 x 2Gy + L19-IL2 and 5 x 2Gy + vehicle. 
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Supplementary figure 2: Tumour volumes depletion study. (A) Primary tumour volumes of different depletion
groups during treatment. (B) Secondary tumour volumes of different depletion groups during treatment. (C)
Tumour volumes at start of depletion. 
 
 
 
Supplementary figure 3: Peripheral immune cells from different treatment groups. (A) % of CD8+ and CD8+PD-
1+ T cells of the total peripheral CD45+ cells among different treatment groups at day 4. (B) % of CD8+ and 
CD8+PD-1+ T cells of the total peripheral CD45+ cells among fractionated treatment groups at day 5.  
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Supplementary figure 4: Gating strategy. Gating strategy used (FACS) to investigate immunosuppressive
phenotype T cells. 
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Supplementary figure 5: Study design memory study. (A) Memory study design and (B) gating strategy (FACS). 
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 Supplementary figure 6: subsets memory T cells in spleens and lymph nodes. 
% of CD44+CD62L+, CD44+CD62L-, CD44+CD127+ of total CD8+ T cells in spleens and lymph nodes. 
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ABSTRACT 
Background and Purpose 
Recently, we have shown that radiotherapy (RT) combined with the immunocytokine 
L19-IL2 can induce long-lasting anti-tumour effects, dependent on ED-B expression and 
infiltration of cytotoxic T cells. On the other hand, in certain tumours, IL2 treatment can 
trigger a natural killer cell (NK) immune response. The aim of this study is to investigate 
the therapeutic effect of our combination therapy in the ED-B positive F9 
teratocarcinoma model, lacking MHCI expression and known to be dependent on NK 
immune responses. 
Material and methods 
In syngeneic F9 tumour bearing 129/FvHsd mice tumour growth delay was evaluated 
after local tumour irradiation (10 Gy) combined with systemic administration of L19-IL2. 
Immunological responses were investigated using flow cytometry. 
Results  
Tumour growth delay of L19-IL2 can be further improved by a single dose of RT 
administrated before immunotherapy, but not during immunotherapy. Furthermore, 
treatment of L19-IL2 favours a NK response and lacks cytotoxic T cell tumour infiltrating 
immune cells, which may be explained by the absence of MHCI expression. 
Conclusion 
An additive effect can be detected when the NK dependent F9 tumour model is treated 
with radiotherapy and L19-IL2 and therefore this combination could be useful in the 
absence of tumoural MHCI expression. 
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INTRODUCTION 
Radiotherapy (RT) affects both the tumour and its micro-environment, leading to the 
release of tumour-associated antigens, damage molecular patterns (DAMPs) and the 
upregulation of immunomodulatory cell surface molecules, thereby starting an anti-
tumour immune response (1-3). Recently, we have shown that the RT induced anti-
tumour effect can be enhanced by administration of the immunocytokine L19-IL2 (4) 
which has been shown to have excellent tumour targeting properties and improved 
therapeutic outcome over IL2 treatment alone (5). The IL2 moiety of this 
immunocytokine is able to stimulate the proliferation of not only cytotoxic T cells, but 
also natural killer (NK) cells and can therefore be used to strengthen a broad RT-induced 
immune response (6). The L19 moiety binds to extra domain-B (ED-B), a part of the 
fibronectin present in tumour neovasculature and overexpressed in many solid tumours 
(7). RT combined with L19-IL2 has therefore the potential to create powerful synergistic 
tumour eliminating effects, as confirmed by our group. 
Recently, we reported that the success of this combination treatment is highly 
dependent on the presence of cytotoxic T cells (4). Cytotoxic T cells are able to 
recognize and eliminate tumour cells that express tumour-associated peptides on their 
MHCI. In the high ED-B expressing C51 model, these immune cells were responsible for 
75% of tumour cure and in the intermediate ED-B expressing LLC model an additive 
effect could be detected. However, in certain tumours, or in later stages of progression, 
tumour cells can downregulate their MHCI expression to escape from T cell mediated 
killing. As a consequence, tumour cells become more prone to be killed by NK cells, 
since MHCI expression of tumour cells inhibits the cytotoxic killing of NK cells (8). As not 
all tumours demonstrate MHCI expression, it is unclear if the combination of RT with 
L19-IL2 is also beneficial in these kinds of tumours. To explore this clinically relevant 
question, we made use of the ED-B positive F9 teratocarcinoma model as it is 
independent of T cells and known to induce NK cell responses when treated with IL2-
based therapeutics (6, 9). In this study we investigated whether the combination of RT 
with L19-IL2 can provoke a NK cell mediated immune response in the F9 tumour model 
and whether this immune response leads to a therapeutic effect. 
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MATERIAL AND METHODS 
In vivo experiments 
All experiments were performed in accordance with local institutional guidelines for 
animal welfare and were approved by the Animal Ethical Committee of the University of 
Maastricht. Approximately 8 weeks old 129/SvHsd immune competent mice (Harlan 
Laboratories) were subcutaneously injected with 3x106 F9 teratocarcinoma cells 
resuspended in matrigel (MatrigelTM, BD Biosciences). F9 cells were cultured in 
Dulbecco's Modified Eagle Medium (DMEM; Lonza) supplemented with 10% fetal calf 
serum in 0.1% gelatin coated dishes. Upon an average tumour volume of 200 mm³, 
therapy was started using three different schedules: (I) a single dose of 10Gy 
radiotherapy (RT) was locally given to tumours on day 0, combined with systemic 
therapy (vehicle PBS / L19 13.3µg / IL2 6.7µg / L19-IL2 20µg) on day 1, 3 and 5 (figure 
2a), (II) animals were treated as in I, however sacrificed on day 4 of the treatment 
schedule and used for flow cytometry analysis of tumours, spleen and lymph nodes and 
(III) systemic therapy was given on day 0, 2 and 4 with local radiotherapy on day 2 
(figure 3a). For treatment schedule I and III, tumour growth and treatment toxicity 
(based on body weight) were monitored on a daily basis until the tumour volume 
reached 4 times the volume at the start of therapy (T4xSV). To calculate T4xSV volumes 
were normalized to the start of treatment (day 0). To correctly compare control groups 
with radiotherapy groups in treatment schedules I and III, data were normalized to the 
start of treatment. 
Flow cytometry 
Flow cytometric analysis was performed on single cell suspensions from tumours, 
spleen and lymph nodes excised at day 4 as previously described (4). Analysis was 
performed with RBC lysis buffer (eBioscience, San Diego, CA), FC-block CD16/CD32 (BD 
Biosciences) and a combination of antibodies CD3-FITC, CD4-APC-H7, CD8-PE-CY7, 
CD19-PE, CD45-V500, CD45-Percp, CD45-PE, CD45-FITC, CD45-APC, CD45-PE-CY7, 
CD3e-eFLUO450, CD4-FITC, CD8a-V500 (BD Biosciences) and NKp46-APC (Miltenyi 
Biotec B.V.).  
Immunofluorescence 
7μm frozen sections were fixed in acetone (4°C) and stained for ED-B, CD31 and CD8 
according to previous published methods (4) using L19-SIP and KSF-SIP biotinylated 
(Philochem), rat anti-CD31 (BD Biosciences) and rabbit anti-CD8 (clone 53.62.7, 
Department of Pathology, MUMC, Maastricht, The Netherlands), respectively. For MHCI 
staining, sections were blocked with 10% normal goat serum, incubated overnight at 
Combination of radiotherapy with the immunocytokine L19-IL2: additive effect in a NK 
cell dependent tumour model 
97 
4°C with primary antibody (rat anti-MHCI, 1:50 in antibody diluent, Abcam). 
Visualization was done using streptavidin Alexa 488 antibody, goat anti-rabbit IgG Alexa 
488 (Life Technologies), goat anti-rat IgG Alexa 488 or goat anti-rat IgG Alexa 594 (BD 
Bioscience). Fluorescent imaging was performed as described before (4). 
Statistics 
Statistical analyses were performed using GraphPad Prism Software (v5.03, San Diego, 
CA). For all parameters medians with [10th-90th percentiles] are reported. Non-
parametric Mann-Whitney test was used to determine statistical differences. p-values 
smaller than 0.05 were considered statistically significant. 
RESULTS 
F9 tumours are ED-B positive and MHCI negative 
As the immunostimulatory effect of L19-IL2 is dependent on ED-B expression, we 
verified ED-B expression together with the vascular marker CD31 in the F9-teratoma 
model. Representative sections are shown in figure 1A. F9 tumours showed high ED-B 
expression associated with CD31 expression. To investigate a possible mechanism 
underlying RT+L19-IL2 induced NK cell versus cytotoxic T cell responses, we investigated 
MHCI expression of F9 tumours. F9 tumours cells were negative for MHCI expression, 
only other structures (i.e. endothelial cells and mouse stromal cells) stained positive for 
MHCI. The previously investigated tumour model C51, which was dependent on 
cytotoxic T cells (4) was included as positive control for MHCI staining (figure 1B). 
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Figure 1A: Representative images of ED-B expression in F9 teratocarcinoma. ED-B expression (left) or control 
(right) in green, vessels (red) and cell nuclei (blue). B: MHCI expression (green) and vessels (red) in the F9 
teratocarcinoma (left) and MHCI expression in the C51 colon carcinoma (green), cell nuclei in blue. Scale bar 
represents 100 µm. 
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Combination therapy provides an additive effect 
No toxicities were observed based on body weight measurements and animal welfare 
monitoring. Combination treatment was performed using two schedules to optimize the 
best timing for irradiation when compared with L19-IL2 (figure 2A and 3A). According to 
the animal welfare regulations, we reduced the amount of animals by re-using the 
tumour growth data of single treatment control groups in schedules I and III.  
Radiotherapy before immunotherapy  
Compared to vehicle PBS treated animals (T4xSV = 3.2 [1.7-4.7] days), L19 treatment 
(3.3 [2.5-4.5] days P=0.9) and IL2 (4.4 [2.5-5.6] days P=0.2) treatment alone did not lead 
to an enhanced growth delay. Both RT (4.3 [3.0-8.9] days P<0.05) and L19-IL2 (7.7 [2.7-
13.3] days P<0.001) monotherapies significantly enhanced tumour growth delay 
compared to vehicle. Upon combination of RT with L19-IL2, a highly significant anti-
tumour effect (11.5 [7.9-21.4] days P<0.0001) was observed compared RT+L19 (4.6 
[3.0-7.4] days P<0.0001) and RT+IL2 (4.7 [3.0-6.9] P<0.0001) (figure 2B). Flow 
cytometric analysis demonstrated that the percentage of baseline NK cells of all 
lymphocytes (i.e. CD45+ population) in the tumour was low in vehicle (0.9% [0.3-1.2]) 
and RT+vehicle (0.9% [0.5-1.9]) treated animals. This number was significantly increased 
upon treatment with L19-IL2 (5.4% [2.1-11.5] P<0.001) and RT+L19-IL2 (2.7% [1.0-11.7] 
P<0.01). Furthermore, basal levels of CD8+ T cells inside F9 tumours were low and not 
increased upon treatment (figure 2D). 
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Figure 2A: treatment schedule. B: Time to reach 4 times start volume (T4xSV) for the different treatment 
groups (left) and Kaplan-Meier curves showing fraction of tumours not reaching T4xSV (right). C,D: Results of 
flow cytometry analysis, showing the percentage of NKp46+ cells (C) and CD8+ cells (D, right) shows of all
CD45+ cells present in the tumour and representative image of a fluorescent CD8 staining. *P<0.05, **P<0.01,
***P<0.001. 
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Radiotherapy during immunotherapy schedule 
Local irradiation of F9 tumours with 10Gy (day 2) significantly increased time to reach 
T4XSV in combination with IL2 (7.1 [5.6-8.9] days P<0.001) compared to IL2 treatment 
alone (4.0 [2.7-6.4] days). However, RT did not show any additional effects on L19-IL2 
treatment (10.1 [7.6-17.7] days P=0.12) compared to the immunocytokine treatment 
alone (8.9 [3.2-14.9] days). Combining RT with L19-IL2 did significantly delay tumour 
growth compared to the IL2 combination treatment group (P<0.001).  
 
 
Figure 3: A: Treatment schedule. B: Scatter-plot showing T4xSV (left) and Kaplan-Meier curves showing the 
fraction of tumours not reaching T4xSV (right). *P<0.05, **P<0.01, ***P<0.001.  
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DISCUSSION 
Radiotherapy causes immunogenic death of tumour cells, promotes antigen presentation 
and alters the tumour microenvironment (10). Recently, we and others have shown that 
the selective delivery of IL2 to the tumour is a promising approach to enhance the 
therapeutic potential of RT (4, 11). In this study, we investigated the therapeutic 
potential and underlying immune response of the RT and L19-IL2 combination treatment 
in the ED-B positive but MHCI negative F9 teratocarinoma tumour model.  
Combination of RT with L19-IL2 significantly retarded tumour growth compared to mice 
treated with RT plus IL2, regardless of RT timing. RT given before L19-IL2 treatment 
showed a therapeutic gain compared to the RT control groups and compared to single 
treatment arms. However, RT combined with L19-IL2 did not retarded tumour growth 
compared with RT plus IL2 treatment group when the single RT dose was delivered 
during the immunotherapy treatment. Therefore the former effective treatment 
schedule was used to investigate underlying immunological mechanisms in more detail. 
Previously, we described that long-lasting anti-tumour effects of RT combined with L19-
IL2 are highly dependent on expression of ED-B and the presence of cytotoxic T cells 
inside tumours (4). In this study, we showed that in the ED-B positive F9 
teratocarcinoma model the number of infiltrating NK cells, but not the number of 
cytotoxic T cells, are increased upon L19-IL2 treatment compared to vehicle or RT 
treatment arms. These results are in agreement with previous publications, where it 
was shown that, dependent on the tumour model, the efficacy of targeted IL2 
treatment by F16-IL2, F8-IL2, L19-IL2 or NHS-IL2 can be based on NK-cells (9, 12), T-cells 
(11, 13-15), or a combination of both (6, 16). A few possible explanations are available 
to clarify what favours an NK or T cell response after treatment with RT+L19-IL2. The 
low expression of MHCI may be an important one, since down-regulation or inactivation 
of tumour MHCI (which is involved in antigen processing and presentation) will prevent 
cytotoxic T cells from recognizing and eliminating tumours cells (10). On the other hand, 
downregulation of MHC expression on their surface causes tumour cells to be more 
vulnerable for NK cell killing (10), which is in agreement with our recent findings. 
However, in clinical setting, tumours tend to have a heterogeneous expression of MHCI 
(17) and therefore a mixture of cytotoxic T cells and NK cells may become activated 
when patients are treated with stereotactic body radiation therapy (SBRT) and L19-IL2 
in our clinical study (NCT02086721).  
Furthermore, treatment with L19-IL2 alone delays tumour growth significantly, which is 
in line with previous studies (6), and was further enhanced by a single dose of 10 Gy 
applied prior to L19-IL2 treatment schedule (figure 2A) but not by a single dose of RT 
given during the immunotherapy treatment schedule (figure 3A). A possible explanation 
is that RT the anti-tumour immune response that can be enhanced by L19-IL2, and 
therefore RT needs to be administrated before immunotherapy. Furthermore, RT might 
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be able to kill infiltrating immune cells and therefore RT administrated during the 
immunotherapy schedule may not have additional benefit.  
However, for the systemic IL2 treatment, we detected a significant anti-tumour immune 
response when administered before RT (figure 3A). This effect was not detected in the 
other treatment schedule, were IL2 was administered at day 1, 3 and 5 after RT (figure 
2A). Similar to our findings, Milas et al (18) showed that stimulation of the innate and 
adaptive immune system (by CpG oligodeoxynucleotides) prior to a single dose of local 
RT, is able to improve the outcome for RT treatment in mouse fibrosarcoma. 
Interestingly, the ´radiosensitizing effect´ of systemic IL2 was not detected when IL2 was 
administered in the targeted form (L19-IL2) before RT. Since L19-IL2 binds to ED-B and 
therefore stimulates the immune response only locally and since intratumoural basal 
levels of NK cells are very low, systemic IL2 treatment might have a higher impact 
compared to L19-IL2 in sensitizing tumours to irradiation. Taken together, administration 
of IL2 before but not after radiotherapy is able to delay tumour growth in this model and 
when L19-IL2 is administrated before radiotherapy, this ‘radiosensitizing effect’ is not 
present. 
In conclusion, combination treatment of RT with L19-IL2 is an efficient treatment 
combination in the MHCI negative but ED-B positive F9 tumour model and effects of 
L19-IL2 can be further improved by a single dose of RT before immunotherapy 
treatment. A single RT dose administrated during immunotherapy treatment seems to 
be less efficient. Furthermore, the data suggest that treatment of L19-IL2 favours NK 
and lacks cytotoxic T cell tumour infiltrating immune cells, which may be explained by 
the absence of MHCI expression by these F9 tumours. 
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In his commentary, Claus Garbe described our study on the combination of 
radiotherapy (RT) and the immunocytokine L19-IL2 in the F9 fibrosarcoma model (1) 
and discussed our work in a checkpoint inhibitor related context. The author is 
positioning interleukin-2 (IL2) based immunotherapies in the so-called ‘age of the 
checkpoint inhibition’ and concluded that the role of IL2 and/or L19-IL2 should 
preferentially be examined in patients not responding to checkpoint blockade, since 
these patients are not able to develop specific cytotoxic T cell responses.  Therefore IL2 
based immunotherapeutic approaches might circumvent this problem by activating the 
innate immune response against the tumour (2). 
The comparison of IL2 based therapies and checkpoint inhibitors made in this 
commentary is based on the fact that checkpoint inhibitors act on the modulation of an 
already present adaptive immune response (cytotoxic T cells) and IL2 based therapies 
are only able to trigger the innate immune system (NK cells). Indeed, we have shown 
that L19-IL2 (an immunocytokine binding to EDB present in the tumour vasculature and 
known for its locally operating immune modulating effects) is able to cause a significant 
growth delay associated with an intratumoural increase of NK cells in a MHCI negative 
tumour model (1). These effects were significantly higher as compared with equimolar 
levels of IL2 and are explained by the larger proportion of IL2 reaching the EDB positive 
tumour by using L19 as a tumour specific vehicle. Therefore, we agree with the 
statement that the ability of L19-IL2 to activate members of the innate immune system, 
in our study NK cells, indeed creates an interesting alternative for checkpoint inhibitors 
in case the cytotoxic T cell ‘baseline’ is insufficient.  
Furthermore, we have shown that the delivery of a single RT dose prior to the L19-IL2 
treatment schedule further enhanced the anti-tumour response of this treatment, while 
a schedule administrating RT during L19-IL2 treatment was less effective. Since NK cells 
can become activated by L19-IL2 to target MHCI negative tumour cells directly and do 
not necessarily need activation via cross-presentation of antigen presenting cells, this 
may explain why we have found an additive and not a synergistic effect of the 
combination treatment in this model (1). However, in addition to this tumour model we 
found long-lasting synergistic and additive effects of RT administrated prior to L19-IL2 in 
other tumour models. These models were all MHCI positive, therefore the RT + L19-IL2 
combined treatment approach was highly dependent on the action of cytotoxic T cells 
instead of NK cells (3). In clinical setting, tumours tend to have a heterogeneous 
expression of MHCI (4) and therefore a mixture of cytotoxic T cells and NK cells may 
become activated when patients are treated with a combination of radiation and L19-
IL2 based immunotherapy.  
For decades, the focus of RT related research was on its direct and local effects, 
depending on DNA damage and the intrinsic repair capacity of irradiated cells (5). 
However, RT additionally can cause immunogenic cell death of cancer cells, promoting 
IL2 based immunotherapies: Towards a personalized and curative anti-tumour response 
107 
the uptake and cross-presentation of released tumour (neo)antigens by dendritic cells 
(DC) to T cells in the draining lymph node and converting the irradiated tumour into an 
in situ personalized tumour vaccine (6). The concept that personalized vaccination is 
based on the recognition of (neo)antigens generated by tumour specific T cells (7), 
placed the use of RT in a totally different context (8). However, the commentary (2) 
addresses the issue that not all patients respond to treatment with checkpoint 
inhibitors via the release of specific cytotoxic T cells, a problem also observed in our 
MHCI positive tumour models when treated with L19-IL2 as single treatment. Based on 
recent publications (9, 10) and our observations we believe this may be caused by the 
insufficient cross-presentation of specific (neo)antigens to cytotoxic T cells and a 
decreased expression of (neo)antigens on MHCI by the tumour. In our opinion, RT can 
be the solution for both of these problems, and therefore RT can be used to further 
optimize and personalize an immunotherapeutic approach, including L19-IL2 and 
checkpoint inhibitor treatments. Furthermore, L19-IL2 may be favorable in case the RT 
triggered immunogenic cell death is not optimally capable of increasing the tumours 
immunogenicity, i.e. increasing the MHCI expressing tumour specific (neo)antigens, 
providing the immune system an extra cytotoxic tool, the NK cells. 
Radiotherapy (RT) is one of the major treatment options for cancer and approximately 
52% of all cancer patients receive RT during their treatment. The possibilities of RT to 
initiate an anti-tumour response by creating an in situ tumour vaccine and its potential 
to change a tumours (neo)antigen landscape, has the potential to greatly enhance the 
personalization and effectiveness of immune modulating agents. Indeed, the 
mechanisms of checkpoint inhibitors relay on the re-activation of already present but 
exhausted tumour (neo)antigen specific T cells, L19-IL2 function relies more on the 
activation and proliferation stage of these tumour specific T cells. In other words, 
checkpoint inhibitors are able to get rid of the brake, and L19-IL2 is able to push the gas. 
In our opinion, the first line treatment must consist of RT to create a personalized in situ 
vaccine and increase a tumours immunogenicity, followed by L19-IL2 to stimulate the 
proliferation of tumour (neo)antigen specific T cells at the tumour site. When these 
specific T cells become exhausted, expressing CTLA-4 and/or PD1 immune 
downregulating molecules, we see a clear role for checkpoint inhibitors. In case RT was 
insufficient to initiate a proper anti-tumour immune response against the tumour, 
indeed, L19-IL2 is even able to stimulate NK induced cytotoxicity. However, we believe 
that a long-lasting (memory effects) and off target (abscopal effects) anti-tumour 
immune effect can be reached when the right RT dose/schedule will be combined with 
the right immunotherapeutic approach in order to stimulate an immune response of 
adaptive origin.   
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ABSTRACT 
Recently, we have shown that the combination of radiotherapy (RT) with L19-IL2 results 
in RT dose-dependent long-lasting curative anti-tumour effects in an ED-B positive C51 
colon carcinoma model. In this study we investigated the possibility of increasing the 
anti-tumour immune response observed in the lowest RT dose (2Gy) combinational 
treatment approach by the addition of an anti-CTLA-4 checkpoint inhibitor. We 
observed that the trimodal treatment (RT + L19-IL2 + anti-CTLA-4) results in an 
improved anti-tumour response as compared with all other treatments, except for the 
bimodal treatment (RT + L19-IL2). Strikingly, the addition of anti-CTLA-4 significantly 
(p=0.04) decreases the anti-tumour response of the RT + L19-IL2 combination 
treatment and our preliminary data suggest that the PD-L1 immunosuppressive 
mechanism might explain this difference.  
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INTRODUCTION 
Besides its direct cytotoxic effect, tumour irradiation can additionally induce an 
immunogenic cell death, thereby converting the irradiated tumour into an immunogenic 
hub and initiating an anti-tumour response by the creation of a personalized vaccine 
consisting of autologous (neo)antigens (1, 2). This concept places radiotherapy (RT) in a 
different perspective, since this RT-induced in situ vaccine may be a key component in 
personalized immunotherapy (3). 
Recently, we have shown that RT combined with L19-IL2, a stimulatory immunocytokine, 
can induce long-lasting cytotoxic T cell (4) and NK cell mediated (5) anti-tumour effects, 
depending on the tumour model. These findings are currently being investigated in a 
Phase I clinical study (NCT02086721) in our institute in patients with oligometastatic solid 
tumours (https://youtu.be/xHbwQuCTkRc). L19-IL2 contains the monoclonal antibody 
fragment L19, which recognizes the alternatively spliced extra-domain B (ED-B) of 
fibronectin, a marker associated with tumour angiogenesis. ED-B is present in newly 
formed vasculature structures of most solid tumours and absent in healthy tissues (with 
exception of tissues of female reproductive cycle and embryonic tissue), making it an 
interesting tumour targeting protein (6). The synergistic effect of RT combined with L19-
IL2 is however dependent on the radiation dose, i.e. decreases at lower RT dose (4). 
Increasing RT dose is a possible way to create optimal synergy with the 
immunostimulatory cytokine L19-IL2, but RT dose cannot be escalated unlimitedly 
because of normal tissue constraints (7).  
Another possible and novel approach might be the addition of an immune checkpoint 
inhibitor that actively inhibits immune dampening pathways (8). One of the recent FDA 
(Food and Drug Administration) approved immune checkpoint inhibitors, anti-CTLA-4 
(ipilimumab), has indeed shown ability to stimulate T cell proliferation and cytokine 
production (9, 10), which resulted in encouraging durable tumour regression in a 
number of (metastatic) cancer patients (8). CTLA-4 is highly related to CD28 but has the 
opposite function. While CD28 signaling promotes T cell activation, CTLA-4 suppresses 
the T cell response and has an immunoregulatory role (11). Both CD28 and CTLA-4 
interact with CD80/CD86 on antigen presenting cells (12), and competing with CD28 for 
binding with shared ligands is one of the mechanisms that has been proposed to result 
in the inhibitory function of CTLA-4 (13-17). Blocking CTLA-4 using immune checkpoint 
inhibitors can therefore shift the balance into favouring CD28-mediated T cell 
activation, a concept of ‘releasing the brakes’. Moreover, recent reports show that even 
greater success can be achieved by combining checkpoint inhibitors with other 
inhibitors such as against the PD-1/PD-L1 axis, tumour vaccines or radiotherapy (18-22). 
Because ipilimumab is known to prolong the anti-tumour immune response and has 
shown to be even more successful in combination with RT, we hypothesized that we 
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can observe synergistic anti-tumour effects by combining low dose RT and L19-IL2 
(bimodal treatment) with the immune checkpoint inhibitor of CTLA-4. 
RESULTS 
Anti-CTLA4 antibody decreases anti-tumour efficacy of the bimodal treatment 
To investigate if CTLA-4 is a possible target to increase the RT and L19-IL2 induced anti-
tumour immune response, we first confirmed the expression of CTLA-4 on T cells in 
blood from L19-IL2 treated mice. Flow cytometric analysis (FACS) on peripheral blood 
revealed a higher percentage (p=0.03) of circulating CTLA-4 expressing cytotoxic (CD8+) 
T cells [3.9%, 1.8-8.9] in L19-IL2 treated animals as compared with vehicle control mice 
[0.8%, 0.6-1.5] (figure 1A), though the total amount of CD8+ T cells did not differ 
significantly (p=0.25). Since CTLA-4 expression is known to downregulate T cell function 
(23) and the anti-tumour effect of RT + L19-IL2 depends highly on these cytotoxic T cells 
(24), we investigated a trimodal therapy consisting of RT (2Gy), L19-IL2 and anti-CTLA-4. 
We evaluated the T4xSV for all treatment groups in the high ED-B expressing C51 
mouse colon carcinoma model. Any combination treatment with RT, shows an 
increased T4xSV compared to vehicle control (at least p<0.03) or monotherapy 
(p<0.01). RT + L19-IL2 significantly increased T4xSV (10.0 [5.9-21.0] days) compared to 
any other treatment schedule (p<0.001) and resulted in a long-lasting cure in 5 out of 
18 tumours (figure 1B). The combination of RT + L19-IL2 + anti-CTLA4 increased T4xSV 
(p<0.005) as compared with all other treatments, except for RT + L19-IL2. The triple 
combination strikingly reduced (p=0.04) T4xSV (8.0 [6.3-22.0 days) and cure rate (8%) as 
compared with RT + L19-IL2 (Fig. 1B). 
Regulatory T cells in blood do not differ between bi- and trimodal treatment  
Several human and mouse studies have shown that the use of anti-CTLA-4 antibodies 
can lead to the enhancement of regulatory (Foxp3+CD25+CD4+) T cell (Tregs) 
proliferation and overall frequency (25, 26). Therefore, we investigated if addition of 
anti-CTLA-4 to RT + L19-IL2 treatment could increase the amount of circulating Tregs as 
possible explanation for the decreased therapeutic efficacy of the trimodal treatment as 
compared with the RT + L19-IL2 bimodal treatment (figure 1C). The total amount of 
circulating CD8+ T cells did not differ between all treatment groups (data not shown). 
Anti-CTLA-4 treatment does not increase the amount of circulating Tregs in agreement 
with the lack of therapeutic efficacy (figure 1b). Although the trimodal treatment was 
less effective compared to the curative RT + L19-IL2 therapy, no significant differences 
in Tregs expression (Fig. 1c) and Treg/Thelper ratio (data not shown) were observed. 
Furthermore, we have found that L19-IL2 treatment enhances circulating Tregs, L19-IL2 
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+ anti-CTLA-4 (8.9% [7.7-10.7]) and 2Gy + L19-IL2 + anti-CTLA-4 treatment (7.3% [6.0-
9.2]) show a significantly higher percentage of Tregs as compared with anti-CTLA-4 
(3.0% [1.1-4.1], p=0.002) and 2Gy + anti-CTLA4 (4.6% [4.1-5.7], p=0.004), respectively. 
 
Figure 1: Growth delay trimodal treatment and peripheral regulatory T cells. (A) Schedule used for blood 
sampling and quantification of % CD8+ and CD8+ CTLA-4+ of total peripheral CD45+ immune cells. (B) Schedule 
used and fraction of tumours not reaching 4 times start tumour volume. (C) Representative gating and 
quantification of Foxp3+CD25+ T cells of total peripheral CD45+ immune cells. *p<0.05, **p<0.01. 
 
CD25+FoxP3-
2,25
FoxP3+
2,70
0 104 105
Comp-PE-A :: FoxP3
0
-10 3
103
104
105
C
om
p-
AP
C
-A
 ::
 C
D
25
CD25+FoxP3-
1,96
FoxP3+
3,56
0 104 105
Comp-PE-A :: FoxP3
0
-10 3
103
104
105
C
om
p-
AP
C
-A
 ::
 C
D
25
CD25+FoxP3-
2,47
FoxP3+
20,7
CD4+
66,8
CD3e+
54,0
CD45+
44,1
Life
73,0
Singlets
75,5
0 104 105
Comp-PE-A :: FoxP3
0
-10 3
103
104
105
C
om
p-
AP
C
-A
 ::
 C
D
25
CD25+FoxP3-
3,54
FoxP3+
20,3
0 104 105
Comp-PE-A :: FoxP3
0
-10 3
103
104
105
C
om
p-
AP
C
-A
 ::
 C
D
25
CD25+FoxP3-
2,18
FoxP3+
10,0
0 104 105
Comp-PE-A :: FoxP3
0
-10 3
103
104
105
C
om
p-
AP
C
-A
 ::
 C
D
25
CD25+FoxP3-
2,55
FoxP3+
9,41
0 104 105
Comp-PE-A :: FoxP3
0
-10 3
103
104
105
C
om
p-
AP
C
-A
 ::
 C
D
25
CD25+FoxP3-
1,93
FoxP3+
13,1
0 104 105
Comp-PE-A :: FoxP3
0
-10 3
103
104
105
C
om
p-
AP
C
-A
 ::
 C
D
25
CD25+FoxP3-
3,52
FoxP3+
16,4
0 104 105
Comp-PE-A :: FoxP3
0
-10 3
103
104
105
C
om
p-
AP
C
-A
 ::
 C
D
25
Vehicle anti-CTLA-4 L19-IL2Ancestry (gating)
L19-IL2 + anti-CTLA-4 2Gy RT + Vehicle 2Gy RT + anti-CTLA-4
2Gy RT + L19-IL2 2Gy RT + L19-IL2 + anti-CTLA-4
FSC-W x 
FSC-A
SSC-A x 
FSC-A
Histogram 
of CD45+
Histogram 
of CD3+
CD4+ x 
CD8+
FoxP3+
C
D
25
+
>
>
0
0,005
0,010
0,015
0,020
0,025 Vehicle
-IL2L19
U
ni
t A
re
a
CD8+CTLA-4+ T cells 
Ve
hic
le
L1
9-I
L2
0
5
10
15
20
*
%
 o
f C
D
45
+ 
ce
lls
CD8+ T cells
Ve
hic
le
L1
9-I
L2
0
20
40
60
80
100
NS
%
 o
f C
D
45
+ 
ce
lls
0 10 20 30
0
20
40
60
80
100
40 60 80 90 100
Vehicle (n=15)
L19-IL2 (n=19)
anti-CTLA-4 (n=11)
RT (2Gy) + Vehicle (n=13)
L19-IL2+anti-CTLA-4 (n=12)
RT (2Gy)+anti-CTLA-4 (n=12)
RT (2Gy)+L19-IL2+anti-CTLA-4 (n=12)
RT (2Gy)+L19-IL2 (n=18)
Time (days)
Fr
ac
tio
n 
no
t r
ea
ch
in
g
4x
 s
ta
rt 
tu
m
ou
r v
ol
um
e
>
^ ^ ^ ^
RT L1
9-I
L2
/ve
hic
le
L1
9-I
L2
/ve
hc
ile
L1
9-I
L2
/ve
hc
ile
^
an
ti-C
TL
A-
4/v
eh
cil
e
^
Blo
od
 sa
mp
lin
g
 CD8+CTLA-4+ T cells 
>
^ ^ ^ ^
sh
am
L1
9-I
L2
/ve
hic
le
L1
9-I
L2
/ve
hic
le
L1
9-I
L2
0       1        2        3        4       5        
Days
^
Blo
od
 sa
mp
lin
g
0       1        2        3        4       5        
Days
2.4% 3.0% 8.2%
8.8% 5.3% 4.6%
7.1% 7.3%
A B
C
Foxp3+CD25+ T cells (whole blood)
Ve
hic
le
an
ti-C
TL
A-
4
L1
9-I
L2
L1
9-I
L2
+a
nti
-C
TL
A-
4
2G
y R
T +
 Ve
hic
le
2G
y+
an
ti-C
TL
A-
4
2G
y+
L1
9-I
2
2G
y+
L1
9-I
L2
+a
nti
-C
TL
A-
4
0
5
10
15
20
25
*
**
**
*
**
NS
*
*
*
*
**
%
 o
f C
D
45
+ 
ce
lls
Chapter 8 
114 
Resistance to CTLA-4 treatment: PD-L1 expression to escape immune attack? 
Recently, it has been shown that tumours have the ability to escape RT + anti-CTLA-4 
mediated immune killing via the upregulation of PD-L1 (19). Therefore, we next 
investigated the expression of PD-L1 in tumours from the different treatment arms. 
Immunofluorescent stainings revealed that all tumour cells  indeed express PD-L1 and 
tumours isolated from mice who received the trimodal treatment tend to have a higher 
mean PD-L1 expression (1150 ± 91) as compared with the vehicle (1091±124), RT + L19-
IL2 (1023±192) and the RT treated (923) tumours (figure 2), which requires further 
confirmation.  
 
 
Figure 2: PD-1L expression in tumour tissues. Representative image of PD-1L expression in tumour and 
quantification of PD-L1 expressing among different treatment groups. (in blue: Dapi, PD-L1: in red).  
DISCUSSION 
Previously we have shown that the RT + L19-IL2 bimodal therapy can induce long-lasting 
curative cytotoxic T cell responses, depending on the tumour model and the delivered 
RT dose (24) and NK cell mediated responses (5). Addition of an immune checkpoint 
inhibitor (8) might enhance the therapeutic effect of this combination treatment, since 
unlimitedly increasing the RT dose is not recommended because of normal tissue 
constraints (7). Here we investigated the therapeutic potential of a trimodal treatment 
approach, combining RT and L19-IL2 with anti-CTLA-4 (ipilimumab).  
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Although the role of CTLA-4 is controversial (27, 28), anti-CTLA-4 therapy has shown 
encouraging durable tumour regression in a number of (metastatic) cancer patients (8) 
and recent data demonstrate that even greater success can be achieved by combining 
various checkpoint inhibitors with each other, with tumour vaccines or radiotherapy 
(18-22). Indeed, RT can improve the response rate of anti-CTLA-4 (29). The combination 
of anti-CTLA-4 with L19-IL2 also resulted in high cure rates in a preclinical study (30) and 
durable but no synergistic effects (due to high IL2 response rates) could be observed in 
a clinical trial combining anti-CTLA-4 with IL2 administration (31).  
L19-IL2 treatment resulted in a higher percentage of circulating CTLA-4 expressing T 
cells (figure 1A) and it has been shown that RT can improve anti-CTLA-4 efficacy (29, 
32). Therefore, we hypothesized that the addition of anti-CTLA-4 could further increase 
the RT + L19-IL2 induced anti-tumour immune response. In this study, the trimodal 
treatment (RT + L19-IL2 + anti-CTLA-4) increases the time to reach 4 times starting 
volume as compared with all other schedules, except for the bimodal treatment. 
Strikingly, we observed a reduced cure rate in the trimodal treatment group compared 
to RT + L19-IL2. Since it is known that the upregulation of CTLA-4 is a major immune 
dampening feature in order to control the duration and amplitude of a physiological 
immune response with minimal collateral tissue damage (8), our chosen time point of 
anti-CTLA-4 administration (day 2) might be too early to prolong and enhance the 
immune response. 
Since CTLA-4 is not only expressed on exhausted cytotoxic T cells but also on Tregs (33), 
and the use of anti-CTLA-4 antibodies can lead to the enhancement of Treg proliferation 
(25, 26), we first investigated if the reduced anti-tumour effect could be explained by an 
increase in circulating Tregs. Our results indicate that anti-CTLA-4 treatment has no 
effect on circulating Tregs when added as additional therapy and is therefore not the 
underlying reason for the reduced anti-tumour effect of the trimodal therapy. 
Additionally, L19-IL2 monotherapy tends to increase the expression of circulating Tregs 
to a similar extent as high dose IL2 as described before (34). However, previously we 
(24) and others (6) have shown that L19-IL2 shows better anti-tumour responses as 
compared with systemic IL2 treatment, justifying the use of L19-IL2 over IL2 treatment.  
The upregulation of a tumour immune escape mechanism can be another possible 
explanation for the observed resistance after anti-CTLA-4 administration. Recently, it 
was shown that tumours (melanoma) can escape anti-CTLA-4 based therapies by the 
upregulation of PD-L1 (19). Our preliminary results indeed show that PD-L1 is expressed 
in the tumour model used, and therefore it is possible that the PD-L1/PD-1 axis is 
involved as immunosuppressive mechanism. Furthermore, we observed a trend 
towards higher PD-L1 expression in the trimodal treatment; however, these data need 
to be confirmed at a time point shorter after RT + L19-IL2 treatment initiation using 
larger sample size, which is ongoing in our laboratory. Based on recent studies (19) and 
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our first results, the rational of combining anti-PD-1 instead of anti-CTLA4 with RT + L19-
IL2, seems to be a promising combination.  
Furthermore, in the present study we administrated one dose of ipilimumab at day 2. 
This schedule was based on our previous used schedule (RT day 0, L19-IL2 day 1, 3, 5) 
(24) and the anti-tumour activity observed in another preclinical study administrating 
ipilimumab one day after L19-IL2 injections (30). However, since we observe a worse 
anti-tumour effect using the trimodal treatment, the suboptimal timing of this 
checkpoint inhibitor, thereby contrarily inhibiting cells necessary for the optimal anti-
tumour immune response, might be another possible explanation for this observed 
worse anti-tumour response after anti-CTLA-4 administration.  
Based on these findings we conclude that anti-CTLA-4 treatment was not capable of 
increasing the RT + L19-IL2 anti-tumour effect. Upregulation of PD-L1 or PD-1 by anti-
CTLA-4 treatment might be an explanation of the observed resistance occurred in the 
trimodal treatment, but timing of the anti-CTLA-4 treatment might also explain the lack 
of therapeutic benefit.  
MATERIAL AND METHODS 
Tumour cell lines/ reagents/ antibodies for in vivo studies 
Exponentially growing C51 mouse colon carcinoma cell lines (kindly provided by 
Philogen S.p.A., Siena, Italy) were cultured in Dulbecco's Modified Eagle Medium 
(DMEM), supplemented with 10% fetal calf serum (FCS) in a humidified 5% CO2 
chamber at 37°C. The L19-IL2 immunocytokine (Philogen S.p.A.) was diluted with sterile 
phosphate buffered saline (PBS, Lonza) to concentrations of 200µg/ml.  
in vivo experiments 
All experiments were performed in accordance with local institutional guidelines for 
animal welfare and were approved by the Animal Ethical Committee of the University of 
Maastricht. To induce tumours, approximately 8 weeks old immune competent Balb/c 
(Harlan Laboratories) mice were subcutaneously injected with the ED-B positive (24) 1.5 
x 106 syngeneic C51 tumour cells, suspended in Basement Membrane Matrix 
(MatrigelTM, BD Biosciences), during fixation of the mice to obtain a xenograft tumour. 
Injected cells were screened for mice pathological organisms (QM MAP test). During the 
experiment, subcutaneously implanted tumours were measured several times a week 
(depending on speed of tumour growth). For this measurement we used a Vernier 
caliper measuring three orthogonal diameters (A x B x C), which were corrected for 
thickness of the skin. Tumour volume was calculated using the following formula: A x B x 
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C x π/6. Upon an average tumour volume of 200-250 mm³, animals were anaesthetized 
using ketamine/xylazine mix i.p. (100 mg/kg + 10 mg/kg) and tumours were irradiated 
with a single dose RT dose of 2Gy (which was based on our previous RT dose-dependent 
treatment effects (24) and in order to create a window of opportunity for anti-CTLA-4) 
on day 0, followed by systemic therapy (vehicle PBS / L19-IL2 20µg) on day 1, 3 and 5 
and (vehicle PBS / anti-CTLA-4 10 mg/kg i.v) on day 2. All i.v. injections occur in the tail 
vein using a tail fixator. Tumour growth and treatment toxicity (based on body-weight) 
were monitored until reaching 4 times the volume at irradiation time (T4xSV).  
Flow Cytometric analysis 
Flow cytometric analysis was performed on blood samples. Blood samples were collected 
via punction of the vena saphena of L19-IL2 and vehicle treated mice at day 4. Red blood 
cells lysis was performed using RBC lysis buffer (eBioscience, San Diego, CA). Cells were 
incubated with FC-block CD16/CD32 (clone 2.4G2; BD Biosciences, San Jose, CA) and 
stained with a combination of following the antibodies for cell surface markers: anti-
CD45-PerCP (30-F11), anti-CD152 (CTLA-4)-Brilliant Violet 421 (UC10-4B9), anti-279 (PD-
1)-PE-Cy7 (RMP1-30) (Biolegend); anti-CD3e-FLUO 450 (145-2c11), anti-CD4-FITC (RM4-
5), anti-CD8a-V500 (53-6.7) (BD Biosciences), CD25-APC (PC61.5) (eBioscience). For 
intracellular staining, FC blockade and cell surface markers staining was performed, cells 
were washed with a fixation/permeabilization working solution (eBioscience) according 
to manufacter’s guidelines and then stained with anti-mouse/rat FOXp3-PE staining set 
(FJK-16s; eBioscience). Eight-colour flow cytometric analysis was performed with a 
FACSCanto II instrument (BD Biosciences). Data were analyzed with FACSDiva v6.1.2 (BD 
Biosciences) and FlowJo v10.0.8 (Tree Star) software. The total CD45+ immune cells were 
selected from the viable population of cells (filtered for debris and doublets) for further 
sub-classification according to the strategy described previously (24).   
Immunofluorescence 
Tumour sections (7 µm) from the central part of a tumour were fixed with acetone 
(4°C), rehydrated in phosphate buffered saline (PBS), incubated with normal goat serum 
followed by incubation with the primary rat anti-mouse PD-L1 antibody (1:100; Abcam) 
overnight at 4°C and secondary goat anti-rat Alexa594 (1:500, Invitrogen) for 1 hour at 
room temperature. Sections were mounted using fluorescent mounting medium 
(DakoCytomation). All sections we stained on the same day. Whole tumour cross-
sections were scanned using an Olympus BX51WI microscope equipped with a 
Hamamatsu EM-CCD C9100 digital camera, a motorized stage (Ludl Mac 2000) and 10-
fold objective. The same exposure time was used for all recordings. After scanning, 
sections were stained with hematoxylin and eosin for the identification of the viable 
tumour compartment by morphological criteria. Mean intensity of PD-L1 staining was 
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measured in a blinded manner in each tumour cross-section in viable tumour areas, 
which was manually delineated excluding cutting and processing artefacts. 
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The overall aim of this dissertation was to investigate the possibility of transforming the 
effects of local radiotherapy (RT) into a systemic treatment using the immunocytokine 
L19-IL2. This is of major importance, since RT is usually applied locally or locoregionally, 
therefore (micro)metastases outside the radiation field will be missed and have the 
opportunity to grow. However, it is not only of major importance, it is also of enormous 
interest. It is known that RT can initiate an anti-tumour immune response (1). Therefore 
the possibility of transforming and improving this anti-tumour immune response using 
an immunomodulatory approach, holds great potential for creating a personalized, 
multifaceted ‘medicine’. This medicine, the anti-tumour immune response itself, will 
contain elements of a patient’s tumour and has therefore the potential to target this 
heterogeneous disease in the same heterogeneous manner, with a curative intent.  
TOWARDS A MULTI-FACETED CORPUS-DRIVEN TREATMENT - THE FIRST 
STEPS 
In chapter 3 we hypothesized that the combination of RT (10Gy) with the 
immunocytokine L19-IL2 causes a synergistic anti-tumour effect on irradiated tumours 
dependent on the expression of ED-B. Therefore, in this study, we assessed the 
therapeutic potential and related induced anti-tumour immune responses of this 
combination therapy in three different in vivo mouse tumour models: the 4T1 breast 
carcinoma, Lewis lung carcinoma (LLC), and the C51 colon carcinoma, which have 
respectively increasing expression levels of ED-B (2). The combination treatment 
showed no additional therapeutic improvement in the low/negative ED-B expressing 
model 4T1 and merely an additive effect was observed in the intermediate ED-B 
expressing LLC model. Importantly, highly synergistic effects with a cure rate of 75% 
were detected in the high ED-B expressing model C51 (2), in line with the higher L19-IL2 
tumor targeting capacity when having more ED-B expression. ED-B is overexpressed in 
many solid tumors (3-7), making L19-IL2 applicable for the majority of cancers. Previous 
imaging and targeted (radio)immunotherapy studies have shown that L19 targets the 
tumour (vasculature) (8-10). Moreover, the administration of L19-IL2 alone or 
combined with chemotherapy (decarbazine), was safe and showed clinical activity in a 
phase I study in patients with melanoma or renal cell carcinoma (11, 12) and a phase II 
study investigating the efficacy of L19-IL2 combined with L19-TNF in stage III and IV 
melanoma patients is ongoing (NCT02076633).  
Moreover, we showed that the percentage of tumour infiltrating CD8+ cytotoxic T cells 
are higher in ED-B expressing tumours treated with RT + L19-IL2 and a CD8+ depletion 
experiment provided direct evidence that the complete remission of C51 tumours is 
causally related to these immune cells (2). These data are in line with other studies, in 
which KS-IL2 (targeted to epithelial cell adhesion molecule) combined with 
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radiofrequency ablation in a murine colon adenocarcinoma (CT26) showed increased 
growth suppression associated with a larger proportion of CD4+ and CD8+ T cells (13).  
Moreover, the therapeutic effect of F8-IL2 and F16-IL2 (recognizing ED-A/ED-B domains 
of fibronectin and the A1 domain of tenascin-C, respectively) was also shown to be 
mediated by CD8+ T (and NK) cells in an in vivo AML model (14). To investigate the 
dependency of the synergy between RT and L19-IL2 on the RT dose, we additionally 
investigated a single RT dose of 5 and 2Gy. Lower RT doses resulted in a reduced 
number of tumour cures (2). In line with our findings, in vitro studies have shown that 
the immune stimulating effects of radiation are dose-dependent (15), suggesting that 
high RT doses induce more immunogenic effects. However, these effects are largely 
dependent on the complex composition of the tumour microenvironment (16). There is 
no real consensus about the optimal RT dose or regimen to induce the best immune 
initiating effects and therefore resulting in the optimal synergy between RT and an 
immunotherapeutic approach (17). Some studies support the use of a single high RT 
dose (30Gy), others show that a dose of 2Gy or hypo-fractionated doses of 6 or 8Gy are 
the best triggers to be used (18-20). These divergent results might be dependent on the 
tumour model used and might be explained by differences in tumour immunogenicity 
or composition of immune infiltrating cells at start of (RT) treatment (21). A clear read-
out system (i.e. biomarker) to select patients for a certain RT regimen, maximizing their 
personal ‘in situ’ vaccine and therefore creating the best anti-tumour immune response 
starting point, is in my opinion crucial. From there on, selection for the optimal immune 
modulation strategy and patient monitoring (on tumour and systemic level) should be 
performed. Based on our preclinical results described in chapter 3 (2) and clinical results 
proving the higher response rate of high-dose stereotactic body radiotherapy (SBRT) 
(22) with systemic IL2 in patients with metastatic melanoma or RCC (23) as compared 
with historical controls, we suggest that the use of SBRT is sufficient to release DAMPs 
and initiate the anti-tumour immune response. Since L19-IL2 is proven to be safe in 
patients, these findings are translated into a Phase I clinical safety study (NCT02086721) 
combining SBRT and L19-IL2 in patients with oligometastatic solid tumours, which is 
currently ongoing in our institute. So far, preliminary results of this trial indicate that the 
treatment combination is safe for the first dose level, accompanied with pain in the 
tumour region suggesting treatment efficacy. 
Overall, these data prove that a synergy between RT and L19-IL2 exists, and that it is 
possible to develop curative anti-tumour immune-mediated effects in irradiated 
tumours under certain conditions including the presence of ED-B expression and 
cytotoxic T cell infiltrate. In chapter 4 we place the current findings into a broader 
perspective and describe how our findings reported in chapter 3 (2) form the basis for 
following research (24). In my opinion, learning from responders, which reveals 
groundbreaking secrets, is the optimal way to move forward and to translate these 
secrets into usable future knowledge applicable to treat non-responders. Therefore, the 
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following chapters are focusing on the ‘winning medicine’: the RT + L19-IL2 anti-tumour 
immune response triggered in Balb/c mice bearing ED-B positive C51 tumours. Because 
the major aim of this research is to create preclinical evidence for a multi-faceted 
systemic ‘patient-driven’ treatment, we discussed the utility of this experimental set-up 
towards further preclinical translational approaches. This chapter forms a little bridge, 
giving us a sneak-preview about what is coming: translating the research (this winning 
medicine) to other experimental set-ups which enables us to investigate the anti-
tumour immune effect outside the RT field (25), long-term anti-tumour effects, i.e. 
immunological memory against the tumour cells, and the possibility of novel 
combinations, for example, with hypoxia activated prodrugs (26) and checkpoint 
inhibitors (27).  
EXPLORING THE OUT OF FIELD ANTI-TUMOUR EFFECTS  
Based on the results obtained in chapter 4 and since immune cells operate systemically, 
we hypothesized in chapter 5 that the RT + L19-IL2 mediated anti-tumour immune 
effect has long-lasting anti-tumour effects outside the RT field. Since T cells recognize 
tumour-associated (neo)antigens in order to effectively perform their cytotoxic activity 
(28), and RT is known to increase the tumour (neo)antigen expression (1, 29), it is a 
highly relevant question to test: tumours outside the RT field might be a less obvious 
target for these immune cells. Furthermore, the study creates insights into this systemic 
anti-tumour effect which is crucial when treatment will be translated to patients with 
(micro)metastases. Anti-tumour effects outside the RT field, a phenomenon known as 
the abscopal (ab – position away from and scopus – target) effect (30-34), solely caused 
by RT are rare (35). Moreover, since the effect has been observed over decades in 
multiple cancers (36-42) and because of this long-lasting potential, it has been 
established that the RT-induced abscopal effect is immune-mediated (43). In chapter 5, 
we are not solely investigating the RT-induced abscopal effect, but combine it with L19-
IL2, and therefore we propose another terminology for this ‘extended’ abscopal effect, 
namely the Out-of-Field RadioImmune (OFRI) effect.  
In chapter 5 we show for the first time that a single RT dose (15Gy) resulted in a 
curative OFRI effect when combined with L19-IL2 in 20% of the non-irradiated 
macroscopic tumours. Two fractionated RT regimes (5 x 2Gy and 5 x 5Gy) resulted 
additionally in an OFRI effect, though without curative results. The first immunological 
analyses, performed on day 4 of the treatment, revealed an increase in CD4+ T 
infiltration in tumours outside the RT field, suggesting the involvement of CD4+ T cells in 
the RT + L19-IL2-mediated OFRI effect. Depletion of CD4+ T cells, starting on day 5 after 
RT, resulted in faster tumour growth of non-irradiated tumours but this effect was not 
statistically significant. On the other hand, depletion of CD8+ T cells abrogated the OFRI 
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effect of the combination therapy significantly. These data provide direct evidence that 
the growth delay and complete remission of 20% of the non-irradiated tumours is 
predominantly attributed to CD8+ T cells. ‘Immunoscore’, a scoring system which 
classifies cancer based on tumour immune infiltrate, has prognostic value proven for 
several malignancies (44), but might not be useful in case of systemic (metastatic) 
cancer. Therefore, the OFRI effects against metastases (when tumour biopsy cannot be 
investigated) might be predicted using mathematical models in the near future. These 
models, which incorporate physiologic information about T cell trafficking in order to 
estimate the distribution of activated T cells between metastatic lesions, may 
additionally offer insight into the dynamics of systemic disease (45, 46).  
To investigate specificity of OFRI effect, we used another ED-B positive secondary CT26 
tumour (47) and observed a similar growth delay of this mismatched tumour. However, 
the OFRI effect did not result in mismatch tumour cures, suggesting common 
expression of only a part of the (neo)antigens between these secondary tumours, CT26 
and C51. Further investigation into the antigen-specific T cells responsible for the RT + 
L19-IL2 mediated OFRI effect should be performed in order to predict outcome, and we 
believe that the novel technique using peptide-MHCI multimers labeled with DNA 
barcodes is the most reliable and extensive way to continue this research (48).  
Of great importance, we were able to show that part of the out-of-field tumour 
infiltrating T cells have a regulatory (Foxp3+CD25+) phenotype or express PD-1, resulting 
in the tolerance and exhaustion of these cells (49). The expression of PD-1 on T cells is 
identified as an inhibitory mechanism of immune responses (19, 50, 51). Several PD-1 
inhibitors, including nivolumab, have obtained FDA approval (27) and show very 
promising anti-tumour activity (52, 53). Because of the observed immunosuppressive T 
cell phenotype of T cells infiltrating out-of-field tumours, and the availability of highly 
promising FDA approved new therapies, a basis is formed towards an even better OFRI 
effect. This exhausted T cell phenotype as well as increased infiltration of regulatory T 
cells was not observed inside irradiated primary tumours, suggesting that a single RT 
dose can directly shift the effector/regulatory balance into an effective immune 
response, which is in line with published data (1, 54). In contrast, fractionated (5 x 2Gy) 
RT increased PD-1 expressing T cells inside both irradiated and non-irradiated tumours. 
Our results suggest that the addition of a checkpoint inhibitor such as anti-PD-1 is 
therefore useful in case T cells express high levels of PD-1. Comparison between non-
irradiated tumours of 15Gy + L19-IL2 and 5 x 5Gy + L19-IL2 treated primary tumours 
revealed that the single RT dose treated mice have a higher percentage of peripheral 
(blood) CD4+ T cells and a higher percentage of tumour infiltrating CD8+ T cells. Based 
on our previous studies showing that CD8+ T cells are causing the RT + L19-IL2 anti-
tumour effect of irradiated tumours (chapter 3, (2)) and since we have shown that T 
cells are crucial for a RT + L19-IL2 OFRI effect, differences in percentage of circulating 
CD4+ T cells and infiltrating CD8+ T cells may explain why single RT dose is a better 
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inducer of a curative OFRI effect. These data suggest that it might be interesting to 
extent the novel technique using peptide-MHCI multimers labeled with DNA barcodes 
(48) with peptide-MHCII multimers, in order to create a full understanding of the T cell 
mediated OFRI effect in the future. It is known that the RT dose, schedule and 
technique can provoke a pleiotropy of systemic immune responses (1), and as discussed 
above, there is no uniform consensus about the optimal immune activating RT trigger. 
Several preclinical studies showed significant growth delay and complete remission 
outside the RT field when immunotherapy (anti-CTLA-4) was combined with 
fractionated RT but not with a large single RT dose (18, 55). In contrast, Lee et al. 
showed that a single RT dose (20Gy) initiated immune responses and tumour (including 
non-irradiated metastases) growth retardation when combined with immunotherapy 
(ad-LIGHT) (56). These effects were not observed when combined with fractionated RT 
(4 x 5Gy), similar to our findings. Based on the curative results of the single RT dose as 
compared with fractionated RT, we conclude that one single dose of RT is the best 
trigger in combination with L19-IL2 to create maximum tumour control at distance for 
this tumour model. 
Moreover, in this chapter we describe the capability of RT + L19-IL2 cured mice to 
develop long-lasting immunological memory against these tumours. This protective 
immunity was only formed when tumour-bearing mice were treated with RT + L19-IL2, 
showing that the tumour forms the basis for the ‘in situ’ vaccine that can eventually be 
translated into a direct (irradiated), indirect (non-irradiated) and long-lasting (re-
challenged) anti-tumour immune responses. The expression of CD127 is a hallmark of 
primed CD8+ T cells to develop into long-lived memory cells (57-60), however blocking 
of CD127 did not result in a different tumour take and growth upon re-challenging, 
showing that this long-lasting RT + L19-IL2 induced effect is associated with, though not 
caused by CD127. In contrast, mice cured by surgery + L19-IL2 and high dose RT + 
vehicle developed significantly more tumours after re-challenge accompanied by 
elevated normal tissue toxicity levels within the high dose RT treatment group. These 
results clearly show that RT + L19-IL2 tumour cure is absolutely necessary to achieve 
long-lasting anti-tumour protection. Furthermore, we revealed a significant increase of 
CD44+CD62L+ and CD44+CD62L- expression on CD8+ T cells in the lymph nodes, 
indicative for central memory T cells and effector T cells, respectively (58, 61, 62) in 
cured mice able to prevent tumour development. Therefore, we conclude that central 
memory and effector T cells in the lymph node compartments are involved in the 
protection against new C51 tumour formation. The same mice show high expression of 
CD44+CD127+ on splenic, lymph nodes and on circulating (blood) CD8+ T cells, which are 
classified as effector memory T cells (58, 61, 62). Since effector memory T cells are 
significantly increased in the blood of mice able to reject tumour cells upon re-
challenge, these immune cells are systemically associated with an optimal long-lasting 
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protective effect and may serve as biomarker to identify patients who did not develop 
immunological memory and thus is at higher risk of tumour relapse.  
A ROLE FOR NK CELLS 
So far, we observed that the combination therapy of RT + L19-IL2 was T cell dependent. 
In chapter 6, we hypothesize that this combination therapy can also trigger a NK cell 
dependent anti-tumour response in a model (F9 teratocarcinoma) lacking MHCI 
expression, however positive for ED-B expression (63). Indeed, it is known from 
literature that NK cells (belonging to the innate immune system) play a crucial role in 
the anti-tumour activity of a wide variety of tumour cells with reduced or absent MHCI 
expression (64). In this chapter we observed no tumour growth delay when RT was 
delivered during the L19-IL2 treatment schedule (RT day 2, L19-IL2 day 0, 2, 4). 
However, using the same treatment schedule (RT day 0, L19-IL2 day 1, 3, 5) as 
described in previous chapters, the combination treatment showed a therapeutic gain. 
This might be explained by the fact that L19-IL2 treatment stimulates the 
proliferation/activation of NK cells, which are killed when the RT dose is delivered 
during immunotherapy. Indeed, L19-IL2 treatment alone did already result in a 
significant tumour growth delay and showed a significant increase of tumour infiltrating 
NK cells in our study (65). This is in line with literature showing that NK cells do not 
necessarily need prior immunization (in this study by RT) to actively perform their 
cytotoxic activity against tumours (66). Indeed, we show in this chapter for the first time 
that this therapeutic gain in the MHCI negative F9 teratrocacinoma is associated with 
the infiltration of NK cells. In agreement with published data, the efficacy of targeted IL2 
therapy (F16-IL2, F8-IL2, L19-IL2 or NHS-IL2) can be attributed to NK cells (67-69), T cells 
(70-73), or a combination of both (63, 74). Findings of this chapter, clearly showing that 
the anti-tumour effect of the (RT +) L19-IL2 (combination) therapy is present in a MHCI 
negative tumour model, are of great importance. In clinical setting, tumours tend to 
have a heterogeneous expression of MHCI [4] and therefore NK cells might be a crucial 
backup plan in case activated CD8+ T cells have no or limited targets to recognize these 
tumour cells. However, reported data suggest that direct NK cell efficacy against solid 
human tumours is still questionable, due to the immunosuppressive tumour 
microenvironment, but their indirect effects shaping the tumour microenvironment may 
be favoring adaptive T cell responses (75-77). Because we have observed in chapter 6 
that RT + L19-IL2 results in a significant anti-tumour effect and an increase of tumour 
infiltrating NK cells in a MHCI negative tumour model, we provide evidence that this 
treatment has a stimulating/activating effect on NK cells. Therefore, in clinical setting, 
NK cells stimulated by L19-IL2 might additionally increase the cytotoxic potential of RT + 
L19-IL2 stimulated T cells targeting irradiated tumours. In other words, L19-IL2 
stimulated NK cells may induce an anti-tumour response via its indirect tumour 
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microenvironment shaping effects, though we have not found an increase in NK cells in 
MHCI positive tumours treated with the combination treatment (chapter 3, (2)). 
Furthermore, highly interesting recent findings demonstrate that circulating NK cells 
have a role in metastasis control (78) and that impaired NK cell activity in the blood 
circulation can be observed in several malignancies (79-81). Given the fact that RT + 
L19-IL2 can induce anti-tumour effects outside the RT field (i.e. the OFRI effect) as 
described in chapter 5, and this therapy is able to stimulate NK cells as described in this 
chapter (chapter 6), this might hold even more promise for (micro)metastatic tumour 
control.  
In chapter 7 we describe our opinion as answer on a commentary written based on 
chapter 6 (82), which focus on where to place L19-IL2 in ‘the age of the checkpoint 
inhibitors’. As described in the introduction of this thesis (chapter 1), checkpoint inhibitors 
are able to target the inhibitory pathways of cells from the adaptive immune system (83), 
and have shown revolutionary clinical results (84-87). Anti-CTLA4 (ipilimumab) and the 
anti-PD-1/PD-L1 axis inhibitors atezolimab, pembrolizumab and nivolumab are all 
examples of recent FDA approved immune checkpoint inhibitors (88). In chapter 7 we 
discuss the author’s assumption that checkpoint inhibitors act on the modulation of an 
already present adaptive immune response (cytotoxic T cells) and IL2 based therapies are 
only able to trigger the innate immune system (NK cells). We agree with the statement 
that the ability of L19-IL2 to activate NK cells creates an interesting alternative for 
checkpoint inhibitors in case the cytotoxic T cell ‘baseline’ is insufficient, in case MHCI is 
lacking. Mechanisms of checkpoint inhibitors relay on the re-activation of already present 
but exhausted tumour (neo)antigen specific T cells, whereas L19-IL2 function relies on the 
activation/proliferation of these tumour specific T cells. In other words, checkpoint 
inhibitors are able to get rid of the brake, and L19-IL2 is able to push the gas. Because of 
this different mode of action between both immunotherapeutic approaches, and because 
of the discussed immune initiating effects of RT, we believe and conclude in chapter 7 that 
long-lasting (memory effects) and OFRI anti-tumour effects can be reached when the right 
RT dose/schedule will be combined with the stimulating immunotherapeutic approach in 
order to result in an optimal immune response of adaptive origin. As described above, NK 
cells might shape the adaptive anti-tumour immune response, and in this perspective I 
believe the involvement (indirect effects) of NK cells might be crucial. In the same 
perspective, I believe the addition of checkpoint inhibitors might be crucial since they 
have the potential to prolong the RT + L19-IL2 induced anti-tumour effect by blocking 
inhibitory immune dampening pathways (88).  
So far, we conclude that the first line treatment must consist of RT to create a 
personalized in situ vaccine and increase tumour immunogenicity, followed by L19-IL2 
to stimulate the proliferation of tumour (neo)antigen specific T cells (and/or NK cells 
that target MHCI negative tumour cells and/or support cytotoxic T cells). These 
activated cytotoxic T cells have the potential to target tumour cells outside the RT field 
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(OFRI effect). As described above, T cells have the possibility to activate several 
inhibitory pathways in order to maintain self-tolerance and to be able to control the 
duration and amplitude of a physiological immune response with minimal collateral 
tissue damage (88). This is a process researchers want to minimize, since these 
inhibitory pathways also stop the anti-tumour immune response (i.e. exhausted T cell 
phenotype). When these specific T cells become exhausted, they often express CTLA-4 
and/or PD-1 immune downregulating molecules as described in chapter 1. Because of 
these general characteristics, we next investigated the possibility to further increase the 
RT + L19-IL2 mediated immune response by the addition of anti-CTLA-4 (ipilimumab). 
TOWARDS TRIMODAL TREATMENT?  
In chapter 3 we have described that the RT + L19-IL2 bimodal therapy can result in long-
lasting curative cytotoxic T cell responses, depending on the tumour model and the 
delivered RT dose (2) and additive NK cell associated responses (65) in MHCI negative 
tumours, as described in chapter 6. Additionally we have shown in chapter 5 that 
increasing RT dose to 15Gy resulted in a 100% cure rate when combined with L19-IL2. 
Instead of increasing the RT dose, combining the low dose RT + L19-IL2 treatment with 
a checkpoint inhibitor, may also increase therapeutic potential (88). The unlimited 
increase of the RT dose is not clinically feasible because of normal tissue constraints. In 
chapter 8 we investigated the therapeutic potential of a trimodal treatment approach, 
combining RT and L19-IL2 with anti-CTLA-4 (ipilimumab). We hypothesized that we can 
observe synergistic anti-tumour effects by combining low dose RT and L19-IL2 with the 
immune checkpoint inhibitor of CTLA-4. Indeed, we have shown in this study that 
treatment with L19-IL2 resulted in CTLA-4 expressing T cells, making this a promising 
target for further improvement. In chapter 8 we showed that the trimodal treatment 
(RT + L19-IL2 + anti-CTLA-4) prolongs growth delay as compared with all other 
schedules, except the bimodal treatment. Strikingly, we observed a reduced cure rate in 
the bimodal treatment when anti-CTLA-4 was added, which was not attributed to an 
increase in regulatory T cells as described before (89, 90). Recently, it has been shown 
that tumours (melanoma) can escape anti-CTLA-4 based therapies by the upregulation 
of PD-L1 (91) and our preliminary results show indeed that PD-L1 is expressed in the 
tumour cells, and therefore it is possible that the PD-L1/PD-1 axis is involved as 
immunosuppressive mechanism. Furthermore, we only administrated one dose of 
ipilimumab at one time point (day 2). This schedule was based on our previously used 
schedule (RT day 0, L19-IL2 day 1, 3, 5) and the promising anti-tumour activity observed 
in another preclinical study administrating ipilimumab one day after L19-IL2 injections 
(92). However, the latter study administrated multiple ipilimumab injections, and 
therefore additional benefit of the trimodal treatment as compared with RT + L19-IL2 
therapy. However, we observed a worse anti-tumour effect using the trimodal 
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treatment. Therefore, the suboptimal timing of this checkpoint inhibitor, thereby 
contrarily inhibiting cells necessary for the optimal anti-tumour immune response, 
might be a possible explanation for this observed worse anti-tumour response after 
anti-CTLA-4 administration.   
In conclusion, this dissertation showed the possibility of increasing a RT initiated anti-
tumour immune response using the immunocytokine L19-IL2 in a CD8+ and NK+ cell 
dependent manner, dependent on the model. It shows the possibilities to cause tumour 
regression and cure outside the RT field (OFRI effect) in a T cell dependent manner. It 
clearly shows the long-lasting activity of this stimulated immune response, which is 
even able to provide protection against new tumour formation months after the 
termination of this treatment. The combination treatment of RT with L19-IL2 provides 
the immune system with all the necessary tools and has therefore great potential to 
target metastatic disease, with a curative intent. 
FUTURE PERSPECTIVES - THIS DISSERTATION 
The future of RT combined with L19-IL2 bimodal treatment is highly promising. Figure 1 
summarizes several future directions that can lead to a greater success of this 
approach. Based on the results described in chapter 3, a phase I clinical trial is initiated 
which is currently ongoing as described above (animation available: 
https://youtu.be/xHbwQuCTkRc) and a phase II clinical trial has been approved 
(animation available: https://youtu.be/6wDE6RkrikA). The phase II study will investigate 
the combination of SBRT and L19-IL2 in patients with non-small cell lung cancer 
(NSCLC). Using peptide-MHCI multimers labeled with individual DNA barcodes (48), we 
will be able to identify neo-epitope-directed T cell reactivity. This latter technique will 
give us important insights into the T cell reactivity against tumour (neo)antigens, 
opening doors to create profiles of patients based on their anti-tumour immune 
response. This will form the basis for a new biomarker approach, the most important 
future step in oncology research. Furthermore, based on the results described in 
chapter 5, were we found the presence of immunosuppressive T cells (PD-1+) infiltrating 
tumours outside the RT field, we applied for a KWF grant in which we will establish the 
preclinical proof-of-concept of the therapeutic impact of a trimodal treatment for 
metastatic cancer (animation available: https://youtu.be/7ckZeWWyhts). This trimodal 
therapy will consist of RT, L19-IL2 and nivolumab (anti-PD-1). In addition, we will 
identify immune-specific blood and tissue biomarkers that can evaluate therapy 
response and OFRI effects. Novel preclinical findings will be translated to a new phase I 
clinical study in stage IV NSCLC patients, investigating safety as primary and overall 
survival as secondary endpoints respectively. Moreover, it will be interesting to 
investigate the T cells (CD44+CD127+, i.e. effector memory cells) described in chapter 5 
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in blood of patients from the phase II study (or from blood of responders vs non-
responders from another clinical study). Effector memory T cell reactivity against 
tumour (neo)antigens might hold even more promise to identify (long-term) responders 
during or directly after treatment, which enables us eventually to classify patients into 
‘long-term responders’ or ‘non-long-term responders’, and adapt therapy for the latter 
group. The role of NK cells in this anti-tumour immune response also warrants further 
research (chapter 6), and it might be of great value to investigate the effects of RT + 
L19-IL2 in a tumour model with a heterogeneous expression of MHCI and assess to 
what extent NK cells directly target MHCI negative tumour cells or indirectly support 
CD8+ T cell mediated responses, as described previously (75-77).  
 
 
Figure 1: Overview of future perspectives – this dissertation.  
1. The identification of neo-eptitope directed T cells and creation of personalized immune profiles (chapter 3,
4, 5)  
2. The investigation of the role of PD-1/ PD-L1 as trimodal treatment resistance mechanism (chapter 8)  
3. Investigate the role of PD-1 in the OFRI effect and the possibility to increase the OFRI effect using RT + L19-
IL2 + anti-PD-1 treatment (chapter 5)  
4. Investigate possibility to identify long-term responders based on CD44+CD127+ expression on CD8+ T cells 
(chapter 5)  
5. Investigate the effects of RT + L19-IL2 treatment in tumours with varying expression of MHCI (chapter 6) 
FUTURE PERSPECTIVES - A BROADER VIEW 
Based on recent ground-breaking findings (84-87) and their totally different way of 
treating cancer by targeting the tumour indirectly via the immune system, a major 
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change of paradigm has been started (83). At this moment, we are right in the middle of 
this immunotherapeutic revolution. Profound progress in immunotherapy research was 
achieved in for example the field of checkpoint inhibitors (88), adoptive cell therapy 
(including genetically engineered lymphocytes that express conventional T cell 
receptors or chimeric antigen receptors) (93) and immune modulating cytokines 
(including IL2 (94)). The recent advances in cancer immunotherapy clearly illustrate 
long-term clinical benefit in some advanced cancer patients, and the potential for cure 
is realistic (95). Considering the total burden of cancer, and the rising possibilities to 
successfully manipulate the anti-tumour immune response, the few FDA approved 
antibodies (as monotherapy) can in my opinion be considered as ‘tip of the iceberg’. In 
addition, as described in this dissertation and recognized by others (84-87, 91, 96), even 
better clinical responses can be achieved when therapies are combined with each 
other, or with RT. Furthermore, it has been recognized that hypoxic regions present in a 
tumour can prevent adequate anti-tumour immune responses (26) and that increasing 
tumour oxygenation can improve RT efficacy (97, 98). Therefore, the use of hypoxia 
targeting treatment (99) to specifically target hypoxic areas in solid tumours or 
strategies to overcome tumor hypoxia, might hold promise to further increase 
therapeutic potential of immunotherapies and/or radiotherapy. With all these novel 
immunotherapeutic approaches, which can be used in combination with other 
treatment modalities or different RT schedules, the diversity of possible treatment 
options is almost unlimited. Therefore, in my opinion, cancer research should even 
more be executed in a ‘bench-bedside-bench’ approach, and the focus at this moment 
should be on the ‘bedside-bench’ part. However, the bench needs to be seen in a 
broader perspective: the collaboration between biologists, oncologists, immunologists, 
data scientists, mathematicians and medical engineers, will become even more crucial 
the coming decennium. Together, we need to develop a biomarker model, which 
integrates biological information from tumours (28), the anti-tumour immune response 
(44, 48), and other important parameters (including for example microbiota (100-104)) 
into a mathematical framework or platform (105) able to predict an accurate anti-
tumour immune response, which can be used to select patients for optimal treatment.  
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The overall aim of this dissertation was to investigate the possibility of transforming the 
local effects of radiotherapy (RT) into a systemic tumour-targeted therapy, by 
enhancing its initial immune stimulating effects with the immunocytokine L19-IL2. We 
investigated the CD8+ T cell mediated anti-tumour effects of RT in combination with 
L19-IL2 on irradiated tumours (chapter 3 and 4) and on non-irradiated tumours (chapter 
5). We additionally assessed the possibility of this combination treatment to induce a 
protective and long-lasting anti-tumour memory potential (chapter 5) and its capacity 
to activate an effective NK cell mediated anti-tumour immune response (chapter 6 and 
7). Furthermore, in this dissertation we investigated the possibility to combine this 
bimodal treatment with a checkpoint inhibitor, anti-CTLA-4 (chapter 8). In chapter 9 we 
evaluated our data by placing them in a broader view and discussed the future 
perspectives linked to this dissertation.  
The first study in this dissertation (chapter 3) described the therapeutic potential and 
related induced anti-tumour immune responses of RT combined with L19-IL2 in three 
different in vivo murine tumour models: the 4T1 breast carcinoma, Lewis lung 
carcinoma (LLC), and the C51 colon carcinoma, which have respectively increasing ED-B 
expression levels. The therapeutic efficacy was found to be dependent on ED-B 
expression levels, with highly synergistic effects and a cure rate of 75% in the high ED-B 
expressing model C51. These data clearly show the necessity of ED-B expression for an 
appropriate therapeutic benefit of the combination treatment. Since the majority of 
human cancers express ED-B, it makes this treatment highly applicable in patients. 
Furthermore, we proved that CD8+ T cells are causally involved in the anti-tumour 
response of these ED-B+ tumours and we showed that the therapeutic benefit is RT 
dose dependent, since lowering radiation dose resulted in a reduced number of cured 
animals. These findings resulted in the initiation of a Phase I clinical safety study 
(NCT02086721) combining SBRT and L19-IL2 in patients with oligometastatic solid 
tumours, which is currently ongoing in our institute. Preliminary results of this trial 
indicate that the treatment combination is safe for the first dose level tested. 
These curative anti-tumour results clearly show the enormous capability of the 
‘correctly triggered and enhanced’ immune response to distinguish irradiated (i.e. 
damaged) aberrant (i.e. tumours) from healthy tissues and to eliminate these upon 
recognition. In chapter 4 we described the possible next steps in this preclinical 
research; from provoking anti-tumour effects outside RT field to novel treatment 
combination opportunities for further personalization of this therapy. 
The possibility to provoke an anti-tumour effect outside the RT field when combined 
with systemic L19-IL2 treatment was studied in chapter 5. Anti-tumour effects triggered 
by RT observed outside the RT field are called ‘abscopal effects’ (ab = away from, scopus 
= target), however, since we investigate the ‘extended’ abscopal effect by combining it 
with systemic L19-IL2 treatment, we introduced the ‘OFRI effect’ (out-of-field 
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radioimmune) terminology in this chapter. We proved for the first time that a single RT 
dose (15Gy) can result in a curative OFRI effect in 20% of the macroscopic tumours 
when combined with L19-IL2. We additionally investigated two clinically relevant 
fractionated RT schedules (5 x 5Gy and 5 x 2Gy), which also induce OFRI effects, though 
non-curative. The (curative) OFRI effect triggered by 15Gy and L19-IL2 shows an 
increase of CD4+ T cells at day 4 after RT. However, a depletion study (starting at day 5) 
revealed that the curative single RT dose triggered and L19-IL2 mediated OFRI effect is 
caused predominantly by CD8+ T cells. These data suggest that CD8+ T cells are causing 
the OFRI effect from day 5 onwards and that CD4+ T cells are involved at an earlier stage 
in this anti-tumour effect. When investigating the specificity using a CT26 mismatched 
tumour, we observed a growth delay of these tumours, though therapy targeting 
directly the C51 tumour with radiation in combination with L19-IL2 did not result in 
elimination of the mismatched CT26 tumours, suggesting that only a part of the tumour 
(neo)antigens between C51 and CT26 non-irradiated tumours are overlapping. Based on 
these findings it appears that OFRI effect is tumour specific but since tumours of 
different origin may share common (neo)antigens, this therapy has the potential to 
eradicate multiple tumors within a patient.   
In addition we showed that T cells infiltrating non-irradiated tumours have more often a 
regulatory (FoxP3+CD25+) or exhausted (PD-1+) phenotype as compared with irradiated 
tumours from mice treated with the combination treatment. This suggests that the 
OFRI effect may be improved by combatting this immunosuppressive environment with, 
for example, an anti-PD-1 checkpoint inhibitor. However, we have clearly shown that 
only a single RT dose and not fractionated RT can combat this immunosuppressive 
environment as well, since these irradiated tumours had a significantly lower infiltrate 
of regulatory and exhausted T cells. Furthermore, we compared 5 x 5Gy + L19-IL2 with 
15Gy + L19-IL2 and show that the latter had a higher percentage of tumor infiltrating 
CD8+ T cells and a higher number of circulating CD4+ T cells in the blood. These results 
clearly demonstrate how crucial the RT schedule is in initiating the optimal OFRI effect 
and show that a single RT dose is the best trigger for a curative OFRI effect in this in vivo 
model. 
Of great importance, we described the capability of mice, cured from C51 tumours by 
the combination treatment, to develop a long-lasting immunological protection against 
new tumour formation, months after tumour cure. Treatment alone (without C51 
tumours) did not result in this protective effect, proving the necessity of the ‘in situ’ 
immunization process. Treatment with surgery combined with L19-IL2 or high dose RT 
(40Gy) combined with vehicle, showed significantly less protection. These data suggest 
that RT is the best inducer for this long-lasting protection against tumours and that L19-
IL2 is of great importance. Of great interest is the finding that the immune system of 
mice, able to reject tumour formation upon reinjection of these cells, demonstrated a 
significant increase of CD44+CD62L+ and CD44+CD62L- expression on CD8+ T cells in the 
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lymph nodes, indicative for central memory T cells and effector T cells respectively. 
Therefore, we concluded that central memory T and effector T cells in the lymph node 
compartments are involved in the protection against new C51 tumour formation. 
Furthermore, the same mice had a high expression of CD44+CD127+ on splenic, lymph 
nodes and on circulating (blood) CD8+ T cells, which are classified as effector memory T 
cells. Effector memory T cells were significantly higher in the blood of mice able to 
reject tumour cells upon re-challenge and therefore these immune cells are systemically 
associated with an optimal long-lasting protective effect and may serve as (a basis for) 
biomarker to identify patients who did not develop immunological memory and thus 
are at risk for tumour recurrence. 
RT combined with L19-IL2 can trigger the adaptive CD8+ T cells mediated immune 
response, targeting irradiated and non-irradiated tumours and preventing the 
formation of new tumours months after cure and stop treatment. However, tumour 
cells need to express MHCI in order to be recognized and killed by CD8+ T cells, and 
therefore we investigated the anti-tumour potential of this combination therapy in 
tumours lacking MHCI expression in chapter 6. Treatment with L19-IL2 alone already 
resulted in a significant tumour growth delay and showed a significant increase of 
tumour infiltrating NK cells. Furthermore, no therapeutic gain was observed when RT 
was delivered during the L19-IL2 treatment schedule (RT day 2, L19-IL2 day 0, 2, 4), but 
only when RT is delivered prior to L19-IL2, in the same experimental set-up as used 
before (RT day 0, L19-IL2 day 1, 3, 5). The enhancement of tumour response was 
associated with an increase in infiltrating NK cells. The difference in treatment efficacy 
between both schedules might be explained by the fact that L19-IL2 stimulates the 
proliferation/activation of NK cells, which are killed when the RT dose is delivered 
during immunotherapy treatment. To what extend this anti-tumour response is directly 
performed by NK cells, or if they have an indirect role by shaping the tumour 
microenvironment favoring the adaptive T cells response, is not proven yet. However, 
findings of this chapter do show the anti-tumour effect of the (RT +) L19-IL2 
(combination) therapy in a MHCI negative tumour model, which is of great interest 
since tumours tend to have a heterogeneous expression of MHCI in a clinical setting. 
Given the fact that RT + L19-IL2 can induce anti-tumour effects outside the RT field (i.e. 
the OFRI effect) as described in chapter 5, and this therapy is able to stimulate NK cells 
as described in chapter 6, this might hold even more promise for (micro)metastatic 
tumour control.  
In chapter 7 we have expressed our opinion on the role of L19-IL2 in ‘the age of the 
checkpoint inhibitors’ as answer on a commentary. We agreed with the statement that 
the ability of L19-IL2 to activate NK cells creates an interesting alternative for 
checkpoint inhibitors in case the cytotoxic T cell ‘baseline’ is insufficient or in case MHCI 
is lacking. However, especially because of the long-lasting (memory) potential provoked 
by the adaptive immune response, we believe and concluded in chapter 7 that the 
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primary goal of an immunotherapeutic (combination) approach is to induce an anti-
tumour immune response mediated by T cells. NK cells might have a supportive 
(indirect) role in this process as described above, and are able to kill MHCI negative 
tumour cells (as shown in chapter 6).  
Once the anti-tumour immune response contains the right constituents (delivered via 
the RT immunization) and is amplified using the right immunotherapy (in our models 
L19-IL2), it can further be personalized using checkpoint inhibitors able to prolong its 
anti-tumour potential. In chapter 8 we described our approach to combine low dose RT 
(2Gy) with L19-IL2 and a checkpoint inhibitor (anti-CTLA-4/Ipilimumab) in the same 
experimental setting. Here, we have observed that treatment with L19-IL2 results in 
CTLA-4 expressing T cells and that the trimodal treatment (RT + L19-IL2 + anti-CTLA-4) 
prolongs growth delay as compared with all other schedules, except the bimodal 
treatment (RT + L19-IL2). Strikingly, we noticed a reduced cure rate in the trimodal 
treatment. This importantly indicates that, in contrast to our hypothesis, addition of 
anti-CTLA-4 worsens tumour response. An increase in regulatory T cells is not the 
explanation for this reduced treatment efficacy and our first preliminary results show 
that tumour cells express more PD-L1. Therefore, the PD-L1/PD-1 axis might be an 
immunosuppressive counteract mechanism used by tumours after anti-CTLA-4 
treatment in order to escape the immune attack. However, we cannot yet exclude that 
timing of the anti-CTLA-4 antibody (day 2 in treatment schedule) or the lack of 
repetitive administration is the cause of these unexpected findings.  
In chapter 9 we evaluated the described chapters of this dissertation, discussed recent 
relevant literature and described what these results hold for the future. It provides the 
future perspectives that directly resulted from this dissertation, some of which are 
already ongoing. These include the phase I clinical study (NCT02086721, ongoing) and a 
phase II clinical study (approved) investigating RT and L19-IL2 in patients with 
oligometastatic cancer. It additionally includes a planned preclinical (and phase I 
clinical) study combining RT and L19-IL2 with anti-PD-1 (nivolumab) to investigate the 
possibility of increasing the OFRI effect for metastatic cancer. It also includes a broader 
view for future perspectives, stating that cancer research should even more be 
executed in a ‘bench-bedside-bench’ approach, with focus on the ‘bedside-bench’ part. 
The bench is described as a ‘super team’; a collaboration between biologists, 
oncologists, immunologists, data scientists, mathematicians and medical engineers.  
The curative anti-tumour effect observed in this dissertation proves that RT can 
function as major anti-tumour immune response trigger, which can be enhanced by an 
immunotherapeutic approach (L19-IL2 in our models), to kill irradiated and non-
irradiated tumours, and to prevent tumour formation months after cure. It shows the 
synergism between both treatment modalities, opening doors for further personalizing 
in treatment of metastatic disease, with a curative intent.    
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Het ultieme doel van een anti-kanker behandeling is de patiënt te genezen voor lange 
termijn, zonder dat zijn gezonde weefsels teveel schade oplopen. De meest gebruikte 
behandelingsmethoden zijn chirurgie, bestraling en chemotherapie. Waar bij chirurgie 
een maligniteit invasief wordt verwijderd, wordt deze bij bestraling beschadigd door het 
gericht toepassen van een stralingsdosis. Chemotherapie hanteert een systemische 
aanpak welke snel delende cellen doodt, waarvoor onder andere de tumorcellen 
gevoelig kunnen zijn. Recentelijk staat er een compleet andere aanpak om kanker te 
vernietigen in de spotlights, namelijk de immuuntherapieën. Na de ontdekking van 
chemotherapieën in de jaren 40, zijn de opkomst van de immuuntherapieën waar-
schijnlijk de meest veelbelovende en revolutionaire manier om kanker te bestrijden. 
Immuuntherapieën verschillen in hun manier van aanpak van bovenstaand beschreven 
behandelmethoden, omdat deze kanker bestrijden door het immuunsysteem te 
manipuleren. Dit kunnen we tegenwoordig op een steeds verfijndere en gerichtere 
manier, en de toediening van L19-IL2 is hiervan een veelbelovend voorbeeld. L19-IL2 is 
een immuuntherapie welke dankzij zijn L19-deel aan ED-B kan binden, aanwezig in het 
vaatstelsel van de tumor. IL2 is een interleukine, welke door verschillende immuun 
cellen wordt geproduceerd en onder andere NK en T cellen kan activeren tot 
proliferatie. L19-IL2 heeft daarom de potentie om het immuunsysteem gelokaliseerd bij 
de tumor te activeren.  
Het algemene doel van deze dissertatie was het onderzoeken van de systemische anti-
tumor immuun gemedieerde effecten bij de combinatie behandeling van (tumor) gerichte 
bestraling met systemische L19-IL2. Dit is van groot belang, omdat (micro)metastasen zich 
vrijwel altijd buiten het bestralingsgebied bevinden. Deze worden daarom gemist, wat de 
verdere groei van de metastasen mogelijk maakt. Het vertalen van de lokale 
behandelingseffecten van bestraling naar een behandeling die ook systemisch tumoren 
kan vernietigen, is daarom van groot belang. Aan de andere kant is recentelijk aangetoond 
dat tumoren na bestraling een vorm van immunogene celdood ondergaan. Bestraling 
beschadigt de tumor en de vrijgekomen tumor specifieke (neo)antigenen initiëren een 
immuun reactie, welke de constituenten bevat van de tumor en daarom als een soort ‘in 
situ’ vaccinatie fungeert. De immuuntherapie L19-IL2 heeft de potentie om deze initiële 
anti-tumor immuun reactie verder te versterken en daarom kan een combinatie van 
beiden resulteren in de creatie van een gepersonaliseerd en heterogeen ‘super medicijn’. 
Dit super medicijn, de verwekte anti-tumor immuun reactie zelf, heeft de potentie 
gemetastaseerde kanker gericht te vernietigen, ook nadat de behandeling is gestopt, 
mogelijk met een curatief resultaat.  
In hoofdstuk 3 hebben wij de effecten van een dosis bestraling in combinatie met 
systemische L19-IL2 onderzocht op de bestraalde tumoren met een variërende expressie 
van ED-B. Geen additionele therapeutische verbetering werd geobserveerd in het 
lage/negatieve ED-B expressie model 4T1 en een additief effect werd geobserveerd in 
het intermediaire ED-B expressie model LLC. Het model met de hoogste ED-B expressie 
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(C51) toonde een sterk synergisme tussen bestraling en L19-IL2, met een genezings-
percentage van 75%. Dit toont aan dat de werkzaamheid van deze combinatie-
behandeling afhangt van ED-B expressie, en aangezien ED-B in de meerderheid van de 
solide humane tumoren aanwezig is, is de toepasbaarheid van deze behandeling groot. 
We tonen verder aan dat het percentage CD8+ cytotoxische T cellen in tumoren met 
een hoge ED-B expressie verhoogd is na behandeling met bestraling en L19-IL2, en laten 
zien dat er een causaal verband bestaat tussen de effectiviteit van deze combinatie-
behandeling en de aanwezigheid van deze cellen. Een verdere belangrijke bevinding 
omschreven in dit hoofdstuk is de afhankelijkheid van deze synergistische behandeling 
van de gegeven stralingsdosis; een verlaging naar 5 en 2Gy verminderde het aantal 
tumor eliminaties aanzienlijk. De bevindingen van de studie beschreven in hoofdstuk 3 
hebben geresulteerd in de initiatie van een fase I klinische studie (NCT02086721), 
waarbij patiënten met oligometastasen behandeld worden met SBRT en L19-IL2, welke 
momenteel loopt binnen ons instituut. Tot nu toe laat de studie zien dat de behandeling 
veilig is en de milde gemelde pijnklachten die patiënten ervaren bij de tumor regio 
kunnen mogelijk wijzen op de werkzaamheid van deze behandeling.  
Zoals beschreven in hoofdstuk 4, openen de bevindingen beschreven in hoofdstuk 3 de 
deur voor verder onderzoek. Het synergisme beschreven in hoofdstuk 3 is van groot 
belang, ze laten duidelijk zien dat beide therapieën elkaar kunnen versterken zodat de 
snelgroeiende EB-B positieve tumoren volledig verdwijnen. In hoofdstuk 4 staat het 
‘winnende medicijn’, de perfect getriggerde en langdurende anti-tumor immuunreactie 
zelf, centraal. We beschrijven de mogelijkheden voor verder preklinisch onderzoek; van 
de systemische behandeling van kanker tot interessante combinaties met hypoxie 
geactiveerde therapieën (in het geval de tumoren hypoxisch zijn) en checkpoint 
remmers (in het geval het immuunsysteem een immuun suppressief fenotype heeft).  
De mogelijkheid van de perfect getriggerde anti-tumor immuun reactie om tumoren 
buiten het bestralingsgebied te elimineren en zijn capaciteit om langdurige 
bescherming te geven tegen de vorming van nieuwe tumoren, staat centraal in 
hoofdstuk 5. Het elimineren van tumoren buiten het bestralingsgebied is een fenomeen 
dat weinig geobserveerd wordt, maar klinisch erg interessant is: een lokale behandeling 
(bestraling) kan op deze manier namelijk systemisch anti-tumor effect hebben. 
Onderzoek toont aan dat het abscopal effect (ab – weg van, scopus – target) 
gemedieerd wordt door het immuun systeem. Aangezien wij in onze studie anti-tumor 
effecten buiten het bestralingsgebied onderzoeken in combinatie met systemische 
behandeling van L19-IL2, hebben wij een nieuwe terminologie in het leven geroepen, 
namelijk ‘het OFRI effect’ (Out-of-field radioimmune). Het OFRI effect is een anti-tumor 
effect buiten het bestralingsgebied gemedieerd door het eigen immuunsysteem, welke 
door middel van een immuuntherapie versterkt wordt. In hoofdstuk 5 laten we voor de 
eerste keer zien dat 1 dosis bestraling (15Gy) gericht op de tumor resulteert in een 
curatief OFRI effect wanneer gecombineerd met L19-IL2 in 20% van de niet-bestraalde 
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macroscopische tumoren. Wanneer de stralingsdosis in fracties gegeven werd, 5 x 2Gy 
of 5 x 5Gy, observeerden wij ook een OFRI effect, echter zonder een curatief resultaat.  
Tumoren buiten het bestralingsgebied van muizen behandeld met een enkele dosis 
bestraling plus L19-IL2 lieten een verhoging van CD4+ geïnfiltreerde T cellen zien (op dag 
4), wat suggereert dat deze immuun cellen van belang zijn voor het OFRI effect. 
Wanneer deze cellen geëlimineerd werden vanaf dag 5, resulteerde dit inderdaad in 
een snellere groei van de niet bestraalde tumoren, echter dit verschil was niet 
significant. Wel vonden we een significant snellere tumorgroei wanneer de CD8+ T 
cellen werden geëlimineerd en deze data vormen dan ook het directe bewijs dat het 
curatieve OFRI effect veroorzaakt wordt door deze cellen. Om de specificiteit van het 
OFRI effect te onderzoeken, gebruikten we een tweede ED-B positieve tumor (CT26) in 
dezelfde experimentele opzet. We observeerden eenzelfde groeivertraging van deze 
mismatchte tumoren, echter geen van deze tumoren kon geëlimineerd worden door 
het C51 tumor geïnitieerde OFRI effect. Deze resultaten suggereren dat gedeelde 
(neo)antigenen tussen deze tumoren wellicht als aangrijpingspunt voor de T cellen van 
het actieve OFRI effect fungeren.  
We tonen in hoofdstuk 5 aan dat T cellen geïnfiltreerd in niet-bestraalde tumoren van 
muizen behandeld met bestraling en L19-IL2 vaker een immune suppressief fenotype 
hebben in vergelijking met vehicle controle muizen. Onder andere vonden we een 
verhoogd infiltraat van PD-1+ en van regulatoire (Foxp3+CD25+) T cellen, wat resulteert 
in tolerantie en uitputting van deze cellen. Recentelijk zijn er een aantal PD-1 remmers, 
zoals nivolumab, goedgekeurd als nieuw anti-kanker middel voor bepaalde 
kankersoorten. Onze bevindingen (hoog PD-1 op T cellen) en deze recente 
ontwikkelingen, geven de mogelijkheid om het OFRI effect op relatief korte termijn zelfs 
nog te vergroten. Wanneer muizen behandeld werden met bestraling en L19-IL2, 
bevatte het immuun infiltraat van bestraalde tumoren een zeer laag percentage 
regulatoire of uitgeputte (PD-1+) T cellen in vergelijking met de niet-bestraalde 
tumoren. Dit laat zien dat één dosis bestraling op de tumor de samenstelling van het 
immuun infiltraat kan veranderen van immuun suppressief/regulatoir naar een 
effectieve immune respons. Fracties bestraling in combinatie met L19-IL2 resulteerde in 
een hoge expressie van PD-1+ T cellen geïnfiltreerd in tumoren buiten en binnen het 
bestralingsgebied, in vergelijking met vehicle controle. Wanneer niet-bestraalde 
tumoren van muizen behandeld met 15Gy + L19-IL2 en 5 x 5Gy + L19-IL2 direct met 
elkaar vergeleken werden, bleek de eerste groep meer CD8+ tumor infiltrerende T 
cellen en meer CD4+ circulerende T cellen in het bloed te hebben.  
Uit deze bevindingen kunnen we concluderen dat niet-bestraalde tumoren van muizen 
behandeld met bestraling (1 dosis) en L19-IL2 een hoog percentage geïnfiltreerde 
regulatoire en uitgeputte T cellen bevatten in vergelijking met de bestraling en vehicle 
controle. Dit immune suppressieve fenotype is ook terug te vinden in zowel de 
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bestraalde als niet-bestraalde tumoren van muizen behandeld met fracties bestralingen 
en L19-IL2 (vergeleken fracties bestralingen en vehicle). Echter, een directe vergelijking 
tussen één dosis bestraling en fracties wanneer beiden gecombineerd worden met L19-
IL2, laat zien dat de eerste groep meer CD8+ tumor infiltrerende T cellen en meer CD4+ 
circulerende T cellen in het bloed te hebben.  
We laten verder in hoofdstuk 5 zien dat wanneer muizen genezen zijn van hun tumoren 
door de combinatiebehandeling (bestraling plus L19-IL2), ze niet meer in staat zijn 
nieuwe tumoren te vormen. Muizen verkrijgen een langdurig immunologisch 
beschermend geheugen tegen deze tumoren. Deze immunologische bescherming wordt 
niet gevormd wanneer muizen zonder tumoren de combinatie behandeling ontvangen, 
wat aantoont dat de tumor inderdaad de basis vormt voor deze ‘in situ’ vaccinatie. De 
tumor kan uiteindelijk vertaald worden in een direct (bestraalde tumor), indirect (niet-
bestraalde tumor) en langdurig (opnieuw geïnjecteerde tumor) anti-tumor immuun 
effect. Muizen genezen van de tumoren door chirurgie plus L19-IL2 en hoge dosis 
bestraling plus vehicle, ontwikkelden significant vaker tumoren na her-injectie van 
tumorcellen. De eerste groep toont aan dat bestraling en de tweede groep toont aan dat 
L19-IL2 beiden noodzakelijk zijn voor een optimale langdurige immunologische 
bescherming tegen tumorvorming. Muizen die niet meer in staat zijn tumoren te 
vormen, hebben een verhoogd percentage centraal geheugen T cellen (CD44+CD62L+ op 
CD8+) en effector T cellen (CD44+CD62L- op CD8+) in hun lymfeklieren. Daarom 
suggereren wij dat deze cel subsets betrokken zijn bij de bescherming tegen de vorming 
van nieuwe tumoren. Dezelfde (tegen nieuwe tumorvorming) beschermde muizen, 
hebben een hoge expressie van CD44+CD127+ op CD8+ T cellen in hun milten, 
lymfeklieren en bloed. Deze cellen worden geclassificeerd als effector geheugen T cellen. 
Het blokkeren van CD127 had echter geen invloed op het tumor beschermende 
vermogen van de muizen. Dit laat zien dat CD127 wel sterk geassocieerd is met het 
vermogen van de muizen om beschermd te zijn tegen tumoren, maar dat dit 
beschermende vermogen niet afhankelijk is van CD127. Aangezien de effector geheugen 
T cellen in het bloed van muizen welke bescherm zijn tegen de vorming van nieuwe 
tumoren verhoogd is, zouden deze cellen als biomarker kunnen gaan fungeren om een 
(niet) langdurig immunologisch anti-tumor potentiaal te op te sporen.  
De hoofdstukken 1 tot en met 5 richten zich op de T cel gemedieerde anti-tumor 
immuun response, echter, in hoofdstuk 6 laten we zien dat bestraling en L19-IL2 ook 
een NK gemedieerde anti-tumor immuun response kunnen induceren. In dit hoofdstuk 
maken we gebruik van een MHCI negatief, maar ED-B positief, tumor model (F9 
teratocarcinoom). In de literatuur staat omschreven dat tumoren zonder MHCI 
expressie inderdaad als alternatief mechanisme door NK cellen kunnen worden 
geëlimineerd. In dit hoofdstuk hebben we twee behandelingsschema’s gebruikt. 
Behandeling met alleen L19-IL2 laat een significante tumorgroei vertraging zien. Dit is in 
lijn met de literatuur welke laat zien dat NK cellen niet noodzakelijk geïmmuniseerd 
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hoeven te worden (door bijvoorbeeld bestraling) voor hun activatie. Geen additionele 
tumorgroei vertraging werd geobserveerd wanneer bestraling in het midden van het 
L19-IL2 schema gegeven werd (bestraling dag 2, L19-IL2 dag 0, 2, 4). Het 
behandelingsschema startend met bestraling (bestraling dag 0, L19-IL2 dag 1, 3 en 5) 
vertraagt de tumorgroei significant. Mogelijk kan dit verschil verklaard worden doordat 
bestraling gegeven op dag 2 de door L19-IL2 gestimuleerde NK cellen beëindigt. 
Inderdaad laten we in hoofdstuk 6 zien dat de anti-tumor reactie van de MHCI 
negatieve tumoren geassocieerd is met een verhoogd percentage tumor infiltrerende 
NK cellen. Deze bevindingen zijn van groot belang, in de praktijk zullen tumoren 
namelijk een heterogene expressie hebben van MHCI en de uitgevoerde studies laten 
zien dat bestraling plus L19-IL2 niet alleen een T cel response kan induceren, maar ook 
een NK cel response. Dit vergroot de toepasbaarheid van deze therapie. Zoals ook 
omschreven wordt in hoofdstuk 7, is de mogelijkheid van deze combinatiebehandeling 
om NK cellen te activeren tot het elimineren van tumorcellen zeer voordelig vergelijken 
andere therapieën, zoals checkpoint remmers, welke alleen maar het adaptieve 
immuunsysteem kunnen moduleren. Echter concluderen we in dit hoofdstuk dat een 
optimaal geïnduceerde anti-tumor immuun effect van adaptieve origine de meeste 
potentie heeft, vooral gezien zijn langdurende bescherming tegen nieuwe 
tumorvorming. Echter, de indirecte rol van NK cellen om het adaptieve immuunsysteem 
te moduleren, is wellicht cruciaal voor een optimaal eindresultaat.  
In hoofdstuk 3 laten we zien dat bestraling plus L19-IL2 een curatieve en langdurende 
CD8+ T cel gemedieerde immuun response kan mediëren, welke curatief is in bestraalde 
tumoren. In hoofdstuk 5 laten we zien dat het verhogen van de bestralingsdosis naar 
15Gy (plus L19-IL2) resulteert in een curatief effect in 100% van de bestraalde tumoren. 
In plaats van de bestralingsdosis verhogen, is het ook een optie om een lage dosis 
bestraling (immuun initiërende trigger) te combineren met L19-IL2 (immuun response 
versterker) en een checkpoint inhibitor (haalt de rem van de T cellen af/verlengt de 
anti-tumor immune response), om zo de mogelijke stralingsdosis afhankelijke gezonde 
weefseltoxiciteit te beperken. In hoofdstuk 8 hebben we daarom een behandeling van 
bestraling (2Gy), L19-IL2 en anti-CTLA-4 (ipilimumab) onderzocht in het ED-B positieve 
C51 colon carcinoom model. Onze hypothese was dat toevoeging van anti-CTLA-4 aan 
de bimodale behandeling in een extra groeivertraging of eliminatie van de tumoren zou 
resulteren. Echter vonden wij dat toevoeging van anti-CTLA-4 resulteerde in een 
significant minder anti-tumor effect dan behandeling met de bimodale therapie zonder 
anti-CTLA-4. Geen verschil in circulerende regulatoire T cellen kon worden 
geobserveerd. De eerste resultaten wijzen op een toename van PD-L1 expressie van 
tumorcellen na de trimodale behandeling, wat mogelijk als een belangrijk immune 
suppressief ontsnappingsmechanisme kan fungeren. Echter, het is ook mogelijk dat de 
gekozen timing van de anti-CTLA-4 injectie (dag 2) niet optimaal is in dit schema.  
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Samenvattend laat deze dissertatie zien dat bestraling in combinatie met L19-IL2 kan 
resulteren in een CD8+ T cel en NK cel gemedieerde anti-tumor immuun response, 
afhankelijk van het model. Het laat de mogelijkheid van deze behandeling zien om de 
CD8+ T cel response te activeren zodat deze zelfs tumoren buiten het bestralingsgebied 
kunnen elimineren en maanden na genezing (en beëindiging van de therapie) kunnen 
voorkomen dat nieuwe tumoren gevormd worden. Dit immunologische beschermings-
mechanisme wordt zeer sterk geassocieerd met de systemische aanwezigheid van 
effector geheugen T cellen, welke mogelijk als interessant klinisch uitleessysteem 
(biomarker) kunnen gaan fungeren. Deze studies laten zien dat het mogelijk is het 
immuunsysteem met bestraling en een immuuntherapie (L19-IL2) volledig te moduleren 
in een zeer veelzijdige anti-tumor response. Deze anti-tumor response heeft het 
geweldige potentieel vertaald te worden naar patiënten, met als uiteindelijk doel 
gemetastaseerde kanker te gaan behandelen met een curatieve intentie.  
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In this thesis the long-lasting, protective and curative anti-tumour effects of 
radiotherapy (RT) in combination with the immunocytokine L19-IL2 has been 
successfully demonstrated in preclinical models. To have societal impact, this 
knowledge needs to be translated from preclinical (mice) studies to clinical (human) 
trials to eventually result into new and applicable treatment options. This translational 
process from findings in the lab towards new patient treatment options is complex and 
it often takes decades to be successfully achieved. Furthermore, it is mostly a highly 
disappointing process: despite successful preclinical results, around 85% of early clinical 
trials investigating novel drugs fail and only half of the successful therapies will 
eventually be approved. Therefore, it is important to keep the route from ‘preclinical 
findings’ to ‘a new treatment option’ as short and straightforward as possible. To 
ensure that the successful preclinical results as described in this dissertation have the 
potential to create impact as fast as possible, several key elements favouring this 
translational process are worth to mention. First of all, Maastro clinic has extended 
expertise in treating patients with (stereotactic ablative) RT, a necessary component of 
the tested novel treatment strategy. Second, both Maastro lab and Maastro clinic have 
a long history of conducting translational research leading to clinical trials. At this 
moment several phase I clinical studies are recruiting patients [NCT00691548; 
NCT00777894 and NCT00409994] and three studies are closed with follow-up 
[NCT00704600; NCT00409994 and NCT00969657]. In addition, L19-IL2 as monotherapy 
has already shown to be safe and effective in several clinical trials. Therefore research 
does not need to ‘start from scratch’, which can catalyse the translation process from 
successful preclinical findings towards the patients. The combination of these key 
elements made it possible that the preclinical results described in this dissertation 
already lead to the initiation of a phase I clinical study [NCT02086721], the funding of a 
phase II clinical trial and initiation of a trimodal study, combining RT and L19-IL2 with 
anti-PD-1. The knowledge described in this dissertation is therefore already being 
translated into applicable treatment options, though still in study design, and will 
hopefully result in a new and curative treatment option for patients with 
(oligo)metastatic disease in the near future.  
CLINICAL RELEVANCE 
Cancer is one of the leading causes of death worldwide, accounting for 8.2 million 
deaths in 2012. A major clinical challenge is the management of metastatic cancer, 
which is responsible for 90% of all cancer deaths. Patients with metastatic cancer mainly 
rely on palliative treatment and current treatment strategies result in a disappointing 
median progression-free survival (only 2-12 months for example in metastatic NSCLC). 
Therefore, there is a high need to develop new effective treatment strategies for these 
patients. The combinational treatment strategy investigated in this dissertation is of 
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great clinical relevance. First of all, tumour irradiation will initiate an anti-tumour 
immune response containing the elements of a patient’s own irradiated tumour. 
Therefore, combination of RT and immunotherapy based treatments has the potential 
to trigger a personalized (in situ generated) ‘medicine’. In chapter 3 curative anti-
tumour results are described, showing the importance of ED-B presence in the tumour 
vasculature prior to treatment. Since ED-B expression is restricted predominantly to 
tumours and it is present in the majority of tumours, most patients with solid tumours 
may potentially benefit from the treatment combination with little adverse effects as 
L19-IL2 is a tumour targeted therapy. Furthermore, as described in chapter 5, RT 
delivered to one tumour can additionally trigger curative anti-tumour effects outside 
the RT field (OFRI effect). Therefore, this locally triggered combination treatment has 
the potential to act as an effective systemic therapy. This makes the treatment of great 
interest for patients with metastatic disease. Last, this combination treatment triggers a 
long-lasting anti-tumour (memory) immune response. This is of great clinical relevance, 
since this memory effect enables to target tumour-associated antigens and thus protect 
patients from recurrences and potentially from development of new tumours. 
GAIN FOR SOCIETY 
The successful translation of preclinical data described in this dissertation toward 
society would, firstly and most importantly, benefit a great variety of (metastatic) 
cancer patients. As described above, treatment options for these patients are limited 
and therefore new therapeutic approaches are urgently needed. Introducing a new 
(combination) treatment for these patients will be highly beneficial for this large group 
of patients, since they will have the potential to be treated with curative intend instead 
of receiving palliative therapies. Furthermore, the use of L19-IL2 instead of IL2, to 
specifically target IL2 to tumours, makes this treatment less toxic. Patients may 
therefore experience a higher quality of life, which is a major gain for society. 
Additionally, the long-term anti-tumour effects observed in our studies show that the 
triggered anti-tumour response can prevent tumour formation months after 
termination of therapy. The combination treatment may therefore ‘learn’ the patients’ 
immune system what to target, and these long-living pool of memory T cells have the 
ability to remember their targets months after cure prolonging uncomplicated patients’ 
life. Next, medical doctors will have more opportunities to treat their patients, although 
proper patient selection is necessary before initiating treatment. Preclinical results 
described in this dissertation show that the combination treatment is effective in ED-B 
positive tumour models. Therefore, the development of a biomarker selecting patients 
based on the intratumoural ED-B expression prior to treatment, would additionally be a 
major benefit for society. This way, patients with a high chance to benefit from 
treatment can be selected and patients with a low chance of benefit could receive 
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alternative therapies. This prevents using ineffective treatments and thus decreases the 
costs. We additionally showed that CD8+ cytotoxic T cells are highly increased inside 
tumours that can be eliminated due to the combination treatment and that mice able 
to prevent new tumour formation have a high level of circulating memory T cells as 
compared with control groups. All of these findings have, once translated into clinical 
use, the potential to monitor patients during treatment and adapt or extend treatment 
when necessary. This increases the treatment efficacy and therefore it provides another 
gain for society. The initiation of the phase I clinical study in our institute 
[NCT02086721] can be seen as the first step to create impact in society.  
IMPROVEMENT IN HEALTH CARE 
The successful translation of the described preclinical results will greatly improve the 
health care for (metastatic) cancer patients. It is expected that this novel bimodal 
treatment modality will increase cure rates as well as control metastatic disease thereby 
prolonging patients´ life. The efficacy of this treatment approach needs to be proved in 
clinical trials which have been already initiated in our department. Additionally, several 
(immunological) parameters (ED-B expression, increase in CD8+ T cells) associated with 
elimination of irradiated and non-irradiated tumours when combined with L19-IL2 as 
well as the presence of memory T cells in long-term protected mice, have the potential 
to be translated into predictive biomarkers. These biomarkers could be implemented and 
used for the selection and monitoring of patients in the near future. Therefore, health 
care will be improved directly, because a new treatment option will be provided. 
Indirectly, the implementation of new predictive biomarkers to select patients, will have 
a big advantage since only potential responders will receive treatment. Other 
treatments, more effective in the cohort of non-responders or similarly effective but less 
expensive, will be offered to non-responders. This will reduce costs of the treatment and 
will spare these patients from possible therapy induced side-effects.   
NOVELTY OF CONCEPT 
The conversion of RT as a local treatment into an effective systemic treatment can be 
seen as the main conceptual novelty. It is known that the effects of RT on the tumour 
can initiate an anti-tumour immune response, however, this seldom results in the 
systemic regression of un-irradiated tumours. Using a novel immunotherapeutic 
approach, the immunocytokine L19-IL2, we are able to further strengthen the RT 
induced immune response. In our preclinical models, this resulted in the elimination of 
not only irradiated but also a part of non-irradiated tumours. Additionally, this immune 
response was able to prevent new tumour formation months after cure. The novelty of 
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the concept described in this dissertation relies on the interplay between RT and L19-
IL2, which may eventually result in a new treatment opportunity for patients with 
(metastatic) disease.  
ROAD TO THE MARKET 
The phase I clinical study (NCT02086721, animation available: https://youtu.be/ 
xHbwQuCTkRc) is currently ongoing in our institute and will primarily investigate the 
safety of the combination L19-IL2 with SABR in patients with oligometastatic solid 
tumours..Progression-free survival, local control rate, quality of life, non-invasive 
response using PET and overall survival are secondary endpoints. Furthermore, based 
on our findings a phase II clinical trial has been funded (animation available: 
https://youtu.be/6wDE6RkrikA). This phase II study will investigate the combination of 
SBRT and L19-IL2 in patients with non-small cell lung cancer (NSCLC). Additionally, the 
results described in chapter 5, showing the presence of immunosuppressive T cells (PD-
1+) infiltrating tumours outside the RT field, suggest that the RT + L19-IL2 combination 
treatment might be increased in its therapeutic potential by combining it with an anti-
PD-1 checkpoint inhibitor (e.g. nivolumab). Currently, we applied for a KWF grant in 
which we will establish the safety of this trimodal treatment for stage IV non-small cell 
lung cancer (NSCLC) patients (animation available: https://youtu.be/7ckZeWWyhts). 
Secondary endpoints in the latter clinical study include overall survival, progression free 
survival and quality of life. In addition we will include exploratory endpoints to 
investigate correlations of outcome measures with immunological markers in tumours 
and blood.  
Therefore, the clinical studies as described above, will not only investigate the safety 
and effectiveness of radiotherapy combined with L19-IL2, the investigated correlations 
with (immunological) parameters to evaluate therapy response and OFRI effects will be 
a crucial step on the ‘road to the market’. First of all, the development of a fast and 
reproducible assay for the detection of ED-B can be marketed. ED-B can be detected in 
tumours tissues (via ex vivo immunohistochemistry) or using a PET probe. Furthermore, 
ED-B can also be detected in the blood (serum), though clinical studies should reveal if 
ED-B expression in the blood correlates with therapeutic efficacy. Second the presence 
of tumour reactive cytotoxic T cells can form the basis for a marketable product. An 
assay predicting the adequate (OFRI) anti-tumour response based on effector (memory) 
T cell reactivity against tumour (neo)antigens in the blood, is an interesting concept. It 
can become a relevant tool to monitor patients during radiotherapy and L19-IL2 
treatment, however, it could be implemented as a novel tool for a panel of different 
immunotherapeutic approaches. Thus far, there is a lack of reliable biomarkers for the 
use of immunotherapies, such as checkpoint inhibitors, which is a major limitation of 
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these therapies. A recent approach to predict treatment outcome based on tumour 
infiltrating immune cells (Immunoscore) is an interesting development. However, an 
assay based on tumour reactive T cells in the blood has probably even more potential, 
because tumour tissue is not always available.  
In general, the preclinical results described in this dissertation may open doors to the 
development of alternative immunocytokines, for example in the absence of low ED-B 
expression. It may also show that it is possible to repurpose a ‘failed’ immunotherapy by 
providing a radiotherapy trigger prior to administration. Taken together, the preclinical 
research results described in this dissertation will have an important clinical relevance 
and societal impact when successfully translated to the clinic. The preclinical data 
already resulted in the initiation and approval of phase I and II clinical studies, which will 
be used to investigate therapeutic efficacy and will form the basis for identifying blood 
and tissue biomarkers for the selection and/or monitoring of patients in the near future, 
which can all be marketed. 
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